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ABSTRACT 
Cardiovascular diseases (CVD) remain one of the leading causes of morbidity and mortality 
worldwide. Current dietary guidelines advocate for a restriction of high intakes of saturated 
fatty acids (SFA), an important risk factor for the development of CVD due to their 
association with increased low-density lipoprotein cholesterol (LDL-C). Dairy foods are 
major contributors of total SFA intake. The literature review explored aspects of dairy 
consumption on CVD risk, highlighting current evidence which suggests a beneficial effect of 
certain dairy products. A reduction of dietary SFA is also dependent on a suitable replacement 
macronutrient. Supplementation of the dairy cow diet with plant oils/seeds provides an 
alternative strategy to partially replacing SFA in milk fat with monounsaturated fatty acids 
(MUFA). Few interventions studies have extensively investigated the impact of fatty acid 
(FA) modified dairy products on traditional and novel CVD risk markers. The RESET 
intervention study aimed to address this knowledge gap in both a chronic and acute-within-
chronic setting in adults at moderate CVD risk. A food-exchange model (38% total energy 
(%TE) from fat) was implemented and adherence assessed from 4 day weighed food diaries 
and phospholipid FA (PL-FA) analysis. Consumption of the FA-modified diet for 12 weeks 
(dietary target: 16%TE SFA; 14%TE MUFA) led to a significant attenuation in fasted LDL-C 
concentrations from baseline values and compared to matched control products (19%TE SFA; 
11%TE MUFA). At the beginning and end of each dietary intervention, the postprandial 
investigation was performed using sequential test meals representative of the assigned dairy 
diet. Following the FA-modified diet and test meals, a decrease in the postprandial iAUC 
summary response for apolipoprotein B (apoB) was observed, suggestive of an effect on 
triacylglyceride-rich lipoproteins (TRL). Changes in postprandial summary responses of 
plasma total lipid FA reflected the intake of the test meals. Additionally, the FA-modified diet 
appeared to modestly impact on both fasted concentrations and postprandial responses of 
nitrite, which may be indicative of an effect on endothelial function. Little to no impact was 
observed for other outcome measures. The impact of APOE genotype, retrospectively 
assessed, fasted and postprandial outcome measures following the two dairy diets, was 
explored. Significant pre-intervention fasted baseline differences in high-density lipoprotein 
cholesterol (HDL-C), small and medium HDL particle distribution and non-esterified fatty 
acids (NEFA) between E4 carriers and E3/E3, were observed. There was no interaction 
between genotype and treatment on any of the outcome measures. In summary, consumption 
of FA-modified dairy products appear to beneficially impact on certain markers of CVD risk, 
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compared to matched control products. However, further research should address the impact 
of other types of FA-modified dairy products in both healthy and at risk populations.     
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 Chapter I: Literature review: Dairy and cardiovascular risk: 
friend or foe?  
 
The aim of this chapter is to provide a review of the current evidence on the association 
between dairy intake and CVD risk and present evidence of the impact of fat modified dairy 
products on risk factors of cardiovascular disease. 
Elements from this chapter have been previously published in the following invited review 
(Appendix I) and may appear word for word in the present chapter:  
Markey O, Vasilopoulou D, Givens DI & Lovegrove JA (2014) Dairy and cardiovascular risk: 
friend or foe? Nutrition Bulletin 39; 161-171. 
DV and OM are co-authors of the published review, which was approved by all authors. 
DV expanded on elements of the review presented in this thesis, by including updated data 
and expanding on methodologies relevant to the intervention trial. 
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1.1 Introduction to cardiovascular disease risk 
 
Cardiovascular diseases (CVD) are ranked as the leading causes of death in the UK 
and worldwide, with a number of modifiable and non-modifiable risk factors (1). Considered 
an umbrella term for a group of diseases related to perturbation of blood vessels and heart 
function, conditions include coronary heart disease (CHD), stroke, peripheral artery disease, 
heart attack and pulmonary embolisms (1). In the UK, CVD accounts for 26% of all deaths 
(2). Annual mortality rates have declined in the UK between 1980 and 2015, mainly due to 
lifestyle and dietary changes and better access to treatment (2). Mortality rates within Europe 
vary substantially between countries, with higher figures observed in Eastern Europe, 
attributed predominantly to an increased total energy and fat consumption and a higher 
smoking prevalence (1). The global prevalence of CVD is anticipated to increase and is 
expected to be responsible for over 23 million deaths by 2030, in part due to demographic 
changes with higher obesity rates and an ageing population (3). The financial burden of CVD 
within the European Union (EU) reached an annual cost of €210 billion in 2015, in both direct 
and indirect costs, with the cost per person in the UK exceeding the EU average (4, 5).  
The development and progression of CVD is associated with a number of modifiable 
and non-modifiable risk factors. Modifiable risk factors include physical inactivity, high 
blood pressure, dyslipidaemia (i.e. elevated total and low-density lipoprotein-cholesterol 
(LDL-C) and triacylglycerols (TAG)) and being overweight/obese. Hypertension represents 
the greatest risk factor associated with the development of CHD and stroke in particular (6). 
Dietary risks also account for the greatest loss of global disability-adjusted life years (DALY) 
for disease risk factors, according to more recent data (7). CVD is one of the main 
contributors to lost DALY and an atherogenic diet represents a leading risk factor for CVD (7, 
8). Therefore, on a population level, it remains important to develop effective dietary 
strategies aimed at reducing risk factors associated with CVD development and progression.  
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It is well established that a high intake of total dietary saturated fatty acids (SFA) and trans 
fatty acids (TFA) leads to a higher risk of CVD, an effect linked to an increased plasma 
concentration of fasting LDL-C (9). Current dietary guidelines recommend aiming for a 
population average intake of <10% of total energy intake from SFA and 2% of total enegery 
intake total TFA (10). At present, this target is exceeded by the UK adult population (men and 
women), with the most recent UK National Diet and Nutrition Survey (NDNS) reporting a 
mean population SFA intake of >12% of total energy intake (10). Intakes of total TFA in the 
UK do not exceed dietary recommendations and are estimated at 1.2-1.3% on average (10). 
Data from the current rolling UK NDNS on SFA intake, which show consistently higher 
intakes across all age groups, are summarised in Table 1.1. 
14 
 
Table 1.1 Average intake of saturated fatty acids in absolute terms and as percentages of food and total energy, by age and gender (NDNS 2012/13 – 
2012/14) 
                          
  Boys/Men  Girls/Women 
             
    11-18 years   19-64 years   ≥65 years   11-18 years   19-64 years   ≥65 years 
             
SFA (g/day)  27.1 ± 10.5  28.4 ± 11.2  25.6 ± 9.6  23.0 ± 8.8  22.1 ± 9.6  22.1 ± 8.3 
             
% food energy  12.5 ± 2.7  12.7 ± 2.9  13.2 ± 3.2  12.7 ± 2.6  12.7 ± 3.6  13.7 ± 3.4 
             
% total energy  12.5 ± 2.7  12.0 ± 3.0  13.2± 3.2  12.6 ± 2.6  12.3 ± 3.5  13.3 ± 3.2 
                          
             
Values are mean ± SD. NDNS, National Diet and Nutrition Survey. SFA, saturated fatty acids. 
Adapted from Bates et al. (10) 
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1.2 The process of atherosclerosis 
 
Atherosclerosis, which initiates in the sub-endothelial arterial space (intima) at regions 
of disturbed blood flow, is triggered by interplays of both endothelial dysfunction and sub-
endothelial lipid retention (11). Vascular endothelial cells comprise a dynamic lining of the 
vascular system, responding to both mechanical and humoral stimuli to maintain vascular 
homeostasis (11). The endothelium is the major regulator of vascular wall homeostasis, 
whereby a balanced vascular tone and low levels of oxidative stress is maintained by the 
release of mediators, such as nitric oxide (NO), prostacyclin (PGI2) and endothelin (ET-1) 
and control of local angiotensin-II activity (11). Vascular permeability to plasma constituents, 
platelet and leukocyte adhesion and aggregation is also regulated by the endothelium (11, 12). 
Therefore, endothelial dysfunction is characterised by progressive dysregulation of vascular 
wall homeostasis. Increases in the expression of adhesion molecules, synthesis of pro-
inflammatory and pro-thrombotic factors, oxidative stress and an abnormal modulation of 
vascular tone are all factors which progressively lead to impaired endothelium-dependent 
vasodilation (11). 
Lipoproteins, responsible for the transport of fat within the bloodstream, are divided 
into five major classes based on their relative density: chylomicrons, very low-density 
lipoproteins (VLDLs), intermediate-density lipoprotein (IDLs), LDLs and high-density 
lipoproteins (HDLs) (13). Apolipoproteins (apo), proteins bound to the surface of 
lipoproteins, function as regulators of lipoprotein metabolism (13). They comprise a large 
class of proteins (grouped by function into A, B, C and E). The present thesis will present data 
on two classes, relevant to the dietary intervention study: a) apoB, which is recognised by 
cell-surface receptors that mediate endocytosis (13). Hepatic derived apoB-100 on VLDL, 
IDL and LDL functions as a ligand for LDL receptors (13). ApoB-48, synthesized  by the 
small intestine, is present on chylomicrons and their remnants and is essential for the 
intestinal absorption of dietary fats (14). As LDL particles are derived from the lipolysis of 
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TAGs in VLDLs, the rate of VLDL production and lipolysis of VLDL TAGs influences 
circulating levels of LDL-C (15). Most circulating LDL particles are taken up by the liver, via 
LDL receptors (15). In the liver, LDL receptor expression is regulated by hepatocyte 
cholesterol concentrations (15). However, low LDL receptor activity reduces the rate of LDL 
clearance, which results in prolonged LDL residence in the circulation (15). Consequently, the 
retention of circulating LDL particles and other apoB-containing lipoproteins (such as 
lipoprotein(a)) and remnants undergo modifications, including aggregation, oxidation and 
lipolysis in arterial vessel walls (15). Moreover, the progression of atherosclerosis is also 
influenced by the fed state and particularly following a fat-rich meal, the clearance of 
chylomicrons and their remnants.  
Over time, the sub-endothelial retention of apoB-containing lipoproteins, VLDL-C 
and chylomicron remnants in arterial regions where laminar flow is disturbed by branch 
points or arterial bends leads,  leads to endothelial dysfunction, pathogenic risk factors and 
ultimately atherosclerosis (11). Retained lipoproteins within the arterial wall likely trigger 
low-grade inflammatory responses, which will be discussed further below. Additionally, b) 
apoE (apoE2, -E3 and -E4) plays a critical role in the clearance of VLDL and chylomicron 
remnants from the circulation (13, 16). ApoE is primarily recognised as a regulator of lipid 
levels, playing a role in the homeostatic control of both circulating and tissue lipid content in 
part by binding to high affinity cell-surface lipoprotein receptors (17). The apoE isoforms 
differ in their ability to interact with apoE-containing lipoproteins and lipid complexes to the 
LDL receptor, the LDL-receptor related protein, the VLDL receptor and the apoE-receptor-2 
(17). Additionally, apoE also binds to cell surface heparan sulfate proteoglycans (HSPGs) in 
accordance to differences in the binding affinity of apoE isoforms. The interaction with 
HSPGs attracts and sequesters apo-E containing lipoproteins at cell surfaces, thereby 
facilitating their interaction with the LDL receptor related protein and potentially other 
receptors (16). As atherosclerosis is recognised as a major cause of CVD, low-grade 
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inflammation plays a central role in the development of atherosclerosis and will be discussed 
further below. 
1.3 Dietary fatty acids and CVD risk 
 
Recent meta-analyses of prospective studies (18-20) have questioned whether high 
SFA intake is always a risk factor for CVD. It is also important to recognise that although 
there is strong consistent evidence linking high dietary SFA consumption to an increased risk 
of CVD events, this relationship is complex and influenced by multiple contributing factors 
(21). Among these, but not limited to, are structural variations such as chain length, which 
impact absorption and transport, the inter-individual variability to dietary fat response and the 
overall dietary pattern and food matrix in which SFAs are consumed (22). Additionally, in the 
case of dietary SFA, where the aim is to reduce total intake, it is imperative to consider the 
optimal food or nutrient replacement which would lead to a reduction in CVD risk (23, 24). 
The most significant reduction in CHD risk has been observed when dietary SFA are replaced 
with cis-polyunsaturated fatty acids (cis-PUFA), however little effect was seen on risk of 
stroke (24). Collectively, the evidence from randomized controlled trials (RCT) showed that a 
replacement of 10% and 5% of energy from SFA by cis-PUFA led to a reduction of CVD 
event by 27% and 10% respectively (24, 25). Two classes of PUFA, n-3 and n-6, have been 
widely studied for their impact on CVD risk. In the context of SFA replacement, mixed PUFA 
(n-3 + n-6) reduces CVD risk by improving the lipid profile (26). However, studies have also 
shown that high intakes of n-6 PUFA alone may increase oxidation susceptibility of LDL-C 
(27). This highlights the importance of an adequate n-6/n-3 ratio in the diet in contrast to 
individual nutrients. Replacement of SFA with n-6 PUFA reduces the risk of CVD events and 
mortality, as observed by a meta-analysis of prospective cohort studies, where a 2% energy 
replacement from SFA with n-6 PUFA was associated with an 11% reduced risk of CVD 
mortality and a 7% reduced risk of total mortality (28). However, the food source of SFA 
replacement also needs to be considered. In particular, secondary analysis of the Sydney Diet 
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Heart Study (1966-1973) which investigated the replacement of SFA with linoleic acid 
explained the original divergent results. The study recruited participants who had suffered an 
acute coronary event and were randomly allocated to either a high n-6 PUFA, low SFA diet 
(PUFA 15% and SFA <10% total calories) or a control group. The participants in the high n-6 
PUFA diet had higher rates of all-cause, CHD and CVD death following the 3 year 
intervention (29). These observations were explained by the TFA present in the primary 
source of linoleic acid (stick margarines). (29). Fewer large scale studies have extensively 
reviewed the replacement of SFA with n-3 PUFA, as these are found in smaller amounts in 
dietary sources and usually represent a small proportion of overall dietary fat intake. 
However, analysis of the Nurses’ Health Study and Health Professionals Follow-up Study 
observed a 5% reduction in all-cause mortality, but not CVD mortality, following a 
replacement of 0.3% of energy from SFA with n-3 PUFA (28). Intake of n-3 PUFA has been 
observed to decrease TAG and VLDL-C concentrations (by controlling TAG uptake and 
synthesis in the liver), apoB production and may moderately elevate HDL-C concentrations 
(30). Additionally, n-3 PUFA may also confer beneficial effects on blood pressure, by 
promoting NO production and consequently vasodilation and decreasing the expression of 
pro-inflammatory markers, such as adhesion molecules (30). As previously mentioned, the 
beneficial impact of n-6 PUFA largely depends on the n-6/n-3 ratio, as excess n-6 PUFA 
intake have been associated with pro-inflammatory and oxidative effects, thereby adversely 
impacting on CVD risk by affecting vascular function (27).  
In the case of cis-monounsaturated fatty acids (cis-MUFA), recent reviews report that 
there is still insufficient data to draw definite conclusions (23, 24). A meta-analysis of long 
term studies (>6 months) which compared high cis-MUFA diets (>12% total calories) to 
lower cis-MUFA diets (<12% total calories), concluded that high cis-MUFA diets were 
associated with lower systolic and diastolic blood pressure and lower fat mass (31). 
Additionally, a recent RCT which compared diets high in cis-PUFA with diets high in cis-
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MUFA observed that the latter led to a reduction in abdominal obesity (mainly in men) and 
concomitant reductions in diastolic blood pressure and serum TAGs (32). When considering 
replacing SFA with cis-MUFA, a meta-analysis of RCTs concluded that specific risk 
biomarkers of CVD were reduced (total cholesterol, LDL-C and TAGs) (33). However, the 
effect on CVD, CVD mortality and all-cause mortality following a replacement of SFA with 
cis-MUFA shows mixed results (23). An explanation for these findings may be that dietary 
sources of fatty acids vary among different studies, making it difficult to draw definite 
conclusions (23). The observed beneficial impact of MUFA on CVD risk may be in part 
explained by an improvement in insulin sensitivity (30), however this mechanisms has not 
been fully explored in dietary replacement studies. Lastly, there appears to be no clear 
beneficial evidence of substituting carbohydrates (CHO) for SFA in the prevention of CVD 
(23, 34, 35). This may be explained by the fact that only CHO from fibre rich wholegrains 
appear to confer a modest beneficial impact, while sources of refined CHO do not (23). 
Furthermore, the Cochrane meta-analysis of Hooper et al. (35), identified that a reduction of 
dietary SFA intake with a concomitant replacement by unsaturated fatty acids, and/or 
reduction of total fat, lowered the risk of CVD events by 14% (relative risk (RR) 0.86; 95% 
confidence interval (CI) 0.77-0.96) but had no effect on CVD or total mortality (23).  
The evidence to date suggests that a replacement of SFA with cis-PUFA (with an 
appropriate n-6/n-3 ratio) and cis-MUFA may lead to a beneficial impact on CVD risk. 
Evidence suggests that the beneficial impact on CVD risk of these unsaturated FA, compared 
to SFA, may be explained through reductions of TC, LDL-C, apoB, TAG and pro-
inflammatory markers with a parallel increase in HDL-C and production of NO, among other 
factors. However, the evidence is not conclusive as observed beneficial impact on risk 
markers following SFA replacement with UFAs are dependent on a number of factors, 
including the replacement foods within the diet rather than just single nutrients. These factors 
raise important questions when considering milk and dairy products (including butter), which 
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represent up to 35% of the average total dietary SFA intake in the UK (10). A reduction or 
substitution with low-fat dairy counterparts has been a strategy traditionally implemented to 
reduce CVD risk at a population level; however, the bulk of the evidence from both 
prospective cohort studies and RCTs does not support an association between dairy food 
intake and an increased risk of CVD, with the exception of butter (36). The case of butter 
intake and CVD risk however still remains a matter of debate, as a recent systematic review 
and meta-analysis of prospective observational  studies observed a small positive association 
between butter consumption and all-cause mortality (n =  9 country-specific cohorts as 14 g 
per day: RR = 1.01, 95% CI = 1.00, 1.03, P = 0.045) but no association with incident CVD (n 
= 4; RR = 1.00, 95% CI =  0.98, 1.02, P = 0.704) or CVD subtypes (for CHD, n = 3; RR = 
0.99, 95% CI = 0.96, 1.03; P = 0.537; for stroke n = 3; RR = 1.01, 95% CI = 0.98, 1.03; P = 
0.737) (37). However, as the authors also highlight, substitution of butter for healthier fats, 
such as olive oil, would lead to a greater reduction in CVD risk. 
 
1.4 The consumption of milk and dairy products in the UK 
 
1.4.1 Changing trends in UK dairy consumption 
 
Dairy product consumption in the UK has changed markedly over recent years, a 
trend which may be in part attributed to negative connotations surrounding dairy products 
and SFA content, especially whole fat versions, and a parallel increase in the availability 
of alternative products. According to the Family Food Survey published by the 
Department of Environment, Food and Rural Affairs (DEFRA (38)), average 
consumption of milk is about 1.5 litres per person per week, the majority of which is 
consumed as semi-skimmed milk (70%), followed by whole milk (20%) and skimmed 
milk (10%). Since 2003, there has been an almost 14% decline in consumption of total 
milk, with whole milk consumption declining by an average of 50% (38). Cheese and 
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cream consumption trends have remained fairly constant in recent years while 
consumption of yogurt and fromage frais has steadily increased compared with intakes in 
1970, reaching 200 ml per person per week in 2013 (38). In contrast, butter consumption 
has markedly decreased since the 1970s by approximately 70% and is now estimated at 
42 g per person per week (38). The average contribution of daily total SFA and TFA 
intake from milk and specific dairy products for both children and adults is presented in 
Table 1.2. 
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Table 1.2 Percentage contribution of dairy products to average daily saturated and trans fatty acid intake, by age (NDNS 2012/13 – 2012/14).  
                          
 total SFA contribution (%)   total TFA contribution (%) 
  1.5-3 yrs 4-10 yrs 11-18 yrs   19-64 yrs ≥65 yrs   1.5-3 yrs 4-10 yrs 11-18 yrs 19-64 yrs ≥65 yrs 
              
Milk and milk products   48 31 22  22 24  55 42 32 31 32 
    of which:             
    Whole milk (3.8% fat) 21 8 3  2 2  19 7 3 2 2 
    Semi skimmed milk (1.8% fat) 5 5 4  4 6  9 10 7 7 9 
    Other milk and cream 4 2 2  2 2  2 3 2 2 2 
Cheese 9 8 8  10 9  15 14 14 16 15 
     Cheddar cheese 6 5 6  7 6  9 9 10 11 10 
     Other cheese 3 3 2  3 3  6 5 4 5 4 
Yoghurt, fromage frais  6 3 2  2 2  7 5 3 2 2 
 and other dairy desserts             
Ice cream 3 4 3  2 2  3 3 3 1 2 
Fat spreads 7 9 8  10 14  6 7 7 9 12 
    of which:             
    Butter 3 4 4   6 8   5 6 5 7 10 
             
Values are average percentages. Abbreviations: NDNS, National Diet and Nutrition Survey; SFA, saturated fatty acids; TFA, trans fatty acids; yrs, 
years. 
Adapted from Bates et al. (10) 
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1.4.2 Potential benefits of milk and dairy consumption 
 
Ruminant derived milk and dairy products are regarded as complex foods, containing a 
number of different components. It remains a matter of debate as to whether nutrients within 
dairy foods act independently or synergistically in relation to chronic disease risk, leading to the 
suggestion that the association of dairy SFA with CVD may be dependent on other 
nutrients/macronutrients present within the dairy matrix (39). Despite the heterogeneity of dairy 
products in terms of nutrient content and physical structures, the components that have been 
observed to have an impact on health are the numerous classes of fatty acids, proteins (casein 
and whey), minerals (magnesium, phosphate and calcium) and the components of the milk fat 
globule membrane (MFGM) (21). Table 1.3 provides an overview of the average nutritional 
composition of three dairy products, relevant to the present thesis. Additionally, the bacteria 
present in fermented dairy products, such as yogurt and cheese, may produce bioactive peptides 
and short-chain fatty acids (SCFAs) and may lead to improvements in insulin sensitivity and a 
reduction in inflammation through microbiome and vitamin K related pathways (21). Moreover, 
mineral bioavailability is enhanced by the lack of inhibitors present in milk, including phytates 
and oxalates, and by the presence of lactose and certain amino acids that may promote mineral 
absorption (40). Furthermore, lipids present in dairy products mediate the delivery of essential 
fat-soluble vitamins (such as vitamins A and D), iodine and specific fatty acid classes, such as 
conjugated linoleic acids (CLA), may also have cardio-protective properties, although further 
studies are needed to confirm these associations (41). Therefore, although consumption of dairy 
products significantly contributes to total SFA intake at a population level, it is important to 
recognise that other dairy components also play a role in human health and development.
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Table 1.3 Average energy content and nutritional composition of milk (by percentage fat content), Cheddar cheese and butter (per 
100g). 
                    
 Milk (3.5% fat)  Milk (1.7% fat)  Milk (0.3% fat)  Cheddar Cheese   Butter 
          
Energy (MJ) 0.3  0.2  0.1  1.7  3 
Total fat (g) 3.5  1.7  0.3  35  81 
 SFA (g) 2.3  1.1  0.1  22  51 
 MUFA (g) 1.1  0.4  0.1  9  21 
 PUFA (g) 0.1  Trace  Trace  0.9  3 
 trans (g) 0.1  0.1  Trace  1.4  3.3 
Total protein (g) 3.3  3.6  3.6  25  1 
Lactose (g) 4.7  4.8  4.9  0.3  Trace 
Calcium (mg) 116  120  120  659  15 
Phosphorus (mg) 93  80  85  510  24 
Potassium (mg) 160  161  167  98  25 
Vitamin A  31  20  1  20  10 
(as μg retinol 
equivalent)                   
          
All nutrient values are expressed per 100 g of product and represent average values.  
Adapted from Roe et al (42)
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1.5 The impact of dairy product consumption on cardiovascular disease 
 
1.5.1 Evidence from prospective studies  
The relationship between milk and dairy product intake with different CVD events has 
been investigated in a number of studies. However, a large body of the evidence points 
towards either no relationship or an inverse association between consumption of dairy 
products and CVD risk. 
A meta-analysis of prospective cohort studies, which examined the associations 
between milk and dairy products with health and overall mortality, concluded that the 
available data gathered from fifteen studies indicated a potentially beneficial effect of milk 
and dairy product consumption on CVD risk (43). High milk and dairy product intake resulted 
in a relative risk (RR) of stroke and ischaemic heart disease (IHD) of 0.79 (95% CI 0.75, 
0.82) and 0.84 (95% CI 0.76, 0.93) respectively, relative to low consumption of milk and 
dairy products (43). In a second more extensive meta-analysis, the authors investigated the 
relationship between different types of dairy products with the incidence of vascular disease 
(44). A reduction in RR was observed in subjects with the highest dairy product consumption, 
relative to subjects with lowest dairy intakes: 0.87 (95% CI 0.77, 0.98) for all-cause deaths, 
0.79 for IHD (95% CI 0.68, 0.91) and 0.85 for stroke (95% CI 0.68, 0.91) (44). Furthermore, 
a dose response meta-analysis of seventeen prospective studies resulted in a marginally 
significant inverse association between milk intake and CVD events, although no significant 
association was reported with risk of stroke or CHD (45). In support of these observations, a 
meta-analysis conducted by Qin et al. also reported an inverse association between dairy 
product consumption and overall risk of CVD (nine studies; RR 0.88; 95% CI 0.81, 0.96) and 
stroke (twelve studies; RR 0.87, 95% CI 0.77, 0.99) (46). For specific dairy product, only 
cheese was inversely associated with risk of stroke (RR: 0.91, 95% CI 0.84, 0.98). However, 
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this meta-analysis also reported no association between dairy product consumption, analysed 
as low or high fat dairy, with CHD risk (46). Although it may be suggested that the inverse 
association observed for risk of stroke but not CHD for total dairy and cheese in particular 
may be in part due to the hypotensive effects of specific nutrients within the dairy matrix, the 
meta-analysis was limited due to a lack of dose-response analysis and the broad categorisation 
of the dairy products and outcome variables of the studies included (21). A further meta-
analysis investigated the association of dairy fat consumption with risk of CVD, CHD and 
stroke, using data from three large US cohorts (47). Dairy fat intake resulted in no significant 
association with risk of CVD, CHD and stroke (for a 5% increase in energy from dairy fat, 
RR 1.02; 95% CI 0.98, 1.05; RR 1.03; 95% CI 0.98, 1.09; RR 0.99; 95% CI 0.93, 1.05 
respectively). On the other hand, a 5% energy substitution of dairy fat with an equivalent 
energy intake of n-6 PUFA or vegetable fat led to a 24% (RR 0.76; 95% CI 0.71, 0.81) and 
10% (RR 0.90; 95% CI 0.87, 0.93) lower risk of CVD, respectively (47). In contrast, 
exchanging dairy fat with a 5% energy intake from animal fat was associated with a 6% 
increase in CVD risk (RR 1.06; 95% CI 1.02, 1.09). It is important to note that the origin of 
animal fat which was used as an energy replacement was not specified. Additionally, the food 
in which the dairy fat is contained is not considered, thereby any assessment of the dairy food 
matrix cannot be determined. Nevertheless, the study adds further evidence to confirm that 
dairy fat does not appear to be associated with an increased risk of stroke, CHD and CVD. 
Furthermore, it also highlights the importance of considering which macronutrient replacing 
SFA (or a high SFA food group) would lead to a substantial reduction in CVD risk. The most 
recent dose-response meta-analysis included 29 cohort studies and found no associations for 
total dairy (200 g/day) and milk (12 cohorts; 244 g/day) with all-cause mortality (RR 0.99; 
95% CI 0.96, 1.03; RR 1.00, 95% CI, 0.93, 1.07 respectively), CHD (12 cohorts, RR 0.99, 
95% CI, 0.96, 1.02; RR 1.01; 95% CI, 0.96, 1.06 respectively) and CVD risk (RR 0.97, 95% 
CI 0.91, 1.02; RR 1.01; 0.93, 1.10 respectively) (48). However, marginal inverse association 
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were observed between total fermented dairy (defined as cheese, yoghurt or sour milk; per 20 
g/day) with mortality (RR 0.98; 95% CI 0.97, 0.99) and CVD risk (RR 0.98; 95% CI 0.97, 
0.99) (48). More detailed analyses of individual fermented dairy products (cheese and 
yoghurt) led to a 2% lower risk of CVD for cheese (RR 0.98, 95% CI, 0.95, 1.00 per 10 
g/day) but not yoghurt (48). Although the authors indicate that there was a high degree of 
heterogeneity between the included studies of the meta-analysis, their observations add 
evidence to further examine the impact of specific dairy products on risk markers of CVD in 
well-designed RCTs. 
1.5.2 Cardiometabolic risk factors 
Dietary guidelines which focus on reducing CVD risk have traditionally aimed to limit 
the intake of foods and nutrients which raise fasting LDL-C concentrations, an important 
CVD risk factor (9). The Friedewald equation, first developed in 1972 (49), provides an 
adequate estimate of fasting LDL-C without the use of laborious and expensive 
ultracentrifugation techniques and is routinely used in population studies and RCTs. 
Additionally, it was demonstrated that the concentration of VLDL-C could be estimated by a 
ratio of TAG/2.2 (in mmol/l) (49) (REF), resulting in the following equation of LDL-C:  
LDL-C (mmol/L) = total cholesterol – HDL-C – (TAG/2.2) 
    It is worth noting that the equation assumes a constant ratio of TAG to cholesterol 
in VLDL particle, which may not always be the case for individuals with certain conditions 
such as dyslipidaemia and insulin resistance (50). Additionally, Friedewald’s equation for 
serum LDL-C represents the cholesterol present in all LDL particles, regardless of density and 
particle size. Measurement of LDL particle (LDL-P) number and distribution has been 
suggested as a more sensitive indicator than LDL-C when assessing CVD risk (50). It has 
been proposed that sdLDL-P are particularly atherogenic due to a number of reasons, 
including an increased susceptibility to oxidation, high sub-endothelial permeability, 
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decreased LDL receptor affinity and an increased interaction with food matrix components 
(51, 52). However, estimation of LDL-C using Friedewald’s equation remains an important 
biomarker and is more cost-effective and quick to assess in intervention trials than LDL-P 
size and distribution by nuclear magnetic resonance (NMR) or density gradient 
ultracentrifugation (53).  
As the it has been estimated that every 1% reduction in LDL-C translates to a 1-2% 
reduction in population CVD risk (9), this risk marker remains one of the most widely used to 
assess the impact of dietary fat replacement in intervention studies. Evidence from animal, 
human and in vitro studies suggest that SFA intake leads to inhibition of LDL-C receptor 
activity, enhancement of apoB production and therefore an elevation in TC, LDL-C and LDL-
C:HDL-C ratio which are all risk markers for CVD. On the other hand, MUFA intake may 
lead to a beneficial outcome in CVD risk via a number of suggested mechanisms. These 
include an alteration of the lipid/lipoprotein profile, for example inactivation of sterol 
regulatory element binding protein (SREBP), a transcriptor factor which regulates cholesterol 
synthesis, and increasing the expression of hepatic LDL receptor via stimulation of acyl-CoA 
cholesterol acyltransferase in the liver (54). Additionally, it has also been suggested that 
MUFA lead to a greater diet-induced thermogenesis and greater fat oxidation rates in 
comparison to SFA intake (55). Evidence suggests that total PUFA consumption leads to 
beneficial effect on TC:HDL-C, mainly by modulating a reduction in LDL-C concentrations 
and the apoB pool size (26). Potential mechanisms from animal studies include a 2 fold 
increased LDL fractional catabolic rate when compared to SFA intake (56) 
  In the case of dairy foods, low fat dairy products have been advocated as the 
preferred choice for consumers to limit high consumption of whole fat and total dairy 
products. At the same time, individual SFAs present in foods differentially affect blood lipids: 
elevated serum concentration of LDL-C are associated with intakes of lauric (12:0), myristic 
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(14:0) and palmitic (16:0) acids, whereas limited effects are observed with intake of stearic 
acid (18:0), which is poorly absorbed (9). A number of studies have shown that SFA intake 
from dairy foods may lead to increases in larger, rather than smaller, LDL particle size (57-
59), although the significance of this pattern and its relationship with CVD risk remains to be 
determined.   
A small number of RCTs have compared low- and high-fat dairy foods on LDL-C 
concentrations. Consumption of a high-fat dairy and Dietary Approaches to Stop 
Hypertension (DASH)-type diet did not lead to significant increases in LDL-C concentrations 
compared with the same diet with low-fat dairy in both men and women in a crossover RCT 
(60). On the other hand, the food matrix of dairy products may exert an effect on the change 
observed in LDL-C rather than dairy fat per se. A meta-analysis conducted by Goede et al. 
compared the effect of cheese and butter consumption on blood lipids in five RCTs. Serum 
LDL-C concentrations were significantly lower following intake of cheese, compared to 
butter consumption as observed from pooled data of four of the five RCTs (ΔLDL-C: 0.22 
mmol/L; 95% CI 0.29, 0.14 mmol/L) (61). Ultimately, although it appears that certain types 
of dairy products such as milk, cheese or yoghurt appear to have a relatively neutral effect on 
LDL-C, more robust evidence is needed to assess differences not only in specific dairy foods 
but also dairy fat content on LDL particle size and number.  
 SFA intake also increases HDL-C concentrations, leading to the suggestion that some 
SFAs have a neutral effect on the total cholesterol:HDL-C ratio and consequently on CVD 
risk (9, 62). Despite extensive evidence showing that low HDL-C concentrations are 
associated with a greater risk of CVD (63), there is still disparity on this association as serum 
HDL-C concentrations alone may not reflect the functionality and capacity of HDL to reduce 
risk (63).  Drouin-Chartier et al. reviewed the limited studies which have assessed the effect 
of dairy intake on circulating HDL concentrations, concluding that the evidence shows a 
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neutral effect although recognising that a knowledge gap remains as studies which assess the 
impact of HDL functionality are still needed (64).  
Hypertension 
Hypertension is also a key risk factor in the progression of CVD development, 
affecting up to 30% of adults in the UK (4). Defined as systolic blood pressure (SBP) ≥140 
mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg, it is influenced by a number of 
variables such as gene polymorphisms, diet, environmental determinants and interactions 
between these factors (65). It is recognized as a major risk factor for stroke, CHD and heart 
failure, among other conditions (65). The most common method for the measurement of blood 
pressure (BP) to assess heamodynamic stability, is with the use of a sphygmomanometer (66). 
However, this measurement has potential limitations in reproducibility partly due to the 
‘white-coat effect’ (67). A further, more reliable assessment is measurement of ambulatory 
BP over the course of 24h, considered a predictive measurement for CVD events, mortality 
and morbidity associated with hypertension (67). As previously mentioned, milk and dairy 
products are  a source of micronutrients (such as calcium, potassium, iodine) and protein 
(casein, whey and specific bioactive peptides), which may be associated with beneficial 
hypotensive effects in an independent or synergistic manner (68). A number of mechanisms 
by which dairy components may reduce BP have been proposed (69). The bioactive peptides 
present in whey and casein proteins have been observed to play a role in controlling BP by 
inhibiting the action of angiotensin-I-converting enzyme, resulting in vasodilation (70), by 
modulating the release of endothelin-1 by endothelial cells (71) and acting as opioid receptor 
ligands increasing nitric oxide products, which mediates arterial tone (68). Several studies 
have looked at this relationship, with the DASH study considered as one of the first which 
observed a beneficial association between dairy consumption and a reduction in BP (72). 
However, conclusions cannot be easily drawn from this study alone due to differences in 
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macronutrient composition of the diets in the original DASH trial (73). In a RCT which 
compared a DASH diet with high-fat dairy to one with low-fat dairy, Chiu et al. reported no 
significant effect on BP (60). Furthermore, a meta-analysis of 7 RCTs also concluded that 
there was no significant BP lowering effect of total dairy intake on both systolic and diastolic 
BP (74). In contrast, a meta-analysis of 7 cohort studies which assessed the dose-response 
association between milk intake and risk of hypertension, concluded that each increment of 
200 g/d of milk consumed was associated with a significant 4% reduction in the risk of 
hypertension (RR 0.96; CI 0.94, 0.98) (75). An important consideration is the potential impact 
of a threshold dependency mechanism, whereby benefit is conferred in those at low nutrient 
status (such as calcium), whereas in individuals with adequate baseline status, little effect is 
observed (76). Furthermore, as outlined in Drouin-Chartier et al., short-term RCTs suggest no 
significant effect on BP irrespective of type and fat content (with the exclusion of butter) 
while evidence from prospective cohort studies on total dairy, low-fat dairy and milk intake 
suggest an association towards a reduction in risk of hypertension (77). A suggested 
explanation for this discrepancy is that long term dairy intake may attenuate the increase in 
BP seen as a result of aging and weight gain, thereby reducing the risk of hypertension (77). 
This, and other suggested mechanisms, need to be further investigated.  
Vascular function and elasticity 
Dietary patterns may impact the elasticity and function of blood vessels (78). The 
endothelium, defined as the inner layer of cells of the vascular wall, is a key regulator in 
vascular homeostasis (79). As previously mentioned, NO is the main endothelium-derived 
vasodilator, produced from its precursor L-arginine via the enzymatic action of endothelial 
NO synthase (eNOS) (80). Disturbances in endothelial function, such as reduced vasodilation 
and activation of inflammatory pathways, progressively leads to the development of 
atherosclerosis (79, 81). Assessment of vascular dysfunction, which includes both endothelial 
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dysfunction and arterial stiffness, can be assessed in a number of ways (79). Flow-mediated 
dilatation (FMD), which measures the vasodilatory response of the brachial artery to an 
increase in blood flow-associated shear stress and carotid intima-media thickness, can be used 
to non-invasively assess the endothelial function and arterial structural changes, respectively 
(82). Is it considered as the ‘gold standard’ method to assess endothelial function, with some 
studies regarding FMD response a superior predictive assessment to traditional risk factors, 
including elevated cholesterol concentrations, in individuals with established CVD (83). Of 
note however is the extensive training required to properly conduct this measurement and 
assess response, which may be viewed as a limitation. A surrogate measurement, which is not 
operator dependent like FMD, is the assessment of the carotid intima thickness (cIMT), 
defined as the distance between the media-adventitia interface to the intima-lumen interface 
on the right and left common carotid artery (CCA) (84). It is considered an early marker of 
atherosclerosis (85). However, due to methodological variations and a limited number of short 
term intervention studies, it remains unclear whether cIMT progression can be considered a 
predictor of future vascular events (84, 85). Furthermore, change in the IMT of the carotid 
artery progresses over time and few studies have observed differences as a response to diet 
alone. The intake of total dietary SFA and TFA have been observed to be positively 
associated with cIMT. In particular, it has been shown that a 10 g/day increase in total SFA 
intake and a 1 g/day TFA intake resulted in a 0.03 mm greater cIMT value following 
multivariate adjustments (85, 86). To date few studies have investigated the effect of dairy 
product consumption in relation to changes in cIMT. A cross-sectional study examined high 
(> 100 g/day) and low (< 100 g/day) yoghurt consumption in elderly women (> 70 years) 
(87). It was observed that high consumption correlated with a 0.023 mm lower cIMT, 
compared to low consumption following baseline, dietary and lifetime adjustments (p < 
0.003; (87)). However, the same study concluded that total intake of dairy products, milk and 
cheese was not associated with change in cIMT (87).  
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Cardiovascular events and all-cause mortality are also independently predicted by 
carotid-femoral pulse wave velocity (PWV), regarded as the gold standard measurement to 
assess arterial distensibility and stiffness by applanation tonometry (88, 89). The use of this 
methods is relatively simple and non-invasive, and its principle is that the higher velocity of 
pulse waves measured between two sites translates to stiffer arteries (90). Additionally, PWV 
may also be used as a measure of endothelial function (91), due to the fact that arterial 
compliance is in part determined by endothelium-dependent vasodilation (92). Moreover, the 
augmentation index (AIx), an indirect measure of arterial stiffness, represents the ratio of the 
magnitude of the reflected pulse wave to the initial wave (93). Evidence from the Caerphilly 
Prospective Study highlighted that, with the exception of butter intake, dairy product 
consumption does not impact negatively on PWV (94). Furthermore, the AIx was 1.8% lower 
in men with the highest quartiles of dairy product intake (94). Similarly, findings from a 
cross-sectional study illustrated that dairy food intake was inversely correlated with PWV 
(95). However, cross-sectional studies present predictive limitations, whereby exposure and 
outcome are assessed simultaneously thereby negating a temporal relationship between the 
two (96).  
Inflammation 
A low-grade chronic inflammation and oxidative stress is recognised as a major factor 
contributing to the initial stages of atherosclerosis and disease progression (97, 98). The 
recruitment of leucocytes into the sub-endothelial arterial wall initiates a cascade of reactions, 
primarily mediated by inflammatory mediators (98). Specifically, the increased presence of 
chemokines and cytokines progressively leads towards atherosclerosis via four stages: a) 
increased development of chemokine production followed by expression of adhesion 
molecules (VCAM-1, ICAM-1) on the endothelium which stimulates further leucocyte 
recruitment; b) as a consequence, monocyte entry and differentiation into macrophages, 
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promoting ‘foam cell’ formation beneath a progressively dysfunctional endothelial lining; c) 
initiation of smooth muscle cell proliferation and 4) plaque instability and eventual rupture 
(12, 98). Of interest to the present thesis are inflammatory cytokines, which lead to the  
generation of endothelial adhesion molecules (such as P selectin and VCAM-1), which in turn 
may enter the circulation in soluble form (99). Additionally, from the initial stages of a pro-
inflammatory state, cytokines such as IL-6, IL-8 and TNFα may mediate the increased 
production of acute-phase reactants, such as C-reactive protein (99). Conversely, a healthy 
endothelium is characterized by a balanced concentration of vasoactive mediators, such as the 
potent vasodilator NO which, in response to disturbed blood flow within arteries and 
increased concentration of adhesion molecules, results in a suppressed of NO synthesis (97). 
It is well known that inflammatory processes are affected by dietary fatty acids, impacting on 
membrane and lipid raft composition and function (98). In the case of dietary SFA, there is 
some evidence for a pro-inflammatory effect through increases of fibrinogen and TNF-alpha, 
although most of the evidence is derived primarily from cross-sectional, animal and in vitro 
studies, with limited RCTs comparing SFA replacement and inflammation (98).  Several 
studies have investigated the effect of n-3 PUFA on inflammation. Overall, it appears that the 
anti-inflammatory properties of n-3 PUFA may in part be explained by their conversion to 
biologically active signaling molecules, such as eicosanoids which in turn may lead to 
suppression of inflammation (100). The evidence for cis-MUFA is less clear, although 
proposed mechanisms for a favourable effect on inflammation include a beneficial modulation 
on adhesion molecule production (100).  
Evidence from a review on dairy consumption and inflammatory biomarkers did not 
conclude an adverse association in both overweight and obese individuals, although the 
authors highlighted  that no definite conclusions could be drawn due to the heterogeneity of 
the studies (101). In a meta-analysis of six RCTs by Benatar et al., high dairy consumption 
was shown not to significantly impact on plasma CRP concentrations, compared with low 
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dairy consumption (74). Although there is some evidence supporting a beneficial association 
between dairy consumption and inflammation, the mechanisms involved to support a 
beneficial association between dairy intake and inflammation remain unclear and the limited 
studies available are either underpowered or compare different types of dairy products, 
making it difficult to draw definite conclusions (101).  
In order to monitor changes in inflammatory biomarkers following a dietary 
intervention, a few points need to be considered. Firstly, it is worth noting that in most cases a 
number of inflammatory biomarkers are measured in RCTs as there is no consensus as to 
which in particular realistically represent change in low-grade inflammation (102) in an acute 
or chronic setting (98, 103). One of the main concerns when interpreting observed data from 
intervention studies is that inflammatory biomarkers by themselves do not represent metabolic 
low-grade inflammation (98). Furthermore, a number of modifying factors (age, gender, 
genetics among others) affect the concentration of inflammatory biomarkers at any given 
time, meaning that in both healthy and at risk individuals there will be a wide variability in 
measurements (98). At the same time, measuring changes in the concentration of 
inflammatory biomarkers in response to a dietary challenge still provides useful information 
in relation to the study in question.  
Insulin resistance 
The increasing prevalence of type 2 diabetes (T2D) has also been a focus of tailoring 
dietary recommendations for at risk populations. Within the human body, insulin has a wide 
range of biological functions (104). It functions not only as a key regulator of metabolic 
energy storage and disposal in tissues, but also as an integral factor in the haemodynamic 
activities associated with increased blood flow and cardiac output, probably through increased 
NO production. In contrast, insulin resistance plays a key role in mediating cardio-metabolic 
disorders (105). Measurement of both glucose, insulin and non-esterified fatty acid (NEFA) 
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concentrations allows indices of insulin resistance, such as the homeostatic model assessment 
of insulin resistance (HOMA-IR) and the revised quantitative insulin sensitivity check index 
(rQUICKI) to be derived (106). Epidemiological evidence on dairy consumption and insulin 
resistance appears to indicate a potentially favourable effect (36). However, there is a need for 
suitably powered intervention studies to assess the impact of both dairy fat and specific dairy 
products on insulin sensitivity (64).  
Postprandial lipaemia  
An aspect which has not been extensively investigated in the context of dairy product 
intake, is the impact on the postprandial (fed) state,  where raised concentrations of TAG are 
considered an independent CVD risk factor (107). Standardized methodological protocols, 
using one or two test meal challenges, are used to investigate the impact on postprandial lipid, 
inflammatory and vascular biomarkers following the consumption of FA from different 
sources (108).  
It is well established that the amount and type of dietary fat influences the postprandial 
lipaemic response (108). Following meal consumption, the duration and magnitude of 
postprandial TAG response is in turn influenced by metabolic factors including: the rate of 
TAG secretion from both the intestine and liver; enzymatic activity related to the processing 
of TAG-rich lipoproteins (TRLs; chiefly lipoprotein lipase and hepatic lipase); and the TRL 
remnant clearance rate by receptor mediated processes (107). Additionally, as previously 
mentioned for low-grade inflammation, inter-individual variability affects postprandial TAG 
response to dietary intervention. As detailed in Jackson et al (107) several mechanisms have 
been proposed to explain the effect of TRLs on the vascular wall and how these related to 
CVD risk. Of interest is the impact of a delayed clearance of TRLs from the circulation on 
HDL and LDL metabolism, inflammation and vascular function. In particular, the delayed 
clearance of TRLs from the circulation leads to a remodelling of the lipid contents of LDL 
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and HDL, turning them into substrates for lipase action and leading to the formation of 
sdLDL and sdHDL particles, a process in neutral lipid exchange (107). The latter are quickly 
removed from blood circulation, resulting in decreased HDL-C concentrations (107). This 
results in sdLDL, which have a  lower binding affinity to the LDL-C receptor and remain 
present within the circulation for an extended period of time, increasing their infiltration rate 
into the arterial wall (107). It has been observed that elevated serum TAG (> 1.5 mmol/l) is 
associated with the  remodelling of LDL into sdLDL while in contrast, a reduction in 
concentration (< 1.5 mmol/l) redistributes LDL subclasses into larger particles (53).  
Taken together, the current existing evidence suggests that milk and certain dairy 
products have a neutral impact on lipid-related cardiometabolic risk factors, low-grade 
systemic inflammation and vascular function. There is consistent evidence that milk intake in 
particular appears to be associated with a lower risk of hypertension, although this may also 
be due to other factors such as dietary patterns. It therefore remains challenging to determine 
whether intake of specific dairy products may lead to a beneficial impact on outcome 
measures associated with CVD risk factors. Further long-term, well designed studies are 
needed to fully explore both dairy fat content and product type in relation to defined primary 
CVD risk outcomes and to determine the mechanisms involved. 
Genetic factors and CVD risk 
As has been mentioned, responsiveness to dietary fat replacement measured via 
defined risk markers of CVD presents a degree of inter- and intra-individual heterogeneity. It 
is therefore also of interest to examine non-modifiable risk factors, such as gene 
polymorphisms on the response to specific dietary interventions. A number of gene variants 
are associated with increased CVD risk and have been previously described (109, 110). Of 
interest to the present thesis is the APOE genotype, as it is a well-recognised regulator of 
lipoprotein metabolism and accounts for up to 7% variation in total and LDL cholesterol 
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(111). The polymorphic protein, which result in 6 APOE genotypes derived from three 
common alleles (ε2, ε3, ε4) (112). The ε4 allele is of interest as individuals carrying this allele 
present increased concentrations of total cholesterol, LDL-C, TAG and reduced HDL-C 
concentrations compared to the ε3 allele (111-115). Furthermore, as reported in a meta-
analysis, these increased biomarkers of CVD risk translated into a moderate association 
between ε4 and CAD mortality (OR 1.06, 95% CI 0.99 – 1.12) (112). Results from dietary 
interventions suggest that E4 carriers appear more sensitive to changes in total fat, SFA, 
dietary cholesterol and long chain n-3 PUFA intake compared to E3 carriers  (116-119). 
However, RCTs which have investigated dietary FA manipulation and APOE genotype have 
primarily focused on changes in fasted lipid concentrations with a small number of RCTs 
investigating the postprandial state(116, 119, 120). Thus, there is a need for future studies to 
examine the impact of APOE genotype following FA manipulation in the postprandial state 
and with both traditional and novel biomarkers of CVD risk.  
 
1.6 Altering the bovine diet to manipulate the fatty acid profile of milk 
 
Low-fat dairy consumption has been promoted as a healthier consumer choice, aimed 
at reducing total SFA intake from all food sources. Altering the fatty acid profile of milk 
offers an alternative strategy to lowering SFA intake from dairy products, while at the same 
time preserving the beneficial contributions to the human diet. Supplementation of the bovine 
feed is a strategy that has been widely explored, through inclusion of oilseeds or plant oils in 
forages, leading to partial replacement of SFA with cis-MUFA and, to a lesser extent, cis-
PUFA (121). Considering that the rumen is the primary site for microbial fermentation and fat 
metabolism, microbes transform dietary FAs via two main processes, lipolysis and 
biohydrogenation (122). In the case of biohydrogenation, unsaturated FA are isomerised and 
hydrogenated, with bacterial enzymes as catalysts, to produce a number of conjugated linoleic 
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acid (CLA) isomers and trans-MUFA, which collectively denote ruminant TFA (rTFA) (123). 
The fat in milk and dairy products of conventional dairy products typically contain 2-6% TFA 
(124, 125). Additionally, the predominant CLA isomers in milk and dairy products are cis-9, 
trans-11, followed by trans-10, cis-12-18:2 (126). 
There is strong evidence from both observational and controlled feeding studies that 
substitution of SFA or UFA for TFA detrimentally impact on CVD risk markers. The adverse 
effects of TFA are well established as their consumption raises LDL-C while reduce HDL-C 
and thereby raise the TC:HDL-C ratio (100). Additionally, TFA intake detrimentally affect 
endothelial function, promote low-grade inflammation and reduce the particle size of LDL-C 
and the concentrations of lipoprotein(a) (100, 127). However, the majority of studies have 
focused on the impact of iTFA (18:1t9, trans elaidic, being the most abundant in the diet) as 
these were commonly consumed in partially hydrogenated vegetable oils. However, the 
association between TFA and CVD remains inconclusive, with some studies showing a 
cardio-protective association of rTFA (128, 129) while others an overall detrimental effect 
regardless of TFA source (130). Considering that the latter was published in 2001 a more 
recent  a systematic review and meta-analysis was undertaken by Bendsen et al. (2011) in an 
attempt to resolve conflicting reports (131). They reported that the RR for high vs. low 
quintiles of total TFA intake (10 g to approximately 2.8 g/day) was 1.22 (95% CI: 1.08, 1.38) 
for CHD events and 1.24 (95% CI: 1.07, 1.43) for fatal CHD. rTFA intake (0.5-1.9 g/day) was 
not significantly associated with CHD risk (RR 0.92; 95% CI 0.76, 1.11) although neither was 
iTFA. There was however, a trend towards a positive association (RR 1.21; 95% CI 0.97, 
1.50, P = 0.09). The authors concluded that while iTFA is be positively related to CHD, rTFA 
is not, although the limited number of studies available prevented any firm conclusions 
concerning whether the source of TFA is important (131). Gebauer et al (132) compared the 
effects of the two predominant stereoisomers of rTFA (vaccenic acid, VA; 18:1t11) and iTFA 
(elaidic acid, 18:1t9) respectively, in addition to the most predominant CLA, c9, t11. The 
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diets of this RCT were designed to replace stearic acid with 0.1% of mixed isomers of TFA 
(control), ~3% VA, ~3% elaidic acid (iTFA diet) or 1% c9, t11 of total energy respectively 
consumed in a cross-over design over 24 days by a total of 106 healthy adults (132). The 
authors observed higher concentrations of TC, LDL-C, TAG, lipoprotein(a) and apoB 
following the VA diet and compared to the iTFA diet. Interestingly, HDL-C and apoAI 
concentrations were higher following the VA diet. However, both the VA and iTFA diets led 
to increases in TC, LDL-C, TC:HDL-C and apoB (2 – 6% change, P < 0.05) compared to the 
control diet. On the other hand, the CLA diet lowered fasted TAG (P < 0.01) and did not 
impact on the other lipoprotein risk markers (132). It is worth noting that VA may be the 
predominant rTFA, but is also present in partially hydrogenated vegetable oils, ranging from 
15% to 24% of total trans-18:1 isomers (132, 133). Further research is therefore needed to 
draw firm conclusion on the effect of VA on lipoprotein risk markers, by investigating and 
comparing their effect from different food sources.  
The current dietary intake of TFA in the UK (0.5-0.6% of food energy in adults; DH 
2016) is still below the recommended population maximum (2% of food energy intake (DH 
1991), with milk and milk products contributing to around 25% of this intake (DH 2016). 
Consequently, rTFA intake is not seen as a major cause of concern to CVD health at a 
population level (127). However, it has yet to be determined whether increasing rTFA intake, 
through manipulation of the fatty acid profile of milk and dairy products to reduce SFA 
content, impacts on CVD health (134). 
1.6.1 Impact of fatty acid modified dairy products on cardiovascular disease risk 
factors 
A limited number of studies have investigated the impact of modified feed-reduced 
SFA milk and milk products in healthy and hypercholesterolaemic populations when 
compared to commercially available whole milk dairy products (134). However, the studies 
performed to date have relied on changes in circulating blood lipid levels as predictors of 
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CVD risk and on butter as the main test food (134). Some selected data illustrate that, in 
comparison to conventional milk, cheese, butter and ice cream (70 g/100 g SFA, 28 g/100g 
cis-MUFA), TC and LDL-C were significantly lowered (-0.28 mmol/L, P < 0.001; -0.24 
mmol/L, P < 0.001 respectively) following a 3 week period of consuming matched fat-
modified dairy products (51 g/100 g SFA, 39 g/100g cis-MUFA) (135). It is important to 
note, that in this particular study the resulting changes in fasting TC and LDL-C between the 
two diets did not consider in their statistical analysis the baseline lipid concentrations of the 
participants.  
Additionally, studies have also looked at dairy products enriched with cis-9, trans-11 
CLA (c-9, t11 CLA) and vaccenic acid (trans-11 18:1; tVA), and assessed their impact on the 
blood lipid profile (136, 137). CLAs are of interest due to the potentially beneficial effect on 
lipid risk markers. However, data from RCTs following supplementation with CLAs have 
been inconsistent, which may be explained by methodological variations pertaining to 
different mixtures of CLA isomers and doses (136). One cross-over study investigated the 
impact of a 6-week intake of modified dairy products (UHT cheese, milk and butter) naturally 
enriched with cis-9, trans-11 CLA and vaccenic acid in healthy men (136, 137). The modified 
dairy products provided 1.42 c-9, t-11 CLA g/d and 4.71 tVA g/d compared to control 
products which provided 0.17 c-9, t-11 CLA g/d and 0.31 tVA g/d (136, 137). The c9, t11 
CLA and tVA content was increased in both plasma phosphatidylcholine, TAG, cholesteryl 
esters and peripheral mononuclear cells (136, 137). However, there were no significant 
changes in CVD risk markers as measured in lipid and inflammatory biomarkers, insulin 
resistance, LDL-P or the susceptibility of LDL to oxidation (137).  
The methodology of these studies differed considerably when accounting for the type 
of supplement in the bovine diet, the number of subjects and study design, making it difficult 
to directly compare data and drawing firm conclusions (134). This makes it challenging to 
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evaluate well-powered estimations of CVD risk based on the available data from these dairy 
fat manipulation studies. It is also clear that in dietary intervention studies, the use of a single 
risk marker to assess potential benefits following fat manipulation may not be sufficient. Yet 
there is considerable evidence to suggest that partial replacement of SFA in the diet with an 
appropriate UFA will beneficially impact on CVD risk. The manipulation of dairy FA is most 
successful when MUFA replaces SFA in dairy fat. Considering the beneficial or neutral effect 
of cis-MUFA within the diet on markers ofCVD risk, more evidence from RCTs is needed to 
fully understand the impact of FA-modified dairy products on both traditional and novel CVD 
risk markers. This knowledge gap will be addressed in the study presented in the present 
thesis, which aims to investigate dairy fat manipulation with the use of a wider range of CVD 
risk markers. The results of this investigation may add further knowledge both on 
recommendations for dietary SFA replacement with unsaturated dietary fats and the potential 
beneficial effects of including FA-modified dairy products as the food vehicle to partially 
replace SFA with cis-MUFA in the diet. 
1.7 Aims and objectives of the thesis  
 
The overarching hypothesis, aim and chapter specific objectives of this thesis are 
stated below, with each chapter-specific question, hypothesis and objective pertinent to this 
thesis summarised at the beginning of each chapter. Additionally, my input to the data 
collection, analysis, statistics and writing will be detailed at the beginning of each chapter.  
Hypothesis: Consumption of SFA-reduced, MUFA-enriched dairy products will beneficially 
impact markers of CVD risk in adults at moderate risk, compared to iso-energetic control 
dairy products with a FA profile typical of retail products. Additionally, in a subgroup of the 
study population retrospectively analysed for APOE SNP, the FA-modified dairy products 
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will beneficially impact on fasted and postprandial CVD risk markers in E4 carriers compared 
to E3/E3 participants. 
Aim: To determine the chronic and acute-within-chronic intake of SFA-reduced, MUFA-
enriched dairy products on established and novel CVD risk markers in an adult population 
with moderate CVD risk and compared to conventional retail dairy products. Moreover, to 
explore the potential impact of APOE genotype polymorphisms on outcome measures in both 
the fasted and postprandial setting. 
Objective 1: Assess the evidence to date of the effect of milk and dairy products on 
cardiometabolic health, with a particular focus on dairy fat composition (Chapter 1). 
Objective 2: Describe the implementation and compliance to the food-exchange model with 
data derived from analysis of 4 day weighed food diaries and phospholipid fatty acid analysis 
(Chapter 2). 
Objective 3: Determine in a randomized, double-blind controlled cross-over study the chronic 
impact of SFA-reduced, MUFA-enriched milk, cheese and butter on markers of 
cardiovascular risk in adults at moderate CVD risk (Chapter 3).  
Objective 4: Evaluate the impact of chronic consumption of SFA-reduced, MUFA-enriched 
dairy products on postprandial lipaemia, insulin resistance and inflammatory markers relative 
to conventional dairy products in a sub-cohort of the main chronic study (Chapter 4). 
Objective 5: Assess the impact of the APOE genotype on the responsiveness of the fasting and 
postprandial lipid responses to chronic dairy fat composition (Chapter 5). 
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Chapter II: Plasma Phospholipid Fatty Acid Profile Confirms 
Compliance to a Novel Saturated Fat-Reduced, Monounsaturated 
Fat-enriched Dairy Product Intervention in Adults at Moderate 
Cardiovascular Risk: a randomized controlled trial 
 
Oonagh Markey, Dafni Vasilopoulou, Kirsty E. Kliem, Albert Koulman, Colette C. Fagan, 
Keith Summerhill, Laura Y. Wang, Alistair S. Grandison, David J. Humphries, Susan Todd,  
Kim G. Jackson, David I. Givens,  and Julie A. Lovegrove  
Published in Nutrition Journal; 2017; 16:33 
JAL, DIG and KGJ: designed the human study; OM, JAL and KGJ: designed the food-exchange 
model; CCF, ASG, DJH and DIG: designed and produced the modified dairy products; OM 
and DV: conducted the research (hands-on conduct of the experiment and data collection); 
OM, DV, KEK and AK: analyzed data and performed statistical analysis; KEK, KS and LW: 
performed fatty acid analysis; ST: provided statistical advice; OM and DV: wrote 
the manuscript, which was modified by all co-authors; and JAL had primary responsibility for 
final content. All authors have read and approved the final manuscript. 
 
As this is the first chapter which will begin to describe the RESET intervention trial (Chapter 
II-VI) the following applies for all chapters: 
Chapter input: I had primary responsibility of entering participants’ diet diary data in DietPlan6 
for analysis and subsequent extraction and statistical analysis and contributed to writing 
pertinent sections. 
Throughout the intervention trial I shared responsibilities with Dr Oonagh Markey for the 
following: contacting, recruiting and screening potential participants who I then followed up 
during the timeframe of the trial; during study days I conducted vascular measurements, 
collected and processed blood samples, carried out the whole blood culture experiment, 
45 
 
supervised research students and assistants who assisted with the project in the laboratory. At 
the end of the human intervention trial I carried out most of the biochemical measures (ILAB 
with Dr O. Markey), Luminex assays, nitric oxide HPLC, analysis of cIMT. 
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2.1 Abstract  
 
Background: Dairy products are a major contributor to dietary SFA. Partial replacement of 
milk SFA with unsaturated fatty acids (FAs) is possible through oleic-acid rich supplementation 
of the dairy cow diet. To assess adherence to the intervention of SFA-reduced, MUFA-enriched 
dairy product consumption in the RESET (REplacement of SaturatEd fat in dairy on Total 
cholesterol) study using 4-d weighed dietary records, in addition to plasma phospholipid FA 
(PL-FA) status.  
Methods: In a randomised, controlled, crossover design, free-living UK participants identified 
as moderate risk for CVD (n = 54) were required to replace habitually consumed dairy foods 
(milk, cheese and butter), with study products with a FA profile typical of retail products 
(control) or SFA-reduced, MUFA-enriched profile (modified), for two 12-week periods, 
separated by an 8-week washout period. A flexible food-exchange model was used to 
implement each isoenergetic high-fat, high-dairy diet (38% of total energy intake (%TE) total 
fat): control (dietary target: 19%TE SFA; 11%TE MUFA) and modified (16%TE SFA; 14%TE 
MUFA).  
Results: Following the modified diet, there was a smaller increase in SFA (17.2%TE vs. 
19.1%TE; p < 0.001) and greater increase in MUFA intake (15.4%TE vs. 11.8%TE; p < 0.0001) 
when compared with the control. PL-FA analysis revealed lower total SFAs (p = 0.006), higher 
total cis-MUFAs and trans-MUFAs (both p < 0.0001) following the modified diet.  
Conclusion: The food-exchange model was successfully used to achieve RESET dietary targets 
by partial replacement of SFAs with MUFAs in dairy products, a finding reflected in the PL-
FA profile and indicative of objective dietary compliance.  
Trial registration: ClinicalTrials.gov Identifier: NCT02089035, date 05-01-2014. 
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2.2 Background 
 
Cardiovascular diseases (CVD) are one of the leading causes of mortality in the UK (138). As 
a result of the clear link between a high intake of SFAs and elevated LDL-cholesterol 
concentrations, dietary guidelines for CVD prevention advocate reducing SFA intake to ≤10% 
of total energy (%TE) (9, 139). Despite recommendations, the UK adult population still exceeds 
the target for dietary SFA intake, with a mean intake of 12.1%TE (140).  
Dairy products are major sources of dietary SFA and account for up to 35% of total UK 
SFA intake (140) and therefore reducing consumption of regular-fat dairy foods or replacing 
them with lower fat or fat-free alternatives is often advised (141, 142). However, prospective 
studies have not presented consistent evidence for an adverse link between higher consumption 
of milk and dairy products and increased risk of CVD, regardless of milk fat content (44, 143-
145). Furthermore, this rationalisation does not acknowledge the complex nature of the dairy 
food matrix, which may be fundamental to cardiovascular health (146). Dairy fat contains a 
complex mixture of fatty acids (FA) including SFAs, MUFAs, PUFAs, trans-fatty acids (TFAs) 
and branched-chain FAs (147, 148). Furthermore, milk is rich in micronutrients and bioactive 
peptides, which have been reported to exert cardio-protective effects (149, 150).  
While the findings of some recent epidemiological studies have challenged the traditional 
link between SFA and coronary heart disease risk, and mortality (20, 151, 152), it is important 
to consider the macronutrient that replaces energy from dietary SFA (20, 153). There is 
evidence from a randomized controlled trial (RCT) that replacement of SFA with PUFA had 
minimal effects on CHD mortality (29). However a more recent systematic review and meta-
analysis of RCT suggested that lowering SFA intake could reduce cardiovascular events by 
17%, with SFA replacement with PUFA estimated to reduce these events by 27% (154). Despite 
these apparent discrepancies, current US and EU public health dietary guidelines recommend 
reduction of SFA and replacement with PUFA and/or MUFA respectively (155, 156). In 
support of the latter review and dietary recommendations, a RCT illustrated that replacing SFA 
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with n-6 PUFA for 16-weeks induced a reduction in serum concentration of LDL-cholesterol 
(a major risk factor for CVD) by 13.6%, with a comparable reduction of 11.3% on replacement 
of SFA with MUFA (153).  
It is well documented that partial replacement of milk SFA with unsaturated FAs, 
predominantly in the form of MUFA, through supplementation of the dairy cow diet with plant 
oils or oil seeds is feasible (157-159). At a population level, this initiative could provide a 
sustainable means of reducing SFA in dairy products, whilst limiting the entry of SFA into the 
wider food chain. While limited evidence from human studies suggests that consumption of 
dairy products with a modified FA profile may beneficially impact on CVD risk, there has been 
a heavy reliance on fasting lipid biomarkers as sole predictors of risk (160). Further research is 
needed to elucidate whether FA-modified dairy product consumption has a differential effect 
on more novel risk markers, including endothelial function, arterial stiffness, systemic 
inflammation and ambulatory blood pressure, when compared with dairy products of typical 
milk FA composition (150, 160). 
The REplacement of SaturatEd fat in dairy on Total cholesterol (RESET) study was 
conducted to investigate the chronic and acute effects of two iso-energetic high-fat, high-dairy 
diets, which varied in FA composition, on traditional and novel cardiometabolic risk markers 
in free-living individuals. It is important to evaluate strategies employed for the achievement 
of dietary targets in controlled human intervention studies (161). The purpose of the current 
paper is to describe the RESET dietary exchange strategy that was developed to enable 
manipulation of the FA profile of the diet over two 12-week periods, through the use of SFA-
reduced, MUFA-enriched (modified) dairy products and matched control dairy foods with a FA 
profile typical of retail products for the chronic study. Although it is recognised that specific 
plasma FA levels can be indicative of dietary FA consumption, the composition of the plasma 
phospholipid FA (PL-FA) fraction is believed to be a good biomarker of FA intake over recent 
days to weeks and an objective indicator of dietary compliance (162-164). Thus, this paper aims 
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to report the chronic dietary intervention food-exchange model and the compliance to the FA-
modified and control dietary exchange periods using 4-d weighed dietary records, self-reported 
daily tick-sheets and PL-FA. 
2.3 Materials and methods 
 
2.3.1 Study participants and design 
The RESET study was a double-blinded, randomised, controlled, crossover designed trial 
registered at Clinicaltrials.Gov as: NCT02089035. The study was given a favourable ethical 
opinion for conduct by the University of Reading’s Research Ethics Committee (13/43) and 
was conducted according to the guidelines of the Declaration of Helsinki. All participants 
provided written informed consent prior to study entry.  
Men and women aged 25 – 70 years were recruited from the Berkshire area of the UK in 
three cohorts between February 2014 and April 2016. A modified Framingham risk prediction 
algorithm was employed to identify individuals with moderate CVD risk (164, 165). To meet 
inclusion criteria, participants were required to have ≥ 2 CVD risk points, a score that suggested 
a 50% greater risk of CVD development than the population mean (165). Briefly, this score was 
calculated based on the existence of single or multiple CVD risk factors, including elevated 
fasting total cholesterol, glucose, systolic/diastolic blood pressure, low HDL-cholesterol, 
overweight/obesity or a family history of myocardial infarction. Potential participants were also 
required to meet the following inclusion criteria: BMI 19-32 kg/m2; blood pressure <160/100 
mmHg; total cholesterol <8mmol/L; haemoglobin: >125 g/L for women and 135 g/L for men; 
normal liver and kidney function; not pregnant or lactating; no dietary supplementation; no 
lactose or dairy intolerances/allergies; not taking medication for hyperlipidaemia, hypertension, 
hypercoagulation or inflammatory conditions; no diagnosis of myocardial infarction, stroke or 
diabetes; participating in <20 min x 3 times/week of vigorous aerobic activity and not 
consuming excessive amounts of alcohol (men: <21 units/week; women: <14 units/week).  If 
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known not to interfere with study outcomes, participants continued to take their regular 
prescribed medication,without changes in dosage, for the duration of the study.  
2.3.2 Study foods 
The FA composition of the dairy products (including ruminant cis and TFAs), along with the 
methods for their production, will be described in detail elsewhere (166). Based on a similar 
feeding strategy, it was estimated that our bovine intervention would increase cis-MUFA in the 
milk from 20 to 30 g/100g FA, while reducing SFA from 70 to 55-60 g/100g FA (167). Briefly, 
the diet of recruited Holstein-Friesian cows was supplemented with approximately 1 kg high-
oleic sunflower oil (AAK Ltd., Hull, East Yorkshire, UK) per cow per day for a ≥ 28-d period 
to produce milk which had a portion of SFA replaced with MUFA. Subsequently, raw milk was 
used to produce SFA-reduced, MUFA-enriched (modified) ultra high temperature (UHT) milk, 
Cheddar cheese and butter. Raw milk, provided by Arla UK Plc (Taw Valley Creamery, North 
Tawton, UK), was used to produce control UHT milk. Control Cheddar cheese and butter, with 
a FA profile typical of retail products, were also supplied by Arla UK Plc (Taw Valley 
Creamery, North Tawton, UK). 
2.3.3 Dietary intervention 
The technique of minimization, controlling for gender, age, BMI and total cholesterol was used 
to randomly allocate participants to one of two groups in the study, with Group 1 being assigned 
to receive Diet A (Modified) and then Diet B (Control) during their first and second dietary 
intervention periods, respectively and vice-versa for Group 2 (168). In each group, participants 
completed two 12-week dietary intervention periods, separated by an 8-week washout period. 
One dietary intervention was an iso-energetic high-fat daily dietary exchange (dietary target: 
38 %TE total fat) which was achieved by replacing habitual dairy foods, cooking oil and snacks 
with SFA-reduced, MUFA-enriched UHT milk, Cheddar cheese and butter (modified). The 
second dietary intervention used matched products with a FA profile typical of retail products 
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(control). The dietary exchange periods were rich in dairy foods and were designed to give diets 
of equal fat content that varied in SFA and MUFA composition. The dietary target intake for 
total fat was 38 %TE in both diets, with specific dietary FA targets for the control (19 %TE 
SFA and 11 %TE MUFA ) and modified diets (16 %TE SFA and 14 %TE MUFA).  
Measurements of circulating total cholesterol, composed of LDL and HDL-cholesterol 
(primary outcome), and other established and novel CVD and cardiometabolic risk markers 
were assessed prior to and after each dietary intervention period (chronic study). This 
manuscript will present the 4-d weighed dietary records, tick-sheet records, anthropometric 
measures, and PL-FA analysis to assess dietary compliance. The other clinical outcome 
measures from the RESET study will be published elsewhere. 
2.3.4 Food-exchange model  
The RESET study food-exchange strategy for reducing SFA intake was designed based on a 
model adapted from both the Dietary Intervention and Vascular Function (DIVAS) study and 
the Reading, Imperial, Surrey, Cambridge, and Kings (RISCK) study (164, 169), which were 
based on the National Diet and Nutrition Survey (NDNS) for adults (aged 19 – 64 years) (170). 
The mean habitual energy, total fat, SFA, MUFA and PUFA intakes of participants from the 
RISCK study were used (169), with additional TFA data obtained from the DIVAS study (164), 
as these dietary data represented the intake of UK adults who were at increased or moderate 
CVD risk. Added oils, added fats (butter and spreads), milk, cheese as well as sweet and savoury 
snacks were identified as ‘exchangeable dietary fat’ sources which could be removed from the 
diet and replaced with study foods. The total contribution of these ‘exchangeable fat’ food 
groups to mean daily energy, fat and FA intake were estimated, based on mean population data 
from the 2000/2001 NDNS ‘percentage contribution of types of foods’ (Table 1). The total 
exchangeable fat was subtracted from the RISCK/DIVAS study habitual energy, total fat and 
FA intake to calculate non-modifiable fat intake. This was employed to form the backbone of 
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the food-exchange model, onto which the RESET study foods could be added to create two iso-
energetic dietary exchange periods of dairy products that varied in FA composition (Table 2).  
2.3.5 Implementation of intervention diets  
After completing baseline visits (i.e. at the beginning of each intervention period), participants 
were provided with 1:1 dietary advice on how to replace dietary fat sources in their habitual 
diets (e.g. added oils, milk, cheese, sweet and savoury snacks) with the study dairy foods. They 
were also given dietary guidelines and recipe suggestions to take home. Care was taken to 
ensure that no study visits were arranged during or immediately after the Christmas period (mid-
December to mid-January). Where it was not feasible to avoid holidays and business trips 
during intervention periods, participants were given instructions on how to travel with the study 
products. This was made more convenient by providing UHT milk that did not require 
refrigeration. Furthermore, participants were provided with frozen butter and were advised that 
they could keep butter in a frozen state during transit, with the use of ice packs. Products were 
provided in plain packaging and were only identifiable by a code (A or B), to ensure that 
participants and researchers remained blinded to the intervention arms.  
At the beginning of each intervention period, participants were given adequate study dairy 
foods for a 4-week period. They attended the Hugh Sinclair Unit of Human Nutrition for a food 
collection visit at weeks 4 and 8. During this visit, adherence to the dietary intervention was 
assessed by reviewing completed tick-sheet records and any issues were discussed and resolved. 
In addition, investigators recorded the participant’s weight and any changes ≥ ± 1 kg of baseline, 
were addressed through advice to alter snack, meat and/or carbohydrate intake. Participants 
were asked to maintain their habitual physical activity levels during each intervention period. 
At the end of the first intervention period, participants were asked to return unopened, leftover 
study products and were asked not to consume any leftover study products for the duration of 
the washout period. 
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Assessment of dietary intake. Participants received verbal and written instructions by the 
investigators for recording 4-d weighed dietary records approximately 2 week before the first 
study visit (week 0). Investigators also provided participants with examples of complete diaries, 
including how to record recipes, and digital scales for recording food intake. Exceptions for 
weighing included food consumed outside of the home. On these occasions, portion-size images 
were used to estimate consumed portions and subsequently quantified using published food 
portion tables (171). Participants completed diet diaries on four separate occasions (weeks 0, 
11, 19 and 31): habitual diet intake was represented from baseline diet diaries (weeks 0 and 19), 
while diaries completed during weeks 11 and 31 represented participant compliance to the 
intervention diets. Prior to visit 1, food intake was recorded on three weekdays and one weekend 
day. The same days were repeated for subsequent diaries. Assessment of completion of the 
diaries was undertaken by the investigators during study visits. If necessary, additional 
information was requested to facilitate precise data entry.  
Food diaries were analysed using the NDS Nutrient Database or McCance and 
Widdowson’s (MW7) nutrient databank contained within the nutrient analysis software 
Dietplan 7 (Forestfield Software Ltd.). The nutritional content of the control and modified dairy 
products are previously given in Kliem et al. (166). Energy and macronutrient content (Group 
1 nutritional analysis) was performed in duplicate by SGS UK Ltd. (Ealing, London, UK; ISO 
17025 accredited laboratory). Analysis of sodium, calcium, magnesium and phosphorus content 
was conducted in duplicate by inductively coupled plasma-optical emission spectrometry at 
Quaternary Scientific (QUEST, School of Archaeology, Geography and Environmental 
Science, University of Reading, Reading, UK). Extracted lipids from milk, cheese and butter 
samples were analysed in triplicate for FA composition using a GC-flame ionisation detection 
method (172). A conversion factor of 0.933 was used to estimate the proportion of FAs in the 
total fat content of each dairy product (173). Subsequently, the quantity of SFA, MUFA, TFA 
and PUFA were calculated per daily portion of each study dairy product (g/d). Nutrient 
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composition of the study products was entered manually in Dietplan. For the purpose of 
analysis, the mean daily intakes of energy and macronutrients were recorded and the %TE was 
calculated to adjust for energy intake (EI). Dietary fibre intake was defined using the AOAC 
method (174). 
2.3.6 Assessment of underestimation of energy intake 
Determination of possible underestimation of dietary EI was assessed for each participant. 
Basal metabolic rate, based on age, gender and body weight, was estimated using the Henry 
equation (175). A sedentary lifestyle was represented by a physical activity level score of 1.2 
(164, 176). The Goldberg lower 95% confidence limit was calculated as <1.132 using the CV 
recommended by Black  (n  = 51; 4 d) and was used to identify under-reporters of EI (176).  
2.3.7 Assessment of dietary compliance 
As outlined in Table 2, participants were required to consume the minimum daily portions of 
each of the following study products: 340 g/d milk, 45 g/d cheese and 21.5 or 25.1 g/d of control 
or modified butter, respectively; this ensured that the intervention diets were iso-energetic and 
contained equal quantities of dairy fat (38 %TE total fat; approx. 41 g/d). As a means of 
monitoring compliance with each study product type, participants were required to complete 
tick-sheet records on a daily basis throughout each 12-week dietary intervention period. 
Participants were given the option of marking the tick box if they had consumed the required 
portion size or could choose to record the actual weight of the product consumed. In order to 
calculate dietary compliance, one point was subtracted for each day that participants had not 
consumed a study product. These points were summed over each intervention period and were 
used to calculate percentage dietary compliance for each product type.  
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2.3.8 Assessment of anthropometrics 
Participants were requested to fast overnight for 12 h before each clinical visit, following 
consumption of a standardised low-fat evening meal (< 1.46 MJ; < 7 g total fat) and low-nitrate 
water (Buxton Mineral Water, Nestlé Waters, Buxton, UK). At weeks 0, 12, 20 and 32, fasted 
measurements of BMI and waist circumference were recorded. Height was measured to the 
nearest 0.1 cm using a wall-mounted stadiometer (screening visit only). BMI was calculated 
using the Tanita BC-418 digital scale (Tanita Europe), under normal settings (standard body 
type and -1 kg for clothing) with participants wearing light clothing. Waist circumference was 
measured by a trained investigator, in triplicate, halfway between the iliac crest and the lowest 
rib margin to the nearest 0.5 cm (164).  
2.3.9 Assessment of plasma phospholipid fatty acid status 
Fasting blood samples were collected into lithium heparin tubes for determination of PL-FA 
status prior to and after each 12-week intervention period (week 0, 12, 20, 32). Chilled samples 
were centrifuged at 3000 rpm (1700 g) for 15 min at 4°C and plasma stored at -80°C until 
subsequent extraction and analysis.  
Sequential multipurpose sampler systems (Gerstel GmbH & Co. KG, Mülheim an der 
Ruhr, Germany) were employed for automated sample preparation and derivatization of FAs 
from the phospholipid fraction at the MRC Human Nutrition Research, Cambridge, as 
previously described (177). The phospholipid fraction was isolated from plasma using solid 
phase extraction on Na2SO4 50 mg/NH2 100 mg SPE cartridges (BE Gerstel; Agilent 
Technologies) and the FAME were produced from the phospholipid fraction according to the 
method published by Burdge et al (178). The FAMEs were separated using a 30 m capillary 
column (HP-88; Agilent Technologies, Cheshire, UK) and detected using flame ionization. 
Conditions of the GC analysis were as follows: helium carrier 1.5 ml/min, initial oven 
temperature profile 120°C for 1 minute, then ramped to 170°C at 10°C/min, held for 6 minutes, 
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and finally raised to 210°C at a rate of 3°C/min and held for 1 minute. The injector temperature 
was maintained at 250°C and the detector temperature maintained at 300°C. A post-run period 
(235°C for 3.5 minutes at 2.5 ml/min) was used to eliminate possible interferences. The total 
run time was approximately 30 minutes. Results were expressed as molar percentage of total 
PL-FAs (mol%).  
2.3.10 Power calculation and statistical analyses  
A total number of 54 participants were required for the chronic study to have sufficient power 
to detect a significant change in the primary and key secondary outcome measures. The primary 
outcome (serum total cholesterol) was predicted to result in a ~0.3 mmol/L reduction with a 
population mean of 4.54 ± 0.5 mmol/L, with a power of 80% at P < 0.05, allowing for a 15 % 
dropout rate. The chronic study was also powered to detect a 1.5% inter-group difference in the 
key secondary outcome measure, endothelial-dependent flow-mediated dilatation, with a power 
of 80% at p < 0.05 (179). However, this paper is reporting on the food-exchange model and 
compliance to our high-fat, high-dairy interventions, which varied in FA composition.  
Weighed dietary records, anthropometrics and PL-FA were analyzed using mixed 
models. Change-from-baseline for each variable of interest were modelled. Fixed effects 
included in the model were baseline values of the assessed variable, period, treatment, age, 
gender and BMI. All data were checked for normality and log transformed, if necessary. 
Participants were included as a fixed effect. There were no effects of the period in the model 
for any outcome measure. 
Paired t-tests were used to assess differences in mean dietary compliance scores, as 
assessed by tick-sheet records, and underestimation of EI between the control and modified 
dietary interventions. For confirmation that our randomization approach was effective, 
differences in baseline characteristics between participants randomly assigned to the control 
and modified dietary intervention periods were assessed using independent t-tests and Chi-
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square tests for continuous and categorical variables, respectively. Statistical analyses were 
conducted using the SAS university edition statistical software (version 9.4; SAS Institute lnc., 
Cary, NC, USA). Results are presented as means and standard error of the mean (SEM). 
Differences were considered significant at p ≤ 0.01 to account for multiplicity. 
Orthogonal partial least squares discriminant analysis (PLS-DA) was applied to identify 
patterns between variables in our PL-FA dataset and summarised it by reducing the number of 
dimensions or components (180). Measured PL-FA concentrations of 36 individual FAs were 
subjected to orthogonal PLS-DA at: 1) baseline and 2) post-intervention using Metabolanalyst 
3.0 (181). The R2Y and Q2 values represented the goodness of fit and predictability of the 
models, respectively. Significance of the models were tested using 1000 permutations.  
2.4 Results 
 
Participant flow through the study is illustrated in Fig. 1. Of the 74 participants who were 
randomly assigned and commenced the study, 54 (31 males and 23 females) completed the 
study. Participants continued to take their regular prescribed medication for the duration of the 
study (n = 2 levothyroxine for hypothyroidism; n = 1 proton pump inhibitor for heartburn; n = 
1 hormone replacement therapy for menopausal symptom relief; n = 1 tricyclic antidepressant 
for depression; n = 2 fluticasone and salmeterol for mild asthma; n = 1 etonogestrel 
contraceptive implant and n = 1 levonorgestrel-releasing intrauterine contraceptive device). The 
breakdown of the ethnicity of the study group was as follows: White, 89% (n = 48);  Asian, 4% 
(n = 2); Black, 4% (n = 2) and Chinese/Far Eastern, 4% (n = 2). There were no significant 
differences between participants randomly assigned to Groups 1 and 2 at baseline (Additional 
file 1: Table S1). Two participants were excluded from the dietary analysis due to insufficient 
data.  
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2.4.1 Dietary analysis 
Recorded dietary intake at baseline and following diets that incorporated the control and 
modified dairy products (post-intervention) are shown in Table 3. In agreement with target 
intakes (Table 2), significant treatment effects were evident for dietary intakes of SFA and 
MUFA. Following introduction of the modified diet, there was a smaller increase in SFA and 
greater increase in MUFA and TFA, relative to baseline, when compared with the control.  
2.4.2 Underestimation of energy intake  
Based on the assumption that participants were in energy balance, it was estimated that recorded 
EI were underestimated for 35 and 22% of participants at baseline and post-intervention, 
respectively. Underestimation of EI was not considered further in the mixed model analysis. 
2.4.3 Dietary compliance 
On the basis of tick-sheet records, mean daily intake (± SEM) of the dairy products across each 
12-week dietary exchange was as follows: milk (control: 343.5 ± 1.8; modified: 347.8 ± 2.8 
g/d), cheese (control: 46.5 ± 0.6; modified: 45.9 ± 0.4 g/d) and butter (control: 22.0 ± 0.2; 
modified: 25.6 ± 0.3 g/d). Mean daily dietary compliance did not vary according to treatment: 
milk (control: 96.6 ± 0.01; modified: 96.5 ± 0.01%; p = 0.92), cheese (control: 96.6 ± 0.01; 
modified: 96.8 ± 0.01%; P = 0.83) and butter (control: 96.5 ± 0.01; modified: 97.0 ± 0.01%; p 
= 0.70).  
2.4.4 Anthropometric measures 
Relative to baseline, there was no significant treatment effect for BMI (control: 25.8 ± 0.5 vs. 
26.2 ± 0.5 kg/m2 for baseline vs. post-intervention; modified: 25.8 ± 0.5 vs. 25.9 ± 0.5 kg/m2; 
p = 0.13) or waist circumference (control: 88.9 ± 1.4 vs. 89.8 ± 1.5 cm; modified: 89.3 ± 1.5 
vs. 89.1 ± 1.5 cm; p = 0.53). 
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2.4.5 Plasma phospholipid FA status 
After the 12-week intervention, there were significant differences in PL-FA composition 
between the modified and control groups (p ≤ 0.01). Consumption of the modified dairy 
products led to a small but significant decrease in abundance of total SFAs from baseline 
(change: -0.60 ± 0.21 mol%) vs. control (change: 0.01 ± 0.17 mol%) (Table 4). Following the 
modified diet, there were significant increases in cis-MUFAs and trans-MUFAs from baseline 
vs. control (Table 4). There was a minor increase in the abundance of 16:0 from baseline 
following the control diet (change: 0.16 ± 0.13 mol%), while a decrease from baseline was 
evident following the modified diet (change: -0.46 ± 0.15 mol%) (Fig. 2.b). Compared with 
baseline, 18 : 1cis-9 and 18 : 1trans-9 increased following the modified diet vs. control (Fig. 
2.b). Following the control diet, there was a significant increase in 20 : 3n-6 vs. the modified 
diet. 
2.4.6 Orthogonal Partial Least Square Discriminant analysis of plasma phospholipid 
FA data 
For the baseline PLS-DA, the first component representing the maximum differentiation 
between the two diets represented 4.7% of variation and was retained to interpret the FA profiles 
of the clusters on the score plots. PLS-DA of the PL-FA data revealed a lack of distinction 
between the control and modified intervention groups at baseline (R2Y = 0.142 and Q2 = -0.35, 
empirical P-values R2Y: p = 0.99 (986/1000) and Q2: P = 0.76 (763/1000), suggesting that the 
population was indistinguishable with regard to PL-FA profiles prior to commencement of the 
dietary exchange periods (Fig. 3.a). Additional file 2: Table S2 illustrates the loadings.  
Following the intervention, the first component representing the maximum differentiation 
between the two diets represented 5.4 % of the variability in the data. The loadings are 
illustrated in Additional file 2: Table S2. In contrast to baseline, the post-intervention score plot 
identified a clear separation (R2Y=0.612 and Q2=0.451, empirical p-values R2Y: p < 0.001 
(0/1000) and Q2: p < 0.001 (0/1000) in PL-FA profiles of participants when they were assigned 
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to the modified and control intervention diets (Fig. 3.b). The FAs that mainly contributed to this 
dietary status separation were: 18 : 1trans-9, 16 : 1trans, 18 : 1cis-9, that were higher following 
the modified diet, while 16 : 0, 14 : 1 cis, 14 : 0, 15 : 0 and 20 : 3n-6 were higher following the 
control diet. 
2.5 Discussion 
 
The food-exchange model was used for the implementation of two iso-energetic high-fat, high-
dairy diets varying in FA composition in the RESET study, through the use of SFA-reduced, 
MUFA-enriched dairy products and control alternatives with a FA profile typical of retail dairy 
products. Specific dietary targets following treatments were largely achieved in a free-living 
population at moderate risk of CVD. Analysis of weighed dietary records confirmed that it was 
possible to lower the mean SFA intake by 2.5 %TE and increase MUFA intake by 3.7%TE 
following the diet containing modified dairy products compared with the control products. 
Previously, Noakes et al. reported differences of 2.2 %TE SFA and 2.8 %TE MUFA (described 
as oleic acid intake only) following consumption of dairy products that were produced 
following a protein-encapsulated lipid (rapeseed and soybean oil) bovine supplementation 
period, when compared to control dairy foods (135). There was a significant difference in 
recorded SFA intake between interventions in our study, however the reduction in SFA intake 
following the modified diet was slightly less than predicted by our food-exchange model. 
Compliance was further confirmed by assessment of dietary tick-sheet records.  
To our knowledge, this is the first human study to assess the impact of modified milk, 
cheese and butter consumption on PL-FA concentrations, in comparison to control dairy 
products with a FA profile typical of retail products. In line with previous findings (164, 182-
184), objective dietary compliance was confirmed by assessment of PL-FA profiles, with 
consumption of the control and modified dairy products leading to differential effects on total 
plasma phospholipid SFAs and MUFAs and their sub-classes. The consumption of the SFA-
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reduced, MUFA-enriched dairy products led to a small decrease in the abundance of total SFAs, 
and increases in total cis-MUFAs, including 18 : 1cis-9 in the PL-FA profile, when compared 
to the control products. These changes are comparable to the proportion of PL-FA total SFAs 
and MUFAs observed in the DIVAS study following a 16-week MUFA-rich diet (9 %TE SFA; 
19 %TE MUFA; 4 %TE n-6 PUFA) (164). Previous literature has suggested that SFAs and 
MUFAs with even numbered carbon chain length can be endogenously synthesised by humans 
and may be less affected by dietary intake (185). Hodson et al. suggested that this may be 
because it is difficult to alter the proportion of FAs that are already relatively abundant in the 
diet and that increases in SFA intake are not reflected in increases in the plasma FA profiles 
(163). However, changes in PL-FA concentrations observed in the RESET study mirrored the 
FA composition of our intervention dairy foods (166). PLS-DA provided a means for 
visualizing adherence to a dietary intervention. Despite using a relatively homogenous 
population and a modest dietary exchange, our PLS-DA plot highlighted some distinction 
between the PL-FA profile of the participants following the modified and control dietary 
exchange periods, suggesting a small but significant response to our intervention. This analysis 
only explained approximately 5 % of the overall variability in our dataset but the affected FAs,  
including 18 : 1trans-9 and 18 : 1cis-9 and 16 : 0, were relevant to our interevntions. 
Furthermore, it provided further evidence that PL-FA were illustrative of short to medium-term 
FA intake (162-164).  
 Supplementation of the dairy cow diet with unsaturated FA leads to increased levels of 
ruminant trans-fatty acids (rTFA) in the milk and dairy products, through ruminal 
biohydrogenation of unsaturated FA (150, 158, 160). There was a calculated dietary increase 
of 1.3 %TE in total TFA intake following the modified, when compared with the control diet. 
It was not possible to quantify our participants’ voluntary intake of specific TFA isomers (i.e. 
ruminant or industrial TFA intake) from weighed dietary records using our nutrient analysis 
software. However, based on the differences in TFA composition between our control and 
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modified dairy products (166), it is apparent that the majority of the increased TFA intake 
recorded following the modified diet was derived from ruminant sources. In contrast to the 
recognised detrimental impact of industrially-produced TFA on cardiovascular health, 
consumption of rTFA may not be adversely linked to CVD risk (186), except possibly at high 
intakes (132, 187). It should be noted that the calculated dietary TFA intake following our 
modified intervention (2.5 ± 0.1 %TE) exceeded the recommended population maximum of 2 
% food energy (139) which does not discriminate between ruminant and industrial sources, and 
is higher than the current mean TFA intake in UK adults (0.5 %TE and 0.5 % of food energy) 
(140). This may be in part explained by the high dairy fat content of our intervention diets. In 
support of this we also observed that consumption of the SFA-reduced, MUFA-enriched dairy 
products lead to significant increases in total trans-MUFA and 18:1 trans-9 concentrations in 
the PL-FA. Whilst our PL-FA analysis approach was unable to identify specific trans isomers 
other than 18:1 trans-9 (177), the detailed FA analysis of the dairy foods used in the RESET 
study (166) suggest there was likely to be a complex mixture of TFA in the phospholipid pool. 
It may be that feeding strategies that limit increases of TFA in milk fat following bovine 
supplementation with plant oils, such as the use of encapsulation protection technology may be 
advantageous (160, 188). However, further work is justified to determine whether rTFA are 
detrimental to cardiovascular health (160). 
Our intervention presented some challenges. As outlined previously, our bovine 
supplementation strategy was successful in altering the FA profile of the milk (166). Alongside 
this, we  observed a depression in milk fat content following supplementation of the bovine diet 
with high-oleic sunflower oil which has been reported previously (189). As a result of this, it 
was necessary to standardise the fat content of the raw control milk prior to UHT so that it was 
equivalent to that of the modified milk. Furthermore, our modified cheese had a lower fat 
content compared with conventional cheese and it was necessary for our participants to 
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consume an additional 3.6 g/d of butter during the modified dietary exchange period to 
standardize the fat intake of the two intervention periods.  
A challenge faced by some participants was incorporating sufficient quantities of 
products, especially cheese, into their habitual diets on a daily basis. In line with recent NDNS 
data (140), some of our participants were not accustomed to consuming the quantities of dairy 
products that were prescribed in our food-exchange model (unpublished data obtained by food 
frequency questionnaire). Although it was not logistically feasible for us to include a wider 
range of dairy products in the RESET study, it is possible that a greater variety of items may 
have reduced the likelihood of ‘product boredom’ and minimized the potential for compliance 
issues (190). Compliance with the dietary exchange was cited as the main reason for dropout 
by nine of our participants, predominantly in the early stages of the intervention. It should be 
noted that a similar number of participants withdrew from the modified and control dietary 
exchange periods, suggesting that the two regimens were equal in terms of acceptability. For 
those who completed the study, our tick-sheet records suggested that compliance to the dietary 
regimens was excellent and our PL-FA data provided further objective evidence of dietary 
adherence. It is acknowledged that there may have been discrepancies in tick-sheet recordings 
as a result of ‘desirability bias’, i.e. participants may have recorded the portions that they were 
required to eat as opposed to what they had actually consumed (190), and this may have led to 
more modest differences in PL-FA profiles between the two dietary exchange periods.  
We observed a moderately high amount of under-reporting assessed by EI at baseline, 
however, this was similar to that observed in previous free-living populations (164, 191). A 
high proportion of participants (61 %; n = 33) in the RESET study were classified as overweight 
(BMI of ≥ 25.0 kg/m2). It is recognized that overweight or obese individuals may be more prone 
to selective bias and omission of foods with a negative health image, leading to potential under-
reporting of dietary intake (192). We observed a lower degree of under-reporting following the 
intervention, when our replacement model predicted that the dairy products would contribute 
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to over 25 % of daily EI. It could be speculated that participants had a greater appreciation of 
the importance of giving an accurate account of their dietary intake whilst on the intervention. 
The present study has illustrated that through the incorporation of dairy products with an altered 
FA profile into the habitual diet, it was possible for free-living participants to successfully 
improve their dietary fat quality. This was in agreement with previous successful food-
exchange models (164, 169, 190). Our dietary interventions were designed to contain a high 
quantity of dairy fat (~ 41 g/d). Both intervention periods increased relative intake of total fat 
and SFA over baseline. However, it is feasible that a similar, but more moderate, approach 
could be used for assisting in the reduction of dairy SFA intake at a population level, without 
reducing dairy consumption. Furthermore, we have previously reported that consumers 
generally accepted the SFA-reduced, MUFA-enriched dairy products, when tasted in a blinded 
manner (193).  
2.6 Conclusions 
 
We sucessfully implemented a high-fat, high-dairy food-exchange model that was suitable for 
replacing dairy products with a FA profile typical of retail products with SFA-reduced, MUFA-
enriched alternatives over a 12-week period in a free-living population at moderate risk of CVD. 
Changes in the dietary intake of SFA and MUFA between our interventions was confirmed by 
changes in the concentrations of these FAs in the plasma phospholipid fraction, indicative of 
adherence to our dietary intervention. 
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Table 1 The RESET food-exchange modela 
  
Total 
energy Total fat SFA MUFA TFA PUFA 
 (MJ/d) (g/d) (g/d) (g/d) (g/d) (g/d) 
Total habitual intake (including alcohol)b 8.25 80.1 29.6 26.6 1.0 13.1 
Total habitual intake, %TE 
 
36.6 13.5 12.1 0.4 6.0 
Exchangeable fat intake 
      
Added oils, g/d 0.35 8.5 0.8 3.3 
 
4.0 
Added fats (butter and spreads), g/d 0.35 8.6 3.3 2.9 0.2 1.7 
Milk, g/d 0.45 4.0 2.4 1.0 0.0 0.3 
Cheese, g/d 0.25 4.5 2.8 1.0 0.1 0.1 
Sweet and savoury snacks, g/dc 0.87 10.0 4.4 3.4 0.1 0.6 
Total exchangeable fat intake, g/d 2.27 35.5 13.6 11.6 0.4 6.6 
Total exchangeable fat intake adjusted for habitual 
intake, g/d 2.22 38.5 14.4 12.5 0.4 7.3 
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Non-exchangeable fat intake, g/d 6.03 41.7 15.3 14.1 0.6 5.9 
TFA, trans-fatty acids; %TE, percentage of total energy. aAdapted from Weech et al. (164); bMean daily dietary intakes (total energy, total fat, SFA, 
MUFA and PUFA) from a population with increased cardiovascular disease risk (169). Mean daily dietary TFA intake from a population at moderate 
cardiovascular disease risk (164); cIncluded buns, cakes, pastries, potato chips and chocolate confectionary. 
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Table 2 Replacement model for diets containing control and modified dairy products for use in the RESET studya 
 
Quantity 
 
Total 
energy 
 
Total fat 
 
SFA 
 
MUFA   TFAb   PUFA 
  (g/d)   (MJ/d)   (g/d)   (g/d)   (g/d)   (g/d)   (g/d) 
              
Non-exchangeable fat intake 
  
6.03 
 
41.7 
 
15.3 
 
14.1 
 
0.5 
 
5.9 
Control dietary exchange 
             
   Exchangeable fat intakesc 
             
      Butter 21.5 
 
0.65 
 
17.4 
 
11.1 
 
4.5 
 
0.7 
 
0.6 
      Cheese 45.0 
 
0.76 
 
15.1 
 
10.2 
 
3.5 
 
0.5 
 
0.4 
      Milk 340.0 
 
0.75 
 
8.6 
 
5.7 
 
2.1 
 
0.3 
 
0.3 
Total intake 
  
8.19 
 
82.8 
 
42.3 
 
24.2 
 
2.0 
 
7.2 
Total intake, %TE 
    
38.1 
 
19.4 
 
11.1 
 
0.9 
 
3.3 
Target intake, %TE     38.0  19.0  11.0  0.9   
              
Modified dietary exchange 
             
73 
 
   Exchangeable fat intakes 
      Butter 25.1 
 
0.76 
 
20.4 
 
10.2 
 
8.1 
 
2.1 
 
0.7 
      Cheese 45.0 
 
0.69 
 
12.6 
 
6.3 
 
5.0 
 
1.4 
 
0.4 
      Milk 340 
 
0.79 
 
8.8 
 
4.4 
 
3.6 
 
0.9 
 
0.3 
Total intake 
  
8.27 
 
83.4 
 
36.0 
 
30.8 
 
4.9 
 
7.3 
Total intake, %TE 
    
38.0 
 
16.4 
 
14.0 
 
2.1 
 
3.3 
Target intake, %TE     38.0  16.0  14.0  2.0   
              
Mean difference between dietary exchange periods   -0.6   6.2   -6.7   -2.9   -0.2 
 
 
%TE, percentage of total energy. aTotal intake is the sum of exchangeable and non-exchangeable intakes based on MJ/d for energy and grams/d for FAs; 
bTotal TFA intake (%TE) is calculated based on recorded energy intake at baseline (MJ/d) in the DIVAS study (164); cEnergy and fat content of the 
dairy products is based on nutritional analysis conducted by SGS United Kingdom Ltd. (Ellesmere Port, Cheshire). The FA composition of dairy products 
was determined using a GC-flame ionisation detection method (172), with a conversion factor of 0.933 used to estimate the proportion of FAs in the total 
fat content of each product (173, 194).  
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Table 3 Recorded dietary intake at baseline (week 0) and following diets that incorporated the control and modified dairy products (week 12) in adults 
at moderate cardiovascular disease risk and target FA intakesa 
 
 Control  Modified 
 Baseline Post Tb Δ  Baseline Post T Δ pc 
Energy, MJ/d 8.5 ± 0.4 9.0 ± 0.3  0.5 ± 0.3  8.2 ± 0.3 9.2 ± 0.4  1.0 ± 0.4 0.60 
Total fat, 
%TE 
36.5 ± 0.8 39.5 ± 0.7 38.0 3.0 ± 0.9  36.1 ± 0.8 41.1 ± 0.8 38.0 5.0 ± 1.1 0.03 
SFA, %TE 13.9 ± 0.5 19.1 ± 0.4 19.0 5.2 ± 0.6  14.2 ± 0.5 16.9 ± 0.4 16.0 2.7 ± 0.6 <0.001 
MUFA, %TE 11.9 ± 0.4 11.8 ± 0.3 11.0 -0.1 ± 0.3  11.7 ± 0.4 15.3 ± 0.4 14.0 3.6 ± 0.5 <0.0001 
n-6 PUFA, 
%TE 
4.6 ± 0.2 3.3 ± 0.2  -1.3 ± 0.2  3.9 ± 0.2 3.4 ± 0.2  -0.5 ± 0.2 0.08 
n-3 PUFA, 
%TE 
0.8 ± 0.1 0.6 ± 0.0  -0.2 ± 0.1  0.7 ± 0.0 0.6 ± 0.0  -0.1 ± 0.1 0.34 
Total PUFA, 
%TE 
5.8 ± 0.4 4.4 ± 0.5  -1.4 ± 0.3  4.6 ± 0.2 4.0 ± 0.2  -0.4 ± 0.2 0.14 
TFA, %TE    1.0 ± 0.1 1.3 ± 0.1  0.3 ± 0.1  0.9 ± 0.1 2.5 ± 0.1  
1.6 ± 0.1 <0.0001 
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Protein, %TE 16.3 ± 0.5 16.1 ± 0.4  -0.2 ± 0.5  16.9± 0.5 16.2 ± 0.3  -0.7 ± 0.6 0.80 
Carbohydrates, 
%TE 
46.3 ± 0.9 43.3 ± 0.9  -3.0 ± 0.9  46.6 ± 1.3 42.2 ± 1.0  -4.4 ± 1.5 0.19 
Alcohol, %TE 3.1 ± 0.5 3.1 ± 0.5  0.0 ± 0.4  2.9 ± 0.5 2.7 ± 0.4  -0.2 ± 0.5 0.35 
Dietary fiber 
(AOAC), g/d 
20.4 ± 1.1 22.0 ± 1.1  1.6 ± 0.9  20.2 ± 1.1 19.4 ± 1.1  -0.8 ± 1.2 0.03 
Sodium, g/d 2.7 ± 0.2 2.2 ± 0.1  -0.5 ± 0.1  2.5 ± 0.2 1.9 ± 0.1  -0.6 ± 0.1 0.03 
 
AOAC; Association of Official Analytic Chemists; %TE, percentage of total energy. aValues are means ± SEM. Dietary intakes estimated from 4-d weighed dietary 
records at baseline (week 0) and after intervention (week 12); bTarget FA intakes for the control and modified dietary exchange periods; cOverall effect of treatment 
based on change-from-baseline was calculated by mixed model analysis, with adjustments made for fixed effects of baseline values of the assessed variable, period, 
treatment, age, gender and BMI.  Participant was included as a random effect. p ≤ 0.01 deemed as significant. 
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Table 4 Plasma phospholipid fatty acids at baseline (week 0) and following diets that incorporated the control and modified dairy products (week 12) in 
adults at moderate cardiovascular disease riska 
  Control Modified            
 mol% Baseline Post Δ Baseline Post Δ pb 
SFAs 
       
11:0 0.0000 ± 0.0008 0.0013 ± 0.0008 0.0000 ± 0.0011 0.0000 ± 0.0011 0.0002 ± 0.0000 0.0025 ± 0.0010 0.35 
12:0 0.0230 ± 0.0018 0.0242 ± 0.0015 0.0012 ± 0.0019 0.0245 ± 0.0000 0.0225 ± 0.0000 0.0019 ± 0.0016 0.22 
13:0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.16 
14:0 0.35 ± 0.01 0.42 ± 0.02 0.07 ± 0.02 0.35 ± 0.02 0.38 ± 0.02 0.03 ± 0.01 0.04 
15:0 0.23 ± 0.01 0.26 ± 0.01 0.04 ± 0.01 0.22 ± 0.01 0.24 ± 0.01 0.02 ± 0.01 0.02 
16:0 30.70 ± 0.16 30.86 ± 0.17 0.16 ± 0.13 30.78 ± 0.13 30.32 ± 0.13 -0.46 ± 0.15 <0.001 
17:0 0.39 ± 0.01 0.40 ± 0.01 0.01 ± 0.01 0.38 ± 0.01 0.38 ± 0.01 0.00 ± 0.01 0.03 
18:0 13.95 ± 0.18 13.67 ± 0.14 -0.29 ± 0.12 14.05 ± 0.12 13.83 ± 0.12 -0.22 ± 0.13 0.33 
20:0 0.14 ± 0.00 0.13 ± 0.00 -0.01 ± 0.00 0.13 ± 0.00 0.12 ± 0.00 -0.01 ± 0.00 0.76 
21:0 0.0128 ± 0.0037 0.0130 ± 0.0043 0.0001 ± 0.0036 0.0093 ± 0.0000 0.0147 ± 0.0000 0.0054 ± 0.0034 0.62 
22:0 0.23 ± 0.01 0.22 ± 0.01 -0.01 ± 0.01 0.22 ± 0.01 0.22 ± 0.01 0.00 ± 0.01 0.69 
23:0 0.10 ± 0.00 0.11 ± 0.00 0.01 ± 0.00 0.10 ± 0.00 0.11 ± 0.00 0.01 ± 0.00 0.34 
24:0 0.25 ± 0.01 0.25 ± 0.01 0.00 ± 0.01 0.25 ± 0.01 0.24 ± 0.01 -0.01 ± 0.01 0.85 
Total SFAc 46.37 ± 0.17 46.36 ± 0.13 0.01 ± 0.17 46.52 ± 0.21 45.92 ± 0.15 -0.60 ± 0.21 0.006 
MUFAs 
       
18:1 cis-9 9.81 ± 0.15 9.98 ± 0.16 0.17 ± 0.15 9.99 ± 0.15 10.93 ± 0.15 0.93 ± 0.19 <0.0001 
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18:1 trans-9 
22:1 cis-9 
0.08 ± 0.00 
0.0202 ± 0.0037 
0.08 ± 0.00 
0.0206 ± 0.0030 
0.01 ± 0.00 
0.0004 ± 0.0045 
0.07 ± 0.00 
0.0182 ± 0.0000 
0.17 ± 0.00 
0.0201 ± 0.0000 
0.10 ± 0.01 
0.0000 ± 0.0019 
<0.0001 
0.52 
Total cis-MUFAd 11.02 ± 0.16 11.24 ± 0.17 0.21 ± 0.15 11.21 ± 0.18 12.20 ± 0.23 0.99 ± 0.20 <0.0001 
Total trans-MUFAe 0.12 ± 0.00 0.12 ± 0.00 0.01 ± 0.00 0.10 ± 0.00 0.23 ± 0.01 0.12 ± 0.01 <0.0001 
PUFAs 
       
18:2 n-6 22.26 ± 0.42 22.40 ± 0.37 0.14 ± 0.28 22.00 ± 0.28 22.29 ± 0.28 0.30 ± 0.29 0.87 
18:3 n-6 0.08 ± 0.01 0.10 ± 0.01 0.02 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 0.00 ± 0.01 0.51 
18:3 n-3 0.31 ± 0.02 0.31 ± 0.01 0.00 ± 0.01 0.31 ± 0.01 0.29 ± 0.01 -0.02 ± 0.01 0.58 
20:3 n-6 3.07 ± 0.08 3.39 ± 0.11 0.32 ± 0.07 3.12 ± 0.07 3.17 ± 0.07 0.06 ± 0.06 0.007 
20:4 n-6 9.88 ± 0.27 9.53 ± 0.22 -0.35 ± 0.13 9.77 ± 0.13 9.41 ± 0.13 -0.36 ± 0.21 0.74 
20:5 n-3  1.27 ± 0.08 1.25 ± 0.06 -0.02 ± 0.07 1.24 ± 0.07 1.14 ± 0.07 -0.10 ± 0.07 0.14 
22:5 n-6 0.20 ± 0.01 0.20 ± 0.01 0.00 ± 0.01 0.20 ± 0.01 0.20 ± 0.01 0.00 ± 0.01 0.17 
22:5 n-3 0.99 ± 0.03 1.02 ± 0.02 0.03 ± 0.02 1.00 ± 0.02 0.95 ± 0.02 -0.05 ± 0.03 0.55 
22:6 n-3 3.77 ± 0.16 3.39 ± 0.13 -0.37 ± 0.09 3.79 ± 0.09 3.44 ± 0.09 -0.35 ± 0.10 0.74 
Total n-3 PUFAf 5.35 ± 0.23 4.96 ± 0.17 -0.39 ± 0.14 5.34 ± 0.21 4.87 ± 0.17 -0.47 ± 0.14 0.58 
Total n-6 PUFAg 36.15 ± 0.34 36.30 ± 0.27 0.15 ± 0.26 35.83 ± 0.32 35.86 ± 0.33 0.03 ± 0.33 0.32 
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aValues are given as means ± SEM; bOverall effect of treatment based on change-from-baseline was calculated by mixed model analysis, with adjustments made for 
fixed effects of baseline values of the assessed variable, period, treatment, age, gender and BMI.  Participant was included as a random effect; cTotal SFAs include: 
11 : 0, 12 : 0, 13 : 0, 14 : 0, 15 : 0, 16 : 0, 17 : 0, 18 : 0, 20 : 0, 21 : 0, 22 : 0, 23 : 0 and 24 : 0; dTotal cis-MUFAs include: 14 : 1cis, 15 : 1cis, 16 : 1cis, 17 : 1cis, 18 : 
1cis-9, 20 : 1cis, 22 : 1cis-9 and 24 : 1cis. Where no bond position is listed it is unknown, as previously outlined in Wang et al. (177); eTotal trans-MUFAs include: 
16 : 1trans (bond position unknown) and 18 : 1trans-9 (177); fTotal n-3 PUFAs include: 18 : 3n-3, 20 : 5n-3, 22 : 5n-3 and 22 : 6n-3; gTotal n-6 PUFAs include: 18 : 
2n-6, 18 : 2trans, 18 : 3n-6, 20 : 2, 20 : 3n-6, 20 : 4n-6 + 20:3n-3, 22 : 4 and 22 : 5n-6. Where no bond position is listed it is unknown (177). 20 : 4n-6 + 20 : 3n-3 co-
eluted, but as 20 : 3n-3 concentration in human samples is negligible, this peak was identified as 20 : 4n-6 (177).
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Figure 2.1 Flow of participants through the different stages of the RESET study. 
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Figure 2.2 Change-from-baseline in the plasma phospholipid profile of SFA: 16 : 0 (a) and MUFAs: 
18 : 1cis-9 and 18 : 1trans-9 (b) following 12-week diets that incorporated control and modified dairy 
products. Values are means ± SEM, n = 54. Significance shown as * P <0.001, ** P < 0.0001. 
 
(a)                  (b) 
 
Figure 2.3 Orthogonal PLS-DA, score plots at baseline (a) and on post-intervention (b) calculated 
using plasma phospholipid FA concentrations in adults at moderate risk of cardiovascular disease (n = 
54). FA, fatty acid; PLS-DA, partial least squares discriminant analysis. 
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Supplementary Table 2.1 Baseline characteristics for participants’ based on the order of 
allocation the control and modified dietary exchange periodsa 
 
Group 1b Group 2 Pc 
 
(n = 30) (n = 24) 
 
Age, y 52 ± 2 51 ± 3 0.41 
Gender, %M/%F 53/47 63/38 0.50 
BMI, kg/m 25.0 ± 0.6 25.8 ± 0.7 0.99 
Waist circumference, cm 86.7 ± 1.9 90.2 ± 2.2 0.83 
Fasting total cholesterol, mmol/L 5.60 ± 0.20 5.45 ± 0.18  0.80 
Fasting HDL-cholesterol, mmol/L 1.46 ± 0.04 1.49 ± 0.08 0.92 
Fasting glucose, mmol/L 5.37 ± 0.17 5.46 ± 0.22 0.84 
Systolic blood pressure, mmHgd 119 ± 2 122 ± 2 0.67 
Diastolic blood pressure, mmHgd 71 ± 1 74 ± 2 0.82 
Family history of premature MI, %e 16.7 12.5 0.36 
Risk Scoref 3.2 ± 0.3 2.8 ± 0.2 0.28 
 
aAll values are given as mean ± SEM; bGroup 1= participants were randomly allocated to 
consume control dairy products during their first dietary exchange period. Group 2= 
participants were randomly allocated to consume modified (SFA-reduced, MUFA-enriched) 
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dairy products during their first dietary exchange period; cDifferences in baseline 
characteristics between participants randomly assigned to the control and modified dietary 
exchange periods were assessed using independent t-tests and Chi-square tests for continuous 
and categorical variables, respectively. P ≤ 0.01 deemed as significant; dMeasured over 24 h 
using ambulatory blood pressure monitors approximately 48 h before clinical visit 1 at wk 0; 
eFamily history of prematurely diagnosed MI in parents or siblings (≤55 years for male 
relatives; ≤65 years for female relatives); fA score of ≥2 points relates to a 50% greater risk of 
CVD than the population mean. 
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Supplementary Table 2.2 Factor loadings identified by orthogonal partial least squares discriminant 
analysis of plasma phospholipid fatty acid profiles at baseline (week 0) and following diets that 
incorporated the control and modified dairy products (week 12) in adults at moderate cardiovascular 
disease risk. 
 Baseline  Post-intervention 
 
Loading 
(t1) 
OrthoLoading 
(to1) 
 Loading                   
(t1) 
OrthoLoading 
(to1) 
10:0 -0.008 0.153  -0.038 0.109 
11:0 0.167 -0.076  -0.116 -0.193 
12:0 0.013 0.158  -0.095 -0.055 
13:0 0.089 0.111  -0.011 -0.312 
14:0 -0.027 0.272  -0.238 0.224 
14:1 cis 0.247 0.000  -0.255 0.005 
15:0 -0.291 -0.107  -0.226 0.188 
15:1 cis 0.292 -0.031  0.103 -0.285 
16:0 0.105 0.129  -0.247 -0.085 
16:1 cis -0.451 -0.093  0.392 0.264 
16:1 trans 0.036 0.233  -0.001 0.182 
17:0 -0.216 -0.365  -0.147 0.115 
17:1 cis 0.221 0.019  -0.123 0.174 
18:0 0.222 0.026  0.088 0.033 
18:1 cis-9 -0.383 0.053  0.579 0.235 
18:1 trans-9 0.061 0.277  0.258 0.374 
18:2 cis-6 -0.177 -0.152  0.070 0.038 
18:2 trans-6 -0.148 -0.065  0.023 -0.101 
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18:3 n-6 0.118 0.241  -0.136 0.115 
20:0 -0.181 -0.262  -0.053 -0.357 
18:3 n-3 -0.038 0.182  -0.152 0.102 
20:1 cis -0.403 0.126  0.186 0.443 
21:0 -0.094 -0.214  0.068 -0.123 
20:2 -0.129 -0.026  -0.037 0.030 
20:3 n-6 0.014 0.221  -0.158 0.214 
22:0 -0.095 -0.423  0.087 -0.297 
20:4 n-6 -0.037 -0.056  0.009 -0.132 
22:1 cis-9 -0.078 0.023  -0.042 -0.003 
23:0 -0.084 -0.427  -0.056 -0.240 
20:5 n-3 -0.042 -0.094  -0.146 0.065 
24:0 0.052 -0.220  0.040 -0.255 
22:4 0.044 0.083  -0.062 -0.046 
24:1 cis -0.113 -0.432  -0.021 -0.495 
22:5 n-6 0.063 0.052  0.023 0.070 
22:5 n-3 0.105 -0.072  -0.201 0.045 
22:6 n-3 0.065 -0.261  0.020 -0.217 
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Chapter III: Impact of dairy fat manipulation to replace 
saturated with unsaturated fatty acids in milk and dairy products 
on cardiovascular disease risk markers: findings from the RESET 
randomized controlled trial 
 
Dafni Vasilopoulou, Oonagh Markey, Kirsty E. Kliem, Colette C. Fagan,  Alistair S. Grandison, 
David J. Humphries, Susan Todd, Kim G. Jackson, David I. Givens,  and Julie A. Lovegrove.  
In preparation for submission to AJCN 
JAL, DIG and KGJ designed the human study; CCF, ASG, DJH and DIG designed and 
produced the modified dairy products; DV, OM, KEK conducted the research and analysed 
data; ST provided statistical advice. 
DV analysed the data presented in this chapter (with OM for biochemical ILAB and BP 
analysis and statistics), performed statistical analysis on all other outcome measures and 
wrote the manuscript for this thesis, which was approved by all authors. 
DV was also responsible for finding and contacting the NMR company to analyse the 
samples. 
Results of the FMD analysis will not be presented in this chapter. 
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3.1 Abstract 
 
Background: Modifying dairy fat composition by increasing the monounsaturated fatty acid 
(MUFA) content is a potential strategy to reduce dietary saturated fatty acid (SFA) intake for 
cardiovascular disease (CVD) prevention in the population.  
Objective: To determine the effects of a high-dairy diet containing SFA-reduced, MUFA-
enriched (modified) dairy products, versus conventional dairy products (control), on the 
fasting lipid profile, vascular function and other CVD risk markers in adults at moderate CVD 
risk. 
Design: A double-blind, randomized, controlled cross-over intervention was conducted with 
an 8-wk washout period between the two 12-wk treatments. Participants (n = 76, 25-70 y) 
with a 1.5-fold higher CVD risk, replaced habitual dairy products with study products (milk, 
cheese and butter) to achieve a high-dairy iso-energetic daily dietary exchange (38% total 
energy intake (%TE) from fat: control (dietary target: 19%TE SFA; 11%TE MUFA) and 
modified (16%TE SFA; 14%TE MUFA) diet. Linear mixed model analyses determined the 
overall effect of dairy fat composition, based on change-from-baseline values during the 
modified and control interventions. 
Results: Fifty-four participants (31 men; 23 women; 52 ± 3 y; BMI 25.8 ± 0.5 kg/m2) 
completed both arms of the intervention. There was a borderline treatment effect on the 
change in fasting total cholesterol (P = 0.08), but not HDL-C. A significant attenuation in the 
rise of fasting LDL-C was observed following the modified diet (0.9%) compared to the 
control diet (5.5%; P = 0.03), reflected in the lower LDL-C:HDL-C ratio (P = 0.04). 
Additionally, fasting plasma nitrite increased after the modified, yet decreased after the 
control diet (P = 0.01). There were no significant differences in any of the other CVD risk 
markers.  
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Conclusion: A high daily intake of SFA-reduced, MUFA-enriched dairy products for 12-wk 
may have beneficial effects on fasting LDL-C and nitrite concentrations compared with 
conventional dairy products. This trial was registered at www.clinicaltrials.gov as 
NCT02089035. 
Keywords: dairy fat, cardiovascular disease risk, cholesterol profile, flow-mediated 
dilatation, saturated fatty acids, monounsaturated fatty acids, vascular function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
 
3.2 Introduction 
 
High intakes of dietary saturated fatty acids (SFA) have been associated with an increase in 
low density lipoprotein cholesterol (LDL-C) concentrations (9), an established risk factor in 
the development of atherosclerosis (195). Consumption of dairy products contribute up to 
35% of total dietary SFA intake within the UK adult population (10) and reduced-fat dairy 
products are recommended as part of public health guidelines aimed at CVD prevention (196, 
197). However, the adverse association between high SFA intake and CVD is not reflected in 
prospective cohort studies of dairy fat consumption, with the exclusion of butter (36, 47). This 
finding may reflect the complexity of the dairy food matrix, which contains other components 
such as micronutrients and bioactive peptides, both of which have been proposed to reduce 
the risk of cardiometabolic diseases (64, 198). 
Despite recent meta-analyses questioning the link between high SFA intake and CVD 
risk and mortality (18, 19), there is increasing evidence that overall, a reduction in dietary 
SFA, iso-energetically replaced, particularly with PUFA, leads to reduction in CVD risk 
(199). The current evidence for a replacement with MUFA on CVD risk and mortality appears 
less clear, compared to replacement with PUFA (23). This discordance may be attributed to 
variations in sources of fatty acids (FA) within the study designs, and lack of RCTs with hard 
endpoints, as detailed in recent meta-analyses and reviews (23, 33, 199). Partial replacement 
of SFA in milk fat with unsaturated FA can be achieved by supplementing the dairy cow diet 
with plant oils or oil seeds (200). This alternative strategy could limit the entry of SFA from 
the food chain, without removing the beneficial aspects of dairy product consumption (150). 
Current evidence on the impact of SFA-reduced milk and dairy products on risk biomarkers 
of cardiovascular health from RCTs is limited, with most studies focusing on the use of FA-
modified butter consumption as the study product and changes in fasting serum lipid levels as 
biomarkers of CVD risk (134). Additionally, more evidence is needed to investigate the 
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impact of FA-modified dairy consumption on novel CVD risk factors, including inflammatory 
markers, endothelial function  and arterial stiffness(150). 
In order to address this knowledge gap, the REplacement of SaturatEd fat in dairy on 
Total cholesterol (RESET) study was designed to investigate the impact of a high-dairy diet 
incorporating SFA-reduced, MUFA-enriched (modified) dairy products on established and 
novel CVD risk markers, compared to dairy foods with a FA profile typical of retail products 
(control), in adults at moderate CVD risk. We hypothesized that intake of the modified dairy 
products for 12-wk would result in an improvement in fasting TC (composed of LDL-C and 
HDL-C; primary outcome), flow-mediated dilatation (FMD) and other markers of CVD risk 
as secondary outcomes, compared to intake of the control dairy products. 
3.3 Methods 
 
3.3.1 Subjects and study design 
      The RESET trial was given a favourable ethical opinion for conduct by the University of 
Reading Ethics Committee (Project Reference 13/43), registered at clinicaltrials.gov as 
NCT02089035 and carried out in accordance with the Declaration of Helsinki. Men and 
women aged 25-70 y with moderate CVD risk were recruited from Berkshire, United 
Kingdom, from February 2014 to September 2015 in three cohorts. The study was completed 
in April 2016. All participants provided written informed consent. Details of the study 
inclusion and exclusion criteria are reported in Markey et al (201). In summary, a total of 130 
potential participants attended a screening visit, resulting in 76 eligible for randomization 
(Supplemental Figure 3.1 for participant flowchart). Data collected at the screening visit on 
fasting serum TC, HDL-C, glucose, blood pressure, BMI and family history of myocardial 
infarction were used to determine eligibility, whereby a score of ≥2 CVD risk points based on 
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a modified Framingham risk analysis suggested a 1.5-fold higher CVD risk compared to the 
population mean (164, 165, 201). 
The RESET intervention was a double-blind, cross-over RCT with an 8-wk washout 
period between the two 12-wk dietary periods. A minimization technique stratifying by age, 
gender, BMI and fasting serum TC was used by a single researcher to randomise eligible 
participants to one of two dietary intervention groups, whereby Group 1 received the modified 
diet first (Diet A), followed by the control diet (Diet B) and vice-versa for Group 2 (202). In 
brief, participants received individual verbal and written instructions to incorporate the study 
products into their habitual diet following the baseline clinical visit (wk-0). Participants 
achieved an iso-energetic high-fat daily dietary exchange (38%TE from total fat) by replacing 
dairy products, oil/spreads and snacks habitually consumed with either the SFA-reduced, 
MUFA-enriched ultra-high temperature (UHT) milk, Cheddar cheese and butter (modified; 
dietary target: 16%TE SFA, 14%TE MUFA) or matched products with a FA profile typical of 
retail products (control; 19%TE SFA, 11%TE MUFA). The two intervention diets were equal 
in total exchangeable fat content (approx. 41 g/d). Relative to the control diet, consumption of 
the modified diet led to a mean decrease of total SFA intake of 2.5%TE and a parallel mean 
increase of total MUFA intake of 3.7%TE (201) in a diet that contained 38%TE as total fat. 
The nutritional composition of the study products is presented in Table 3.1.   
3.3.2 Intervention diets 
       Full details of the production of the SFA-reduced, MUFA-enriched (modified) milk and 
dairy products have been published elsewhere (203). Briefly, following a 4-wk 
supplementation of the total mixed ration diet of multiparous Holstein-Friesian dairy cows 
with approximately 1 kg/d of high oleic sunflower oil (AAK Ltd, Hull, UK), the milk was 
collected for the purposes of manufacturing UHT milk, Cheddar cheese and butter. Control 
dairy products were provided by Arla Foods UK.  
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A food-exchange model was designed for the RESET study, based on the strategy for 
adults with increased CVD risk followed by the Dietary Intervention and Vascular Function 
(DIVAS) and the Reading, Imperial, Surrey, Cambridge and Kings (RISCK) studies (164, 
204), both based on the National Diet and Nutrition Survey (NDNS) for adults (aged 19-64 y) 
(205) and is described in detail in Markey et al. (201). Participants were provided with the 
study products, in blinded packaging, to take home and were asked to consume 340 g/d of 
UHT milk, 45 g/d of Cheddar cheese and 21.5 g/d (control diet) or 25.1 g/d (modified diet) of 
butter (for nutrient composition, see Supplemental Table 3.1). Compliance was assessed 
using 4-d weighed food diet diaries (weeks 0, 12, 20 and 32), daily records of study product 
consumption and analysis of plasma phospholipid FA (PL-FA) which served as a short-term 
biomarker. To maintain constant body weight, participants were weighed every 4-wk by the 
investigators and any changes ±1 kg were addressed. Results from the analysis of the PL-FA 
composition, which showed a significant difference between the modified and control 
treatments following the two 12-wk interventions (P ≤ 0.01), have been previously presented 
(for a summary of the results, see Supplemental Table 3.2) (201).  
Additionally, self-reported physical activity was assessed using the International 
Physical Activity Questionnaire (IPAQ)-long form (206). A 100 mm visual analogue scale 
(VAS) questionnaire (207) was completed by participants at the end of each 12-wk 
intervention period to assess the visual appeal, smell, taste, palatability and aftertaste of the 
UHT milk, cheese and butter.  
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3.3.3 Study visits 
       Study visits were conducted in a temperature controlled-environment (22 ± 1 °C) at the 
Hugh Sinclair Unit of Human Nutrition, University of Reading, during weeks 0, 12, 20 and 
32. Participants were asked to refrain from alcohol and aerobic exercise for 24 h prior to each 
visit and fast overnight for 12 h after consuming a low fat standard meal (< 1.46 MJ; < 7 g 
total fat) that was provided by the researchers. Participants drank only low nitrate mineral 
water (Buxton) during the 12 h fast and on the morning of the study visit. Following a 30 min 
rest in the supine position, non-invasive vascular function measurements were performed by 
the same trained researcher for all 4 visits for each study participant. Fasted venous blood 
samples were then collected into lithium heparin, EDTA or serum separator blood collection 
tubes (VACUETTE, Greiner Bio-One) and either kept briefly on ice (for plasma samples) or 
left to clot for a minimum of 30 minutes at room temperature (for serum samples) before 
centrifugation at 1700 x g for 15 min at 4C. Plasma and serum were aliquotted prior to 
storage at -80C for further analysis. 
3.3.4 Biochemical analyses, risk scores and predictive equations 
     Serum lipids (TC, HDL-C and triacylglycerol), glucose, apolipoprotein (apo)B, C-reactive 
protein and non-esterified fatty acids (NEFA) were measured using an ILAB 600 
autoanalyzer (TC, HDL-C, triacylglycerol, glucose and C-reactive protein reagents and 
analyzer: Werfen UK Ltd); apoB reagent: Randox laborarories Ltd; NEFA reagent: Alpha 
Laboratories Ltd.). The Friedewald equation was used to estimate fasting LDL-C (49). ELISA 
kits were used to analyze circulating serum insulin (Dako UK Ltd.), plasma vascular and 
intercellular adhesion molecules (VCAM, ICAM), E-selectin and P-selectin (R&D Systems 
Europe Ltd.). Insulin resistance was estimated by HOMA-IR, while insulin sensitivity was 
estimated with the revised quantitative insulin sensitivity check index (rQUICKI), using 
standard equations (106). Measurement of plasma nitrite and nitrate was determined by HPLC 
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(ENO-30, EiCom Corporation, San Diego) coupled with online reduction of nitrate to nitrite, 
and post-column derivatization with the Greiss reagent (ENO-30 Analyzer, EiCom 
Corporation, San Diego) (208). Mean inter-assay CVs were <10% for all assays. 
Risk scores pre- and post-intervention for both diets were calculated using the 
modified Framingham CVD score (201, 209).  
Furthermore, post-intervention changes in dietary total fatty acid intake as assessed by 
the 4-d weighed food diet diaries, were used to calculate the predicted change in TC and 
LDL-C with the use of published equations, which included change in FA intake of total SFA, 
MUFA and PUFA (210-214).  
3.3.5 NMR Metabolomics 
A high-throughput nuclear magnetic resonance (1H-NMR) metabolomics platform 
(Nightingale Health Ltd., Finland) was used to quantify the particle size of LDL and HDL 
lipoprotein subclasses, as previously described (215). This manuscript will present the change 
from baseline following the two intervention diets of the LDL-particle (LDL-P; classified by 
their mean diameter size as small (S-LDL-P, 18.7 nm), medium (M-LDL-P, 23 nm) and large 
(L-LDL-P, 25.5 nm)) and HDL-particle (HDL-P; classified as small (S-HDL-P, 8.7 nm), 
medium (10.9 nm), large (12.1 nm) and very large (14.3 nm) concentrations. 
3.3.6 Assessment of vascular function and 24h ambulatory blood pressure 
       Prior to assessing the vascular function measurements, clinic supine BP was measured on 
the left upper arm with the use of a validated BP monitor (Omron MX2 Digital Automatic 
Upper Arm Blood Pressure Monitor; OMRON, UK). Endothelial function was assessed using 
FMD as described elsewhere (83). Briefly, trained researchers used a CX50 CompactXtreme 
portable ultrasound system (Philips HealthCare, UK) to determine endothelial-dependent 
vasodilation of the brachial artery following defined guidelines. Electrocardiogram-gated 
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images were captures at 0.25 frames/s with the use of an image-grabbing software (Medical 
Imaging Applications LLC, USA) (83). A single researcher, blinded to diet allocation, 
analyzed the images in duplicate with the use of a wall-tracking software. The maximum 
change in post-occlusion brachial artery diameter relative to the baseline diameter represented 
the calculated FMD response, expressed as a percentage (%FMD). The carotid intima media 
thickness (cIMT), defined as the distance between the media-adventitia interface to the 
intima-lumen interface, was assessed using a 12-3 linear array transducer and CX50 
ultrasound system (Philips HealthCare, UK) on the right and left common carotid artery 
(CCA), following published guidelines (216). For each side of the neck, a minimum of three 
images of the far-wall IMT of the artery were captured when the carotid vessel was at its 
widest diameter, reflecting artery expansion, using an automated edge-tracking software 
(Philips, QLAB) (84).  The IMT value represents the average of left and right CCA images, 
when images of the carotid vessel were at its widest diameter. 
Radial pulse wave analysis and carotid-femoral pulse wave velocity (m/s) were 
measured in triplicate using a SphygmoCor (AtCor Medical, Australia) (217). Pulse wave 
analysis determined the augmentation index corrected for a heart rate of 75 beats/min (%). 
The stiffness index (m/s) and reflection index (%) were determined by digital volume pulse 
(Pulse Trace PCA2; Micro Medical Ltd., UK) and provided measures of arterial stiffness and 
vascular tone, respectively (218). 
Ambulatory blood pressure (ABP) and heart rate were measured using A/A grade 
automated oscillometric ABP monitors (A&D Instruments Ltd., UK) every 30 min from 0700 
h to 2159 h and every 60 minutes from 2200 h to 0659 h. Participants were asked to wear the 
ABP monitors for at least 48 h prior to each of the four visits and repeat each measurement on 
the same selected day of the week. Sleep times were recorded by the participants and used to 
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estimate mean 24-h day and night measurements. Pulse pressure was calculated as the 
difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
3.3.7 Statistical analysis 
       For our primary outcome (serum TC, composed of LDL-C and HDL-C) a total of 54 
eligible participants were required to achieve a ~0.3 mmol/L predicted reduction in TC, 
calculated using Keys equations and taking into consideration a difference of 4.0%TE from 
SFA and a population mean of 4.54 mmol/L (SD 0.5), 80% power, 5% significance level, 
allowing for a 15% dropout rate. The same cohort size was also sufficient to detect a 1.5% 
inter-group difference in the FMD response (key secondary outcome), with a power of 80% at 
P < 0.05 (179). A P < 0.05 was considered significant for the primary and key secondary 
outcomes. For all other variables, a P < 0.01 was considered significant to adjust for multiple 
comparisons. 
Statistical analyses were predominantly conducted using the SAS 9.4 University 
edition statistical software (SAS Institute Inc., Cary, NC, USA). All variables were checked 
for normality and data was logarithmically transformed where needed. Treatment effects were 
evaluated using a linear mixed model, with the differences from baseline (Δ; wk-12 – wk-0 
and wk-32 – wk-20) as the dependent variable, adjusted for fixed effects of baseline values of 
the assessed variable, period, sequence, treatment, age, gender and BMI. Participant was 
included as a random effect. Results from the VAS questionnaire were analysed using paired 
t-test to assess differences between study product ratings. As this is a proof-of-concept study 
rather than a confirmatory trial, a per-protocol analysis approach was adopted. No period 
effects were observed for any outcome measure.  Results in tables are presented as means ± 
SEMs. 
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3.4 Results 
 
3.4.1 Study participation, anthropometric measures and product rating 
A total of 76 eligible participants were randomly recruited to the intervention, 54 of 
whom completed both arms of the study successfully (Supplemental Figure 1). Baseline 
screening characteristics of the participants who completed the study, have been previously 
published (201). Briefly, 31 men and 23 women had the following characteristics (mean ± 
SEM):  age 52 ± 3 y; BMI 25.8 ± 0.5 kg/m2; waist 89.8 ± 1.4 cm; TC 5.49 ± 0.12 mmol/L; 
HDL-C 1.48 ± 0.04 mmol/L; glucose 5.37 ± 0.11 mmol/L; clinic SBP 123 ± 2 mm Hg and 
clinic DBP 74 ± 1 mm Hg). Based on screening parameters, participants had a CVD risk score 
of 3.0 ± 0.2, indicating a 1.5-fold higher risk. Participant activity scores, based on the IPAQ 
questionnaire, did not significantly differ between treatments (change post modified diet: 364 
± 128 min/week¹; change post control diet: -641 ± 247 min/week¹; P = 0.17). The VAS 
questionnaire, which assessed the visual appeal, smell, taste, aftertaste and palatability of the 
three dairy products in the modified and control diet, showed no significant treatment effect 
(data not shown). 
3.4.2 Fasting serum lipids, biochemical analyses and predictive equations 
There was a borderline impact on the change from baseline in serum TC between the 
two diets (P = 0.08). However, there was a significant attenuation in the rise of LDL-C 
following the modified diet, compared to the control diet (0.9% and 5.5% respectively, P = 
0.03; Table 3.2). There was no significant difference in change from baseline in HDL-C 
between the two diets. There was a significant differential effect of the diets on the LDL-
C:HDL-C ratio, which decreased by 2.5% following the modified diet, while it increased by 
2.1% following the control diet (P = 0.04) (Table 3.2). No significant treatment effect was 
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observed for any other component of the lipid profile or indexes of insulin 
sensitivity/resistance (Table 3.2). 
Using the published equations, greater changes in TC and LDL-C concentrations were 
predicted compared to the observed study results (Supplemental Table 3.3). Compared to 
baseline values, TC concentrations following the modified diet were predicted to increase by 
3.1% (210-213) or 2.7% (214) compared to the observed 2.2%. Following the control diet, 
predicted increases in TC were calculated to increase by 6.7% (210-212), 5.7% (213) and 
5.3% (214) respectively, compared to the observed 5.5%. Similarly, change from baseline in 
LDL-C concentrations following the modified diet were predicted to increase by 3.5% (211, 
212), 2.3% (213) and 4% (214), whereas following the control diet values were predicted to 
increase by 7.6% (211, 212), 6.4% (213) and 8.2% (214) compared to the observed 0.9% and 
5.5% of the modified and control diet, respectively. 
3.4.3 NMR metabolomics 
There were no significant differences in the concentrations in both LDL-P and HDL-P 
subclass distributions following the two intervention diets and compared to baseline values 
(Table 3.2). 
3.4.4. Vascular function and 24-hour blood pressure, markers of endothelial 
activation, nitric oxide and inflammation 
      The additional measures of vascular function (cIMT) and arterial stiffness measured by 
PWA (augmentation index), PWV and DVP (stiffness index and reflection index) and blood 
and pulse pressure (Table 3.3) did not result in any significant differences following the two 
intervention treatments.  
There was a differential effect of the dairy fat diets on fasting plasma nitrite 
concentrations, with a 15.4% increase observed relative to baseline after the modified diet and 
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a 26.7% decrease observed for the control diet (Table 3.3). There was no significant effect of 
the diets on plasma nitrate or any of the markers of endothelial activation or inflammation 
(Table 3.3).  
3.4.5 Risk scores 
Risk scores, calculated with the use of the modified Framingham risk score, did not 
significantly differ following the two intervention diets and relative to baseline values (Table 
3.3). 
3.5 Discussion 
To our knowledge this is the first study to report on the long-term effects of partially 
replacing SFA with MUFA in a variety of dairy products on the fasting lipid profile, FMD 
and CVD markers, in adults at moderate CVD risk. We observed a tendency for a difference 
in TC compared to baseline values between the two diets, which did not reach statistical 
significance. However, we observed that the modified diet significantly attenuated the LDL-C 
and TC:HDL-C ratio, raising effect of the control diet with no impact on HDL-C or LDL-P 
and HDL-P size distribution. With the exception of a significant decrease in fasting nitrite 
concentrations following the modified diet, little impact on other vascular function and CVD 
risk markers were found. 
Investigating how to optimally replace dietary SFA with a suitable macronutrient 
presents a number of challenges, as both the single nutrient and the food source should be 
considered within dietary patterns and risk markers. (23). The existing body of evidence, from 
RCTs and prospective cohort studies, which have investigated a replacement of SFA with cis-
MUFA to reduce CVD mortality, is limited. Lack of clarity may in part be explained by 
limited studies with hard endpoints, variation in design of RCTs and ultimately the source of 
MUFA, as it appears that a beneficial outcome on risk markers is primarily observed from 
sources of plant oils and nuts, while other sources may lead to neutral results (23).  
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As dairy products represent the largest food source of dietary SFA intake in the UK 
(10), this food group provides a suitable vehicle for investigating partial SFA replacement 
with MUFA. A review of previously published human trials investigating the impact of FA-
modified dairy products, indicated a tendency towards a beneficial effect on fasting lipid 
markers (134). In an 8-wk crossover study led by Noakes et al. (135), healthy adults (49 ± 
10.3 y) consumed FA-modified milk, cheese, butter and ice-cream (16%TE SFA, 11.9%TE 
MUFA) or control dairy products (18.2%TE SFA, 9.1%TE MUFA). The study reported a 
significant decrease in TC (-4.3%) and LDL-C (-5.3%) following the modified dairy 
compared to the control diet. However, it is difficult to draw meaningful comparisons 
between the two studies, as baseline values were not included in the statistical analysis 
reported by Noakes et al (135).  
Our results indicate that a high fat, high dairy diet including conventional dairy foods 
(control) led to an increase in LDL-C (5.5%), which was attenuated by the modified diet 
(0.9%). The observed LDL-C attenuation may be associated with the effects of dietary fatty 
acids on LDL-receptor expression and activity (56). There is increasing evidence suggesting 
that dietary SFA intake may differentially impact on LDL subclass concentrations, with small 
LDL-P recognised as more strongly associated with progression of atherosclerosis and CVD 
outcomes than larger LDL-P (219). In our study, the two intervention diets did not 
significantly impact on the particle size distribution of both LDL and HDL subclasses, which 
may be explained from both the dairy nature of the diets and the modest, partial substitution 
of SFA with MUFA in the modified compared to the control diet. 
A comparison of  predictive equations shows that our results appear more in line with 
the equations by Clarke et al. (213). It is worth noting that early predictive equations (210, 
211) did not include a coefficient of change in dietary MUFA, as it was considered a neutral 
FA class with little impact on the lipid profile. Interestingly, the observed attenuation in LDL-
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C following the modified diet was found even though the dietary total trans fatty acid (TFA) 
intake had increased (2.5%TE vs 1.2%TE) compared to the control and relative to baseline 
(201). Although it was not possible to adequately discriminate between the participants’ 
intake of industrial and ruminant TFAs in the two diets using the dietary analysis software, 
supplementation of the bovine diet led to a greater proportion of ruminant TFA (rTFA) in the 
modified dairy products (203). The observed higher TFA intake following the modified diet 
exceeded the maximum 2% recommendation from food energy and the current mean TFA 
intake in UK adults (0.5%TE and 0.5% food energy) (10, 197). However, it is worth noting 
that the observed increased TFA intake following the modified diet did not appear to 
adversely affect fasting lipid biomarkers. This is in agreement with previous studies, which 
concluded that there were no significant adverse physiological effects of rTFA, unless 
consumed in high quantities  (220). Furthermore, the observed increases in LDL-C following 
the control diet were also slightly lower than theoretically predicted. The attenuation in LDL-
C concentrations following both diets compared to predicted changes, may be partly 
explained by the presence within the dairy matrix of bioactive compounds, such as proteins 
and micronutrients, which may mediate an attenuation in LDL-C concentrations through 
synergistic mechanisms (36). As the aim of our study was to provide diets high in dairy with a 
differential FA composition, the protein and micronutrient content of the study products was 
not significantly altered (201, 203). Considering the apparent effect on LDL-C, future 
investigation is warranted to explore potential mechanisms of other components within the 
matrix of the FA-modified dairy products. 
Progression of endothelial dysfunction and arterial stiffness characterize vascular 
dysfunction, mediating CVD risk (150). Recently, a prospective study demonstrated that 
increased milk and dairy product (with the exception of butter) intake was associated with a 
decrease in arterial stiffness in men (94). In our study, we did not observe significant 
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differences in vascular function, vascular stiffness, blood pressure and biomarkers related to 
endothelial function and low-grade inflammation between the two diets. The only exception 
was a statistically significant increase in plasma nitrite concentrations following the modified 
diet, with respect to baseline values and the control diet. Nitric oxide (NO) is essential for 
maintaining vascular homeostasis and a reduced bioavailability may suggest endothelial 
dysfunction (221). These differences in nitrite concentrations between treatments should be 
interpreted with caution as they may reflect not only measures of vascular function but also 
the participants’ dietary intake prior to study visits. Furthermore, the short half-life and rapid 
conversion to nitrate may also have affected the observed results (222).  
Lastly, our results showed no significant treatment effect in fasting indexes of insulin, 
insulin sensitivity and glucose concentrations. This is in agreement with RCTs on modified 
dairy products (34, 223). Although a small number of studies on dairy consumption have 
proposed a beneficial impact on insulin sensitivity (77), well-designed and suitably powered 
RCTs are still needed to confirm effects of specific dairy products on insulin sensitivity. 
      Strengths of our study include its long-term, double-blind and randomized design. We 
employed a food chain approach to reducing SFA in dairy products, an agricultural-based 
reformulation initiative which has the potential to prevent movement of SFA into other food 
chain entry points, and results in clean label products that are favoured by consumers (224). 
Encapsulation technology could provide a potential strategy implemented in the bovine feed 
to limit the observed increase of TFA in the modified milk. Additionally, participant ratings 
by VAS of the study products was further supported by consumers generally accepting FA-
modified milk and dairy products, when tasted in a blinded manner, as recently published 
(225). The implementation of high dairy diets with differential FA composition was used to 
explore traditional and novel biomarkers of CVD risk. This meant that participants consumed 
large quantities of dairy products, which may not reflect habitual dairy intake of the 
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participants (10). However, our findings suggest a favourable impact on fasting LDL-C 
following consumption of FA-modified dairy products compared with commercial retail 
dairy, warranting future investigation with lower, more representative dairy intakes to 
determine if similar effects are observed. Finally, as our participants were at moderate CVD 
risk, our results may not be comparable in a healthy adult population.  
     In conclusion, our study, which is the first to investigate the impact FA-modified UHT 
milk, Cheddar cheese and butter on established and novel CVD risk outcomes, indicates that 
high daily consumption of SFA-reduced, MUFA-enriched dairy products attenuated the rise 
of LDL-C concentration observed with conventional commercially available dairy products, 
without significantly impacting TC and HDL-C. Further research is warranted to explore the 
impact of FA-modified dairy products on CVD risk biomarkers in both healthy and at risk 
populations. 
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Table 3.1 Nutrient composition of the study products of the modified and control intervention diets1 
                
 Modified diet  Control diet 
  UHT Milk Cheese Butter   UHT Milk Cheese Butter 
Daily amount, g 340.0 45.0 25.1  340.0 45.0 21.5 
Energy, MJ/d 0.79 0.69 0.76  0.75 0.76 0.65 
Fat, g/d 8.8 12.6 20.4  8.6 15.1 17.4 
SFA, g/d 4.4 6.3 10.2  5.7 10.2 11.1 
MUFA, g/d 3.6 5.0 8.1  2.1 3.5 4.4 
PUFA, g/d 0.3 0.4 0.7  0.3 0.4 0.6 
TFA, g/d 0.9 1.4 2.1  0.3 0.5 0.7 
CHO, g/d 16.0 1.2 0.2  14.9 1.4 0.4 
Protein, g/d 11.1 12.1 0.1  10.2 10.6 0.0 
Calcium, mg/d 404.0 410.0 4.49   428.0 340.5 3.65 
        
 
1 Values represent daily required intakes of the three study products. Adapted with permission from Markey et al. (201) and Kliem et al. (203).  
CHO, carbohydrates; TFA, trans fatty acids; %TE, percent total energy. 
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Table 3.2 Fasting lipid profile, lipid ratios, particle distribution and indexes of insulin resistance at baseline (wk-0) and post-intervention (wk-12) of the 
modified and control diet¹. 
                          
 Modified diet  Control diet P
2 
             
  Baseline   Post   Δ    Baseline   Post   Δ   
Fasting lipid profile             
 TC, mmol/L 5.54 ± 0.13  5.66 ± 0.14  0.12 ± 0.07  5.47 ± 0.12  5.77 ± 0.13  0.29 ± 0.06 0.08 
 LDL-C, mmol/L 3.47 ± 0.11  3.50 ± 0.12  0.03 ± 0.06  3.43 ± 0.10  3.62 ± 0.11  0.19 ± 0.05 0.03 
 HDL-C, mmol/L 1.51 ± 0.04  1.55 ± 0.04  0.04 ± 0.02  1.50 ± 0.04  1.58 ± 0.05   0.07 ± 0.02 0.55 
 Triacylglycerol, mmol/L 1.24 ± 0.07  1.35 ± 0.10  0.11 ± 0.07  1.18 ± 0.06  1.24 ± 0.07  0.06 ± 0.05 0.32 
 Apolipoprotein B, g/L 1.01 ± 0.03  1.03 ± 0.03  0.02 ± 0.01  1.00 ± 0.03  1.03 ± 0.03  0.03 ± 0.01 0.47 
 NEFAs, μmol/L 567 ± 24  514 ± 23  -53 ± 27  556 ± 27  515 ± 23  -41 ± 27 0.84 
Lipid ratios and particle distribution            
 LDL-C:HDL-C 2.39 ± 0.09  2.33 ± 0.09  -0.06 ± 0.04  2.35 ± 0.09  2.40 ± 0.09  0.05 ± 0.04 0.04 
 TC:HDL-C 3.79 ± 0.12  3.76 ± 0.12  -0.03 ± 0.05  3.74 ± 0.11  3.78 ± 0.12  -0.04 ± 0.03 0.13 
LDL-P (nmol/L)             
 Small 172 ± 4  175 ± 5  3 ± 1  169 ± 4  176 ± 4  7 ± 2 0.36 
 Medium 278 ± 8  282 ± 8  5 ± 2  268 ± 9  284 ± 8  16 ± 8 0.34 
 Large 570 ± 16  581 ± 17  11 ± 5  551 ± 18  581 ± 16  38 ± 19 0.34 
HDL-P (nmol/L)             
 Small 10100 ± 109   10307 ± 128   207 ± 102   10080 ± 125   10354 ± 117  247 ± 112 0.85 
 Medium 3974 ± 102  4106 ± 111   132 ± 52  4028 ± 111  4118 ± 117  87 ± 55 0.46 
 Large 1592 ± 106  1652 ± 106  60 ± 53   1620 ± 91  1656 ± 101  36 ± 43 0.30 
 Very Large 229 ± 12  243 ± 14  14 ± 8  229 ± 11  238 ± 12  13 ± 7 0.33 
Indexes of insulin resistance            
 Glucose, mmol/L 5.38 ± 0.1  5.32 ± 0.1  -0.06 ± 0.07  5.4 ± 0.1  5.44 ± 0.14   0.04 ± 0.09 0.34 
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 Insulin, pmol/L 
 HOMA-IR 
41.3 ± 3.2 
1.66 ± 0.13  
39.5 ± 2.9 
1.55 ± 0.12  
-1.9 ± 1.9 
-0.11 ± 0.08  
39.8 ± 3.5 
1.59 ± 0.14  
47.3 ± 6.1 
1.88 ± 0.22  
7.5 ± 4.5 
0.29 ± 0.12 
0.09 
0.08 
 rQUICKI 0.18 ± 0.00   0.19 ± 0.00   0.01 ± 0.00   0.18 ± 0.00   0.18 ± 0.00   0.00 ± 0.00 0.11 
 
 
1 Values are means ± SEMs. n = 54. Data not normally distributed were log transformed. HOMA-IR, homeostatic model of insulin resistance; NEFA, 
non-esterified fatty acids; rQUICKI, revised quantitative insulin sensitivity index; TC, total cholesterol; Δ, change from baseline.  
2 Linear mixed model analyses were used to calculate overall effect of treatment based on change-from-baseline values, with adjustments made for fixed 
effects of baseline values of the assessed variable, period, treatment sequence, gender, age and BMI. Participant was included as a random effect. For 
primary outcome measure (cholesterol profile), P ≤ 0.05 was deemed significant. For all other secondary outcomes, P ≤ 0.01 was deemed as significant.  
 
 
 
 
 
 
 
 
 
 
 
 110 
 
Table 3.3 Vascular outcomes, blood pressure, endothelial and inflammatory biomarkers and CVD risk scores at baseline (wk-0) and post-intervention 
(wk-12) of the modified and control diet 1. 
                  
  Modified diet  Control diet  
        P
2 
  Baseline Post Δ    Baseline Post Δ   
Endothelial function         
 % FMD         
 Pre-occlusion artery diameter, mm        
Vascular function         
 cIMT, mm 0.59 ± 0.02 0.59 ± 0.02 0.00 ± 0.00  0.58 ± 0.01 0.59 ± 0.02 0.01 ± 0.01 0.83 
 Arterial stiffness         
  PWA, m/s         
   AI at 75 beats/min, % 18.9 ± 1.6 19.1 ± 1.4 0.2 ± 0.7  17.1 ± 1.4 18.5 ± 1.4 1.4 ± 0.8 0.62 
  PWV, m/s 7.6 ± 0.3 7.4 ± 0.2 -0.2 ± 0.5  7.5 ± 0.2 7.8 ± 0.3 0.3 ± 0.44 0.21 
  DVP         
   Stiffness index, m/s 7.6 ± 0.3 7.8 ± 0.4 0.2 ± 0.4  7.9 ± 0.4 8.2 ± 0.3.4 0.3 ± 0.33 0.96 
   Reflection index, % 69.1 ± 1.9 70.8 ± 1.9 1.7 ± 1.9  71.2 ± 1.8 70.3 ± 1.6 -0.9 ± 1.3 0.57 
   PPT, m/s 247 ± 10 241 ± 10 -6 ± 11  236 ± 10 228 ± 9 -8 ± 14 0.61 
Clinic BP, mm Hg         
 SBP 120 ± 2 119 ± 1 -1 ± 1  120 ± 2 119 ± 2 -1 ± 1 0.44 
 DBP 70 ± 1 69 ± 1 -1 ± 1  70 ± 1 70 ± 1 0 ± 1 0.24 
Ambulatory BP, mm Hg         
 24-h SBP 123 ± 2 124 ± 2 1 ± 1  123 ± 2 124 ± 2 1 ± 1 0.90 
 24-h DBP 74 ± 1 74 ± 1 0 ± 1  74 ± 1 75 ± 1.0 1 ± 1 0.60 
 24-h PP 49 ± 1 50 ± 1 1 ± 1  49 ± 1 49 ± 1 1 ± 1 0.64 
 Day SBP 127 ± 2 128 ± 2 1 ± 1  127 ± 2 128 ± 2 1 ± 1 0.92 
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 Day DBP 
 Day PP 
77 ± 1 
50 ± 1 
77 ± 1 
51 ± 1 
0 ± 1 
1 ± 1 
 77 ± 1 
50 ± 1 
77 ± 1 
50 ± 1 
0 ± 1 
0 ± 1 
0.51 
0.72 
 Night SBP 108 ± 2 110 ± 2 2 ± 2  108 ± 2 107 ± 2 -1 ± 1 0.15 
 Night DBP 63 ± 1 65 ± 1 2 ± 1  63 ± 1 64 ± 1 1 ± 1 0.29 
 Night PP 45 ± 1 45 ± 1 0 ± 1  44 ± 1 43 ± 1 -1 ± 1 0.26 
Circulating biomarkers of          
endothelial activation and inflammation        
Nitric oxide, μmol/L 17.88 ± 1.60 17.40 ± 1.29 -0.48 ± 1.49  17.11 ± 1.04 16.74 ± 1.30 -0.37 ± 1.57 0.33 
Nitrite, μmol/L 0.13 ± 0.02 0.15 ± 0.02 0.02 ± 0.01  0.15 ± 0.02 0.11 ± 0.02 -0.03 ± 0.02 0.01 
Nitrate, μmol/L 17.74 ± 1.60 17.25 ± 1.29 -0.49 ± 1.49  16.96 ± 1.03 16.63 ± 1.30 -0.33 ± 1.56 0.51 
VCAM-1, ng/mL 534.9 ± 29.7 537.9 ± 29.7 3.0 ± 20.7  542.8 ± 28.9 499.9 ± 28.3 -40.1 ± 1.7 0.08 
ICAM-1, ng/mL 84.4 ± 6.6 79.2 ± 6.5  -5.1 ± 4.3  80.3 ± 8.6 87 ± 8.6 6.7 ± 5.5 0.64 
E-selectin, ng/mL 27 ± 1.9 25.2 ± 1.7 0.6 ± 0.7  24.3 ± 1.7 25.2 ± 1.9 0.8 ± 0.6 0.84 
P-selectin, ng/mL 25.2 ± 1.4 26.6 ± 1.6 1.5 ± 0.7  25.9 ± 1.5 26.1 ± 1.5 0.1 ± 0.7 0.30 
C-reactive protein, mg/L 2.03 ± 0.76 1.59 ± 0.32 -0.44 ± 0.5  2.12 ± 0.60 1.75 ± 0.42 -0.37 ± 0.62 0.51 
Risk score calculations         
CVD score3 2.7 ± 0.2 2.7 ± 0.2 0.0 ± 0.1   2.5 ± 0.2 2.8 ± 0.2 0.3 ± 0.1 0.09 
 
1 Values are means ± SEMs. n = 54 (except for DVP, where n = 46; PWA, n = 50; PWV, n = 29). Data not normally distributed were log transformed. 
AI, augmentation index; BP, blood pressure; cIMT, carotid intima media thickness; DBP, diastolic BP; DVP, digital volume pulse; FMD, flow-mediated 
dilation; ICAM-1, intercellular adhesion molecule 1; PP, pulse pressure; PWA, pulse-wave analysis; PWV, pulse-wave velocity; SBP, systolic BP; 
VCAM-1, vascular adhesion molecule 1; Δ, change from baseline. 
2 Linear mixed model analyses were used to calculate overall effect of treatment based on change-from-baseline values, with adjustments made for fixed 
effects of baseline values of the assessed variable, period, treatment sequence, gender, age and BMI. Participant was included as a random effect. For 
the key secondary outcome (FMD), P ≤ 0.05 was deemed significant. For all other secondary outcomes, P ≤ 0.01 was deemed as significant.  
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3 Assessed with the use of a modified Framingham risk score, where a score of ≥ 2 points relates to a 1.5-fold higher risk of CVD than the population 
mean (164, 165, 201). 
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Supplemental Table 3.4 Target FA intakes and reported dietary intake at baseline (wk-0) and the change from baseline (Δ) following consumption of 
the modified and control dairy products for 12-wk in adults at moderate risk of cardiovascular disease1. 
         
 Modified diet 
 Control diet  
 Baseline Δ T
2  Baseline Δ T2 P3 
Energy, MJ/d 8.2 ± 0.3 1.0 ± 0.4   8.5 ± 0.4 0.5 ± 0.3 
 0.60 
Total fat, %TE 36.1 ± 0.8 5.0 ± 1.1 38.0  36.5 ± 0.8 3.0 ± 0.9 38.0 0.03 
SFA, %TE 14.2 ± 0.5 2.7 ± 0.6 19.0  13.9 ± 0.5 5.2 ± 0.6 16.0 <0.001 
MUFA, %TE 11.7 ± 0.4 3.6 ± 0.5 11.0  11.9 ± 0.4 -0.1 ± 0.3 14.0 <0.0001 
n-6 PUFA, %TE 3.9 ± 0.2 -0.5 ± 0.2   4.6 ± 0.2 -1.3 ± 0.2 
 0.08 
n-3 PUFA, %TE 0.7 ± 0.0 -0.1 ± 0.1   0.8 ± 0.1 -0.2 ± 0.1 
 0.34 
Total PUFA, %TE 4.6 ± 0.2 -0.4 ± 0.2   5.8 ± 0.4 -1.4 ± 0.3 
 0.14 
TFA, %TE 0.9 ± 0.1 1.6 ± 0.1   1.0 ± 0.1 0.3 ± 0.1 
 <0.0001 
Protein, %TE 16.9 ± 0.5 -0.7 ± 0.6   16.3 ± 0.5 -0.2 ± 0.5 
 0.80 
Carbohydrates, %TE 46.6 ± 1.3 -4.4 ± 1.5   46.3 ± 0.9 -3.0 ± 0.9 
 0.19 
Alcohol, %TE 2.9 ± 0.5 -0.2 ± 0.5   3.1 ± 0.5 0.0 ± 0.4 
 0.35 
Dietary fiber (AOAC), g/d 20.2 ± 1.1 -0.8 ± 1.2   20.4 ± 1.1 1.6 ± 0.9 
 0.03 
Sodium, g/d 2.5 ± 0.2 -0.6 ± 0.1   2.7 ± 0.2 -0.5 ± 0.1 
 0.03 
 
Adapted with permission from Markey et al. (15). 
1 Values are given as means ± SEMs. Dietary intakes estimated from 4-d weighed dietary records at baseline (week 0) and change from baseline (Δ). 
AOAC, association of analytical communities; TE, total energy; TFA, trans fatty acids. 
2 Target FA intakes for the modified and control dietary exchange periods. 
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3 Mixed model analyses were used to calculate overall effect of treatment based on change-from-baseline values, with adjustments made for fixed effects 
of baseline values of the assessed variable, period, treatment sequence, gender, age and BMI. Participant was included as a random effect. P ≤ 0.01 
deemed as significant. 
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Supplemental Table 3.5 Proportion of plasma phospholipid fatty acids at baseline (wk-0) and the change from baseline (Δ) following consumption of 
the modified and control diets for 12-wk in adults at moderate cardiovascular risk1 
       
 Modified diet 
 Control diet P2 
 Baseline Δ 
 Baseline Δ  
Total SFA 46.52 ± 0.21 -0.60 ± 0.21  46.37 ± 0.17 0.01 ± 0.17 0.006 
Total cis-MUFA 11.21 ± 0.18 0.99 ± 0.20  11.02 ± 0.16 0.21 ± 0.15 <0.0001 
Total trans-MUFA 0.10 ± 0.00 0.12 ± 0.01  0.12 ± 0.00 0.12 ± 0.00 <0.0001 
Total n-3 PUFA 5.34 ± 0.21 -0.47 ± 0.14  5.35 ± 0.23 -0.39 ± 0.14 0.58 
Total n-6 PUFA 35.83 ± 0.32 0.03 ± 0.33  36.15 ± 0.34 0.15 ± 0.26 0.32 
 
Adapted with permission from Markey et al. (201). 
1 Values are means ± SEMs.  
2 Mixed model analyses were used to calculate overall effect of treatment based on change-from-baseline values, with adjustments made for fixed 
effects of baseline values of the assessed variable, period, treatment sequence, gender, age and BMI. Participant was included as a random effect. P ≤ 
0.01 deemed as significant. 
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Supplemental Table 3.6 Predictive equations for estimating changes in total cholesterol and LDL-C in response to changes in dietary fatty acids (as 
percent of energy)1. 
   
Predictive equations for estimating change in TC and LDL-C 
according to date of publication 
 Estimated change following the modified and control diet 
   
Keys et al. 1965 (28)  Modified: ΔTC = 0.17 mmol/L 
ΔTC = 0.0621ΔS - 0.0310ΔP  Control: ΔTC = 0.37 mmol/L 
   
Hegsted et al. 1965 (29)   
ΔTC = 0.0543ΔS - 0.03115ΔP - 0.00318ΔM  Modified: ΔTC = 0.17 mmol/L; ΔLDL-C = 0.13 mmol/L 
ΔLDL-C = 0.0449ΔS - 0.0198ΔP  Control: ΔTC = 0.37 mmol/L; ΔLDL-C = 0.26 mmol/L 
   
Mensink and Katan 1992 (30)   
ΔTC = 0.0556ΔS - 0.0031ΔM - 0.015ΔP  Modified: ΔTC = 0.17 mmol/L; ΔLDL-C = 0.13 mmol/L 
ΔLDL-C = 0.033ΔS - 0.006ΔM - 0.014ΔP  Control: ΔTC = 0.37 mmol/L; ΔLDL-C = 0.26 mmol/L 
   
Clarke et al. 1997 (31)   
ΔTC = 0.052ΔS - 0.026ΔP + 0.005ΔM  Modified: ΔTC = 0.17 mmol/L; ΔLDL-C = 0.08 mmol/L 
ΔLDL-C = 0.036ΔS - 0.022ΔP - 0.008ΔM  Control: ΔTC = 0.31 mmol/L; ΔLDL-C = 0.22 mmol/L 
   
Howell et al. 1997 (32)   
ΔTC = 0.0496ΔS - 0.0233ΔP  Modified: ΔTC = 0.15 mmol/L; ΔLDL-C = 0.14 mmol/L 
ΔLDL-C = 0.0468ΔS - 0.0128ΔP  Control: ΔTC = 0.29 mmol/L; ΔLDL-C = 0.28 mmol/L 
 
1Summarized predictive equations according to author and publication year are presented, followed by the predictive change in total cholesterol (TC) 
and low-density lipoprotein cholesterol (LDL-C) for the modified and control diets, as previously published. M; monounsaturated fatty acids. P, 
polyunsaturated fatty acids; S, saturated fatty acids; Δ, change from baseline. 
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Supplemental Figure 3.1 RESET Participant flowchart
Subjects screened for eligibility (n = 130) 
Familiarization visit (n = 80)
Excluded by screening visit (n = 50)
 Declined to participate (n = 4)
Randomly assigned (n = 76)
Allocated to modified diet intervention (n = 37) 
 Received allocated intervention (n =  33)
 Did not receive allocated intervention (n = 4)  
- Declined to participate due to time
commintment (n = 4)
Allocated to control diet intervention (n = 39) 
 Received allocated intervention (n = 37)
 Did not receive allocated intervention (n = 4) 
- Declined to participate due to time 
commintment (n = 2)
Allocation
Enrollment
Discontinued intervention (n = 7)
- Unable to comply (n = 4)
- Declined to continue due to time commitment 
(n = 2)
- Declined to continue for personal issue (n = 1)
Discontinued intervention (n = 6)
- Unable to comply (n = 4)
- Declined to continue due to unrelated health
issues (n = 2)
Allocated to modified diet intervention (n = 31)
Received allocated intervention (n = 30)
Did not receive allocated intervention (n = 1)
- Declined to participate due to unrelated
Allocated to control diet intervention (n = 26)
Received allocated intervention (n = 25)
Did not receive allocated intervention (n = 1)
- Unable to comply (n = 1) 
Follow up
Discontinued intervention (n = 1)
-Declined to continue for personal issue (n = 1)Follow up
Per protocol analysis for primary and key
secondary endpoints (n = 54)
Discontinued intervention (n = 1)
-Declined to continue for personal issue (n = 1)
Crossover
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4.1 Abstract 
 
Background: Chronic dietary fat manipulation has been shown to impact on postprandial 
lipaemia, an independent cardiovascular disease (CVD) risk marker.   
Objective: To determine the impact of long-term consumption of dairy products with a 
different dietary fatty acid (FA) profile on postprandial endothelial function (primary outcome) 
and other CVD risk markers to sequential meal ingestion.  
Design: In a randomized, double-blinded, crossover, controlled design, participants (n = 76; 
25-70 y) with a 1.5-fold higher CVD risk were assigned to receive a high-fat, high-dairy diet 
(38% total energy intake (%TE) from total fat) by incorporating either conventional (control; 
dietary target: 19%TE SFA; 11%TE MUFA) or SFA-reduced, MUFA-enriched (modified; 
16%TE SFA; 14%TE MUFA) dairy products for 12-wk in random order, with an 8-wk washout 
period between diets. A sequential two-meal challenge was performed at the beginning and end 
of each intervention period using the same dairy products as the assigned intervention diet. 
Linear mixed model analyses determined overall treatment effects based on change in 
postprandial summary response measures from the pre-intervention (wk-0) to the post-
intervention study (wk-12) visit on measurements of endothelial function, lipaemia, 
inflammation and plasma total lipid fatty acids FA. 
Results: Fifty-two participants (31 men, 21 women; 53 ± 2 y; BMI 25.8 ± 0.5 kg/m2) completed 
the study. The change in the postprandial apolipoprotein (apo)B incremental area under the 
curve (iAUC) to the modified meals was significantly lower compared to following the control 
meals (P = 0.004). Significant changes in specific plasma total FA were observed which 
reflected the dairy fat composition of the dietary intervention and test meal. There were no 
significant differences in any of the other postprandial CVD risk markers. 
Conclusion: Our findings suggest that chronic consumption of SFA-reduced, MUFA-enriched 
dairy products led to an attenuating response to the postprandial iAUC of apoB, compared to 
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iso-energetic control test meals, suggestive of a beneficial impact on triacylglycerol-rich 
lipoprotein metabolism.   
Keywords: dairy fat, cardiovascular disease risk, sequential test meal protocol, postprandial 
lipaemia, apoB, flow-mediated dilatation, saturated fatty acids, monounsaturated fatty acids, 
vascular function.  
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4.2 Introduction 
 
Postprandial lipaemia is recognised as an independent risk factor of cardiovascular disease 
(CVD)11. In this context, the fatty acid (FA) composition of meals plays an important factor in 
modulating postprandial lipaemia, determining magnitude and clearance of circulating 
triacylglycerol (TAG), glucose and insulin (107, 108).The consumption of moderate to high-
fat meals (36 – 80 g total fat), has been shown to transiently impair endothelial function (218, 
226),  characterized in part by a decreased bioavailability of nitric oxide (NO), raised TAG-rich 
lipoproteins (TRL) and an increased expression of pro-inflammatory cytokines and cellular 
adhesion molecules (227-229).  
A reduction in total saturated fatty acid (SFA) intake and a parallel substitution with 
unsaturated FAs remains a key dietary recommendation aimed at reducing CVD risk (10). 
However, most of the evidence is based on intervention trials which have investigated the 
impact of SFA substitution on fasting outcome measures of CVD risk (23, 199). Although there 
is a wealth of evidence from postprandial investigations on the modulatory effects of dietary 
FA composition, fewer studies have considered the long-term dietary fat substitution followed 
by a postprandial investigation implemented with test meals reflective of the dietary 
intervention (108). Additionally, evidence from intervention trials evaluating the incorporation 
of MUFA in dietary interventions on both fasted and postprandial outcomes have observed 
improvements for CVD risk factors (23, 230, 231). However, the source of MUFA incorporated 
in test meals has been primarily of plant origin and postprandial investigations have mainly 
focused on postprandial lipaemia in isolation from other risk factors (232-236). Furthermore, 
there is evidence of a beneficial effect of MUFA, as olive oil, and FMD response in the fasting 
state (237). Therefore, further studies are needed to determine the mechanisms underlying the 
effects of MUFA on established and novel risk markers, including endothelial function and 
postprandial lipaemia, in response to dietary FA manipulation.  
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Supplementation of the dairy cow diet is a feasible strategy leading to partial 
replacement of SFA in milk fat, whilst maintaining the beneficial properties related to dairy 
consumption and removing SFA from the food chain (150, 203). Dairy products, contributing 
up to 35% of mean total SFA intake in the UK population (10) have not been linked to 
detrimental effects of CVD risk (with the exclusion of butter) (36, 47). Initial findings from the 
RESET study have shown that a 12-wk daily intake of SFA-reduced, MUFA-enriched dairy 
products attenuated the rise in fasting LDL-cholesterol (LDL-C) and increased fasting nitrite 
concentrations, compared to conventional matched dairy products (238). However, little is 
known of the impact of long term consumption of modified dairy products on postprandial 
markers of vascular function, lipemia and inflammatory markers. 
The aim of the REplacement of SaturatEd fat in dairy on Total cholesterol (RESET) 
acute-within-chronic study was to investigate the effects of modified UHT milk, Cheddar 
cheese and butter consumption for 12-wk on postprandial endothelial function, lipaemia and 
other secondary markers of CVD risk, following a two-meal challenge and compared to control 
products. We hypothesized that long-term consumption of SFA-reduced, MUFA-enriched dairy 
products would beneficially impact on postprandial endothelial function (measured as %FMD 
response, primary outcome measure), lipaemia and inflammatory markers (secondary outcome 
measures).  
4.3 Methods 
 
4.3.1 Study design and participants 
 
The RESET trial was given a favourable ethical opinion for conduct by the University 
of Reading Ethics Committee (Reference no. 13/43), registered at clinicaltrials.gov as 
NCT02089035 and carried out in accordance with the Declaration of Helsinki. The trial was a 
double-blind, randomized, controlled crossover 12-wk dietary intervention study with an 8-
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wk washout period between the two intervention arms. The study was conducted at the the 
Hugh Sinclair Unit of Human Nutrition, University of Reading. Between February 2014 and 
September 2015, men and women aged 25-70 y with 1.5-fold higher CVD risk were recruited 
from the Berkshire area (United Kingdom) in three cohorts. The study was completed in April 
2016. All participants gave their written informed consent prior to starting the study. 
Details of the chronic study design including participant recruitment, inclusion and 
exclusion criteria and dietary intervention are presented in detail elsewhere (201, 238). 
Briefly, fasted screening values of serum TC, HDL-C, glucose, blood pressure (BP), BMI and 
family history of CVD were used to assess eligibility. Based on a modified Framingham risk 
analysis, a score of   ≥2 CVD risk points indicated a 1.5-fold higher CVD risk compared to 
the population mean (164). Participants were randomly allocated to one of two dietary 
intervention groups, whereby Group 1 received the modified diet first (wk-0 – wk-12), 
followed by the control diet (wk-20 – wk-32) and vice-versa for Group 2. Randomization was 
performed using a minimization technique which stratified by age, gender, BMI and fasting 
serum TC (202).. An iso-energetic high dairy daily dietary exchange (38% TE from total fat) 
was achieved through replacement of habitually consumed dairy products, oil/spreads and 
snacks with either the SFA-reduced, MUFA-enriched ultra-high temperature (UHT) milk, 
Cheddar cheese and butter (modified dietary target: 16%TE SFA, 14%TE MUFA) or matched 
conventional dairy products (control dietary target: 19% SFA, 11%TE MUFA) (201). At pre- 
and post-intervention visits for each dietary period a sequential meal postprandial study was 
performed, incorporating dairy products from the assigned dietary intervention.   
The 480 min postprandial study visits took place at the beginning (pre-intervention: 
wk-0; wk-20) and end (post-intervention: wk-12; wk-32) of the two dietary interventions. A 
total of 52 participants completed the acute-within-chronic study (see Supplemental Figure 1 
for flowchart). 
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4.3.2 Visits and test meals 
Production of the SFA-reduced, MUFA-enriched (modified) milk and dairy products 
and RESET food exchange model have been described in detail elsewhere (201, 203). As 
previously described (239), during the 12-wk of each intervention period, participants 
consumed daily amounts of the study products, provided in blinded packaging: 340 g UHT 
milk, 45 g Cheddar cheese and 21.5 g (control diet) or 25.1 g (modified diet) butter. 
Compliance was monitored using 4-d food diaries (pre- and post-intervention), daily 
consumption records and plasma phospholipid FA analysis, the results of which have been 
published (201). 
Participants refrained from alcohol and aerobic exercise 24 h prior to each 
postprandial study visit (239). For standardization purposes, a low-fat meal (< 1.46 MJ; < 7 g 
total fat) and low nitrate mineral water (Buxton) were provided for consumption on the 
evening prior to each study visit before fasting overnight for 12 h drinking only water during 
this time. All visits were conducted in a temperature controlled room (22 ± 1 °C) whereby on 
arrival, participants were required to rest for 30 min in the supine position before a cannula in 
the antecubital vein of the forearm was inserted, to allow frequent blood sampling. Fasted 
blood samples were collected and measurement of endothelial function by flow mediated 
dilatation (FMD) was performed. After a second fasted blood draw (0 min), the breakfast test 
meal was provided and consumed within 20 min. The breakfast test meal contained 50 g total 
fat and consisted of a milkshake prepared with study UHT milk (330 g) and strawberry syrup 
(19 g), Cornflakes (38g, Kellogg’s) with UHT study milk (195 g), two slices of toasted bread 
(75 g; Kingsmill white medium) with study cheese (32.6 g) and butter (29.4 g for the control 
and 32.6 g for the modified meals respectively). The test lunch meal provided at 330 min, 
contained 30 g total fat and was consumed within 20 min. It consisted of a milkshake 
prepared with UHT study milk (control: 350 g; modified: 352 g) and 27 g strawberry syrup 
and two toasted slices of bread (60 g) with 15 g study cheese and butter (control: 18.6 g; 
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modified: 19.8 g). Both modified and control test meals contained dairy products identical to 
those assigned in the specific dietary intervention. The nutrient profile of the test meals is 
presented in Table 4.1. During the acute study visit, frequent blood samples were drawn, for: 
TAG, non-esterified fatty acids (NEFA), insulin, glucose at 0, 30, 60, 90, 120, 180, 240, 300, 
330, 360, 390, 420, 480 min; apolipoprotein (apo)B similar time points, with the exclusion of 
30, 90, 330 min time points. Endothelial function, measured by FMD, was assessed at 180, 
300 and 420 min postprandially. At the FMD timepoints, blood samples were also collected 
for the assessment of plasma cellular adhesion molecules, whole blood culture (WBC) for 
determination of LPS-stimulated cytokines, plasma nitrite/nitrate and total lipid FA.  
4.3.3 Biochemical analyses  
Blood samples were collected into lithium heparin, EDTA or serum separator blood 
collection tubes (VACUETTE, Greiner Bio-One) and subsequently processed as previously 
detailed (239). Blood samples collected for the determination of LPS-stimulated cytokines in 
WBC were not centrifuged and were stored at 4 °C until processing. 
TAG, NEFA, apoB and glucose were measured using an ILAB 600 clinical chemistry 
autoanalyzer (TAG and glucose reagents and analyzer: Werfen UK Ltd; apoB reagent: 
Randox Laborarories Ltd; NEFA reagent: Alpha Laboratories Ltd). A HPLC (ENO-30, 
EiCom Corporation, San Diego) coupled with an online reduction of nitrate to nitrite and 
post-column derivatization with the Greiss reagent (ENO-30 Analyzer, EiCom Corporation, 
San Diego) was used for the determination of plasma nitrite and nitrate. Insulin, vascular and 
intercellular adhesion molecules (VCAM, ICAM), E-selectin and P-selectin were analyzed 
with ELISA kits (Dako Ltd. and R&D Systems Europe Ltd., respectively). Mean inter-assay 
CVs were <10% for all assays. 
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4.3.4 Whole blood cultures 
Whole blood samples collected in K2EDTA tubes were diluted 1:9 with RPMI 1640 
medium (Sigma, UK) supplemented with 1% antibiotics, 1% L-glutamine and 1% non-
essential amino acids (Bioscience, UK). Diluted blood samples were cultured in 12-well 
plates (Greiner bio-one, UK) with 0.5 μg/ml of bacterial lipopolysaccharide (LPS; E. coli 
026:B6, Sigma, UK), leading to a final concentration of 0.05 μg/ml. WBC were subsequently 
incubated at 37 °C for 24 h before centrifugation at 700 x g (1000 rpm) to isolate the 
supernatant, which was stored at -20 °C until analysis. Measurement of the monocyte count of 
each sample was performed by the Pathology Department at the Royal Berkshire Hospital 
(Reading, UK). A human cytokine premixed 5-Plex Panel (IL-6, IL-8, IL-1β, IL-10, TNF-α; 
R&D Systems Europe Ltd) and a Luminex 200 with xPONENT software was used to measure 
the concentrations of cytokines in the WBC supernatant in a 1:2 dilution. Cytokine production 
was corrected for the number of monocytes in the whole blood sample. 
4.3.5 Total lipid fatty acid analysis 
Total lipid was extracted from plasma samples isolated from blood samples collected 
at 0, 180, 300 and 420 min on each study visit using the method described by Burdge et al 
(178). Briefly, lipid was extracted using using chloroform-methanol (2:1, v/v), redissolved in 
toluene and methylated (2% H2SO4 in methanol, incubation for 2 h at 50 °C). Resulting 
FAME were resolved on 100 m fused silica capillary column (CP-SIL 88, Agilent 
Technologies, Cheshire, UK) using a gas chromatograph (Bruker 350, Bruker, Germany), 
with a flame ionisation detector. GC conditions were as previously described (188). Plasma 
FAME were identified based on retention time comparisons with an authentic standard (GLC 
#463, Nu-Chek-Prep Inc, Elysian, MN) and cross referencing with previously published 
chromatograms (240). Carbon deficiency in the flame ionization detector response for FAME 
containing 4- to 10-carbon atoms was accounted for using a combined correction factor which 
also converted FAME to FA (241). Results were expressed as g/100 g total FAs.  
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4.3.6 Statistical analysis 
Power calculations were performed for the study’s primary outcome measure: change 
in FMD response. At 80% power and 5% significance, the minimum number of participants 
required to detect a 1.4% inter-intervention difference in FMD with an SD of 2.3% was 
calculated as n = 45 (179). With the allowance for a 15% dropout rate we aimed to recruit a 
minimum of 52 participants.  
Statistical analyses were conducted using the SAS 9.4 University edition statistical software 
(SAS Institute Inc., Cary, NC, USA). All variables were checked for normality and data was 
logarithmically transformed where needed. The total area under the curve (AUC) for the 
postprandial period was calculated for all variables using the trapezoidal rule, which was 
subtracted from the fasting value to derive incremental AUC (iAUC). The inclusion of the 
iAUC summary response measure provides an accurate indication of the change in the 
postprandial response to the sequential meal ingestion (242). For postprandial variables with 
10 (apoB) or 13 (TAG, NEFA, insulin, glucose) time points, maximum concentration (CMax) 
and time to reach maximum concentration (TTMax) were also calculated. Percentage NEFA 
suppression was also calculated since there is initial drop in NEFA concentration following 
meal ingestion. Using a linear mixed-model, treatment effects were evaluated, with 
differences in the postprandial summary measures from the pre-intervention to the post-
intervention study visit calculated (e.g. AUC at wk-12 minus AUC at wk-0) as the dependent 
variable, adjusted for fixed effects of the baseline pre-intervention values of the assessed 
variable, period, sequence, treatment, age, gender and BMI. Participant was included as a 
random effect. A per-protocol analysis approach was adopted due to the proof-of concept 
nature of the study. No period effects were observed for any outcome measure. Postprandial 
summary measures are presented in tables as mean ± SEMs. For the primary outcome 
measure, %FMD response, a P < 0.05 was taken as significant. For all other outcome 
measures, P ≤ 0.01 was considered significant to adjust for multiple comparisons. 
 130 
 
4.4 Results 
 
4.4.1 Participants 
Baseline characteristics of the 52 completing participants are presented in Table 4.2. 
All test meals were well tolerated by the participants. 
4.4.2 Biochemical analyses 
Postprandial responses in apoB, TAG, NEFA, glucose and insulin expressed as AUC, 
iAUC, CMax and TTMax are presented in Table 4.3. We observed a significantly greater 
reduction in the iAUC for the postprandial apoB response following the modified test meals, 
compared to the control test meals (P = 0.004). The AUC, CMax and TTMax for the apoB 
response were not differentially affected by the two dairy test meals. Additionally, the change 
in the postprandial summary measures of TAG, NEFA, glucose and insulin following the 
control and modified test meals were not significantly different. 
4.4.3 Nitric oxide and cellular adhesion molecules 
There was a tendency for a reduction in the iAUC for the nitrite response following 
the modified test meals, compared to an increase in iAUC following the control test meals (P 
= 0.05).  The two dairy test meals did not significantly impact on the postprandial responses 
for plasma nitrate or any of the cellular adhesion molecules (Table 4.4).  
4.4.4 Whole blood culture 
As shown in Table 4.4, there were no significant changes in the postprandial summary 
measures of LPS-stimulated cytokines following the modified and control test meals.   
4.4.5 Postprandial total lipid fatty acids 
Following the two 12-wk dietary interventions, there were significant differences in 
the change in the iAUC summary measure for total FA response between the modified and 
 131 
 
control test meals (Table 4.5). The iAUC response for total SFA significantly decreased after 
consumption of the modified test meals, and compared to control (P = 0.0001). In particular, 
the iAUC of 15:0 and 18:0 were significantly lower following the modified test meals and 
compared to control test meals (P = 0.0001 and P = 0.01, respectively). 
Change in iAUC response of total cis-MUFA was not significantly different between 
the two diets. However, the iAUC change in total trans-MUFA and total trans FA response 
was significantly lower following the modified test meals (P = 0.009 and P = 0.008 
respectively), compared to control.  
For total PUFA, change in iAUC was significantly lower following the modified test 
meals, compared to the control (P = 0.001). Similarly, change iAUC response for both n-3 
and n-6 PUFA reflected the iAUC change in total PUFA (P = 0.002 and P = 0.001, 
respectively).  For all other FAs presented in Table 5.4, postprandial iAUC summary response 
measures were not influenced by the intervention test meals. 
4.5 Discussion 
 
Using an acute-within-chronic design, the aim of this novel study was to compare the 
effect of long-term consumption of FA-modified dairy products and conventional 
counterparts on postprandial changes in endothelial function, lipaemia and inflammation in 
adults at moderate CVD risk. We observed a lower response in the iAUC for apoB response 
following a sequential two-meal challenge of the FA-modified dairy products. Additionally, 
our total lipid FA results reflected the current dietary intervention and test meals fat 
composition. 
ApoB is considered a marker of the number of circulating TRLs (243). Several studies 
have investigated the long-term consumption of diets with a differential FA composition and 
the subsequent impact on the postprandial state following ingestion of test meals 
representative of the dietary intervention. However, it should be noted that most have focused 
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on an enrichment of dietary interventions with PUFA, while sources of MUFA have mainly 
originated from plant oils, particularly olive oil, which is in contrast to our study design (232, 
233). In an 8-wk cross-over study, Roche et al. (232) investigated the long-term effect of two 
dietary interventions (41%TE total fat) rich in either SFA (51% SFA; 38% MUFA) or MUFA 
(39% SFA; 56% MUFA) in the form of spreads and oils, which was followed by a 
postprandial investigation in healthy men. The MUFA-rich diet led to a significant beneficial 
impact in fasting LDL-C and an attenuation in the postprandial activation of factor VII (232). 
An additional study used spreads and cooking oils to implement a chronic substitution of a 
dietary SFA (16% SFA; 12% MUFA) with either a moderate (13% SFA; 15% MUFA) or 
high (10% SFA; 18% MUFA) MUFA diet for 8-wk in 51 healthy adults (244). A sub-cohort 
of the main study’s population completed a postprandial intervention which included a 
standard test meal and resulted in a 30-40% reduction in the postprandial number of 
circulating intestinally derived lipoproteins following the moderate and high MUFA diets 
respectively (244). It is worth noting, that in addition to the implementation of MUFA-rich 
test meals sourced from plant oils, the aforementioned studies also present a degree of 
heterogeneity in study populations which precludes from making definite comparisons with 
our study. However, the evidence from these studies suggests an impact in the kinetics of 
postprandial responses following MUFA-rich diets, influencing the number and size of TRLs 
and increasing the rate of clearance in the circulation (107). The decrease in postprandial 
iAUC of apoB may therefore be related to the observed fasting LDL-C attenuation we 
observed following intake of the SFA-reduced, MUFA-enriched dairy products in the 12-wk 
dietary intervention, compared to conventional dairy products (239). Furthermore, the 
findings from a previously published in vitro study investigating the consumption of a single 
SFA-rich meal, suggested greater competition for LDL-C uptake between circulating TRLs in 
HepG2 liver cells, compared to circulating TRLs following MUFA-rich meals(245). This may 
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in turn suggest a potential mechanism to explain higher circulating LDL-C observed 
following ingestion of SFA-rich diets (245).   
Postprandial studies which have investigated the impact of FA-modified dairy 
products following modifications of the dairy cow diet, have primarily focused on 
implementing a dietary intervention using modified butter fat. Tholstrup et al. (223) compared 
the effects of 4-wk consumption of Danish butter (40%TE from fat; 37% palmitic acid; 15% 
oleic acid) and a FA-modified butter (21% palmitic acid; 25% oleic acid) in 18 healthy men in 
a cross-over design. The postprandial investigation following each standard meal resulted in 
no significant changes in postprandial lipid markers, which the authors suggest may be 
attributed to a 5-fold increase in trans 18:1 in the modified butter compared to the control diet 
(223). However, in contrast to our study design, Tholstrup et al. (223) used only butter fat in 
the chronic intervention and a standard test meal not representative of the dietary intervention 
in a small number of participants, which may explain null findings.  
The FA composition of study meals have specific characteristics, which may influence 
digestion rate and absorption (108). In the current study, we observed significant changes in 
postprandial iAUC responses in the plasma concentration of total lipid FA classes, which 
appear reflective of the FA composition of the test meals. In particular, there was a marked 
difference in the postprandial iAUC response of total trans FA (TFA) and trans MUFA 
following the modified diet, reflecting the observed increase in ruminant TFA (rTFA) of the 
dairy products following supplementation of the dairy cow feed (201, 203). Although there is 
less evidence for a detrimental effect of rTFA compared to their industrial counterparts (220), 
the recommended TFA intake from all sources should not exceed 2% total food energy (10). 
The FA modified study meals had a higher (2.9 g/d) rTFA content compared to the control 
study meals, which do not appear to have detrimental effects postprandially. Similarly, 
differences in the iAUC postprandial response of total and specific classes of SFA is in line 
with the observed partial replacement of SFA in the modified dairy products (201, 203).  
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Inflammation and endothelial function in the postprandial state have also been 
attributed to a progressive detrimental effect on CVD risk, in particular following high SFA 
intake (98). In our previous publication, we observed a significant increase in fasted nitrite 
concentrations following 12-wk consumption of the modified diet, and compared to control 
diet (239). Postprandial TAG and NEFA following, high-fat meals, have been shown to 
reduce concentrations of NO, impacting on postprandial NO-dependent FMD of the brachial 
artery (246, 247). In the current study, we observed a tendency for a non-significant decrease 
in the postprandial iAUC for the plasma nitrite response following the modified test meals, 
compared to control. Interestingly, this response supports the change in fasted nitrite 
concentrations, which significantly increased following 12-wk consumption of the modified 
diet , relative to baseline, when compared with the control (238). 
The two dairy test meals did not significantly impact on the postprandial summary 
response measures of the cellular adhesion molecules. This is in agreement with a study 
which compared the postprandial effects of 3 iso-caloric high fat milkshakes (95 g total fat), 
either high in SFA (54%TE), MUFA (83%TE) or n3 PUFA (40%TE) in lean and obese 
middle aged men (248). Previous studies have demonstrated a triggering of postprandial, pro-
inflammatory cytokine production following high-fat meal intake with a moderate to high 
SFA content (249-251). It is therefore possible that the moderate reduction in total SFA and 
parallel increase of MUFA in the modified dairy products, compared to the control (201, 238), 
did not elicit a differential impact on adhesion molecules or LPS-stimulated cytokines. 
Additionally, the evidence to date on inflammatory postprandial biomarker response to meal 
FA composition remains inconclusive (252). This may allude to variations in measurements 
observed in both healthy and at risk individuals, linked to additional participant characteristics 
which may affect the concentration of inflammatory markers (including age, overall diet and 
genetics) (98). 
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A strength of the current study is the double-blinded, crossover, randomized and long-
term design. Additionally, the sequential two-meal challenge and 480 min postprandial 
investigation more closely reflected Western dietary patterns. Furthermore, the breakfast and 
lunch test meals of the postprandial intervention contained representative quantities of the 
dairy study products which were used in the chronic dietary intervention. Our  study 
population was at moderate CVD risk and evidence supports that compared with healthy 
subjects, individuals at risk may be more sensitive to meal challenges (108). However, as the 
eligibility of participants was based on an overall scoring ≥2 CVD risk markers, baseline 
fasting characteristics of all participants were not homogenous with respect to CVD risk 
factors. This may potentially have led to the lack of an impact on the change in postprandial 
responses of specific markers of postprandial lipaemia, such as TAG and NEFA. Lastly, as 
described in our previous publication (238), there were modest differences in the SFA and cis-
MUFA content between the FA-modified and control dairy products and test meals which 
may also explain a lack of differential postprandial responses in some of our secondary 
outcome measures.  
In conclusion, the present study indicates that 12-wk consumption of SFA-reduced, 
MUFA-enriched dairy products, led to a reduction in the postprandial iAUC response of 
apoB, following sequential test meals representative of the dietary intervention, suggesting an 
effect on TRL metabolism. The results of the postprandial FMD response, particularly in light 
of the postprandial nitrite response, may further add to  a better understanding of the impact of 
FA-modified dairy consumption 
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Table 4.1 Nutritional composition of the sequential test breakfast and lunch meals consumed by participants at baseline (wk-0) and post-intervention 
(wk-12) of the modified and control high-fat, high dairy diets1 
 
                  
 Energy Protein CHO Fat SFA MUFA PUFA Trans MUFA 
  MJ g (%TE) g (%TE) g (%TE) g (%TE) g (%TE) g (%TE) g (%TE) 
Breakfast (0 min)         
 Modified diet 4.3 36.1 (14.1) 105.9 (41.3) 50.6 (44.3) 24.5 (21.5) 20 (17.5) 2.9 (2.5) 3.9 (3.4) 
 Control diet 4.1 39.7 (16.1) 101.4 (41.0) 49.9 (45.5) 31.7 (28.8) 12.3 (11.2) 2.8 (2.5) 2.2 (2.4) 
Lunch (330 min)         
 Modified diet 2.6 20.9 (13.5)  64.6 (41.6) 30.6 (44.3) 14.8 (21.4) 12.1 (17.5) 1.8 (2.7) 2.6 (3.8) 
 Control diet 2.5 19.6 (13.1) 63.3 (42.4) 30.3 (45.6) 19.1 (28.8) 7.4 (11.1) 1.8 (2.8) 1.4 (2.0) 
 
 
 
1Values represent total energy and macronutrient quantities of each test meal according to modified and control diet. CHO, carbohydrates, TE, total 
energy.  
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Table 4.2 Baseline screening characteristics of participants who completed the acute-within-chronic RESET study1 
 
      
  Value 
Total (men/women) n  31/21 
Age, y  53 ± 2 
Weight, kg  76 ± 2 
BMI, kg/m²  26 ± 1 
Waist circumference, cm 90 ± 1 
SBP, mm Hg  129 ± 2 
DBP, mm Hg  75 ± 1 
TC, mmol/L  5.71 ± 0.12 
HDL-C, mmol/L  1.59 ± 0.04 
TAG, mmol/L  1.18 ± 0.06 
Glucose, mmol/L  5.53 ± 0.10 
Risk score2   3 ± 1 
   
 
   
1Values are means ± SEMs, n = 52. DBP, diastolic blood pressure; TC, total cholesterol; TAG, triacylglycerol; SBP, systolic blood pressure. 
2Assessed with the use of a modified Framingham risk score, where a score of ≥ 2 points relates to a 1.5-fold higher risk of CVD than the population 
mean (164, 165, 201)
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Table 4.3 Postprandial summary measures of apoB, lipids, glucose and insulin responses to sequential modified and control dairy test1 
                          
  Modified diet  Control diet  
 Pre   Post   Δ   Pre   Post   Δ P² 
ApoB             
AUC (g/L x 480 min) 475 ± 14  477 ± 15  4 ± 7  467 ± 14  487 ± 14  19 ± 6 0.06 
iAUC (g/L x 480 min) -16 ± 3  -20 ± 3  -4 ± 3  -11 ± 2  -9 ± 2  3 ± 3 0.004 
Cmax (g/L) 1.04 ± 0.03  1.05 ± 0.03  0.01 ± 0.02  1.03 ± 0.03  1.07 ± 0.03  0.04 ± 0.02 0.29 
TTmax (min) 209 ± 23  208 ± 22  -1 ± 31  210 ± 22  224 ± 23  14 ± 29 0.36 
TAG              
AUC (mmol/L x 480 min) 953 ± 52  1018 ± 72  72 ± 55  879 ± 41  906 ± 54  55 ± 40 0.26 
iAUC (mmol/L x 480 min) 354 ± 25  388 ± 30  34 ± 28  321 ± 23  332 ± 27  19 ± 20 0.14 
Cmax (mmol/L) 2.8 ± 0.1  2.9 ± 0.2  0.1 ± 0.1 
 
2.6 ± 0.1  2.6 ± 0.2  0.0 ± 0.1 0.62 
TTmax (min) 359 ± 9  330 ± 10  -25 ± 11  334 ± 9  324 ± 12  -10 ± 25 0.43 
NEFA             
AUC (mmol/L x 300 min) 92 ± 4  95 ± 4  2 ± 4  97 ± 4  97 ± 3  1 ± 3 0.37 
iAUC (mmol/L x 300 min) -108 ± 8  -87 ± 10  18 ± 9  -103 ± 11  -86 ± 9  18 ± 10 0.65 
Cmax (μmol/L) 565 ± 25  523 ± 20  -42 ± 28  555 ± 24  564 ± 24  9 ± 28 0.12 
TTmax (min x 300 min) 172 ± 24  203 ± 24  31 ± 29  227 ± 24  177 ± 23  -50 ± 25 0.34 
suppression (%) 43 ± 2  39 ± 2  -4 ± 2  41 ± 2  38 ± 2  -4 ± 2 0.98 
Glucose             
AUC (mmol/L x 480 min) 2937 ± 61  2925 ± 63  -15 ± 32  2866 ± 59  2888 ± 85  44 ± 42 0.43 
iAUC (mmol/L x 480 min) 345 ± 39  358 ± 49  14 ± 50  283 ± 38  302 ± 38  25 ± 31 0.61 
Cmax (mmol/L) 8.3 ± 0.2  8.4 ± 0.2  0.1 ± 0.2  8.0 ± 0.2  8.1 ± 0.2  0.1 ± 0.2 0.21 
TTmax (min) 223 ± 24  258 ± 25  31 ± 27  251 ± 24  287 ± 23  16 ± 25 0.90 
Insulin             
AUC (nmol/L x 480 min) 122 ± 10  120 ± 12  -2 ± 6  114 ± 8  111 ± 7  -3 ± 3 0.47 
iAUC (nmol/L x 480 min) 102 ± 9  101 ± 11  -1 ± 6  95 ± 7  89 ± 6  -6 ± 4 0.28 
Cmax (nmol/L) 0.57 ± 0.05  0.59 ± 0.06  0.03 ± 0.02  0.52 ± 0.04  0.50 ± 0.03  -0.02 ± 0.03 0.21 
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TTmax (min) 165 ± 24   203 ± 24   20 ± 30   227 ± 24   171 ±23   -63 ± 25 0.34 
 
 
 
1Values are means ± SEMs; Data not normally distributed was log transformed. ApoB, apolipoprotein B; AUC, incremental area under the curve; 
Cmax, maximum concentration; NEFA, non-esterified fatty acids; iAUC, incremental AUC; TAG; triacylglycerol; TTmax, time to reach maximum 
concentration; Δ, change-from-baseline. 
2 Linear mixed model analyses were used to calculate overall treatment effect based on change in postprandial summary measures from the pre-
intervention to the post-intervention study visit, with adjustments made for fixed effects of baseline values of the assessed variable, period, treatment 
sequence, gender, age and BMI. Participant was included as a random effect. For all outcome measures, P ≤ 0.01 was deemed as significant.  
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Table 4.4 Postprandial summary measures of circulating biomarkers of endothelial activation and inflammation before (pre) and after (post) the 
modified and control postprandial dairy diets1 
                    
    Modified diet   Control diet  
  Pre Post Δ  Pre Post Δ P² 
Nitrite          
AUC (μmol/L x 420 min)  64 ± 8 65 ± 8 1 ± 5  64 ± 8 60 ± 10 -4 ± 8 0.50 
iAUC (μmol/L x 420 min)  4 ± 5 -2 ± 3 -6 ± 5  -1 ± 5 10 ± 5 11 ± 7 0.05 
Nitrate          
AUC (μmol/L x 420 min)  5688 ± 519 5622 ± 335 -66 ± 399  5321 ± 270 5633 ± 462 322 ± 370 0.57 
iAUC (μmol/L x 420 min)  -1683 ± 303 -1791 ± 338 -108 ± 381  -1530 ± 310 -1197 ± 307 333 ± 456 0.37 
Adhesion molecules          
VCAM-1          
AUC (μg/mL x 420 min)  226 ± 15 220 ± 14 -6 ± 5  235 ± 16 222 ± 16 -13 ± 7 0.38 
iAUC (μg/mL x 420 min)  -1 ± 4 -7 ± 7 -6 ± 9  2 ± 6 7 ± 6 5 ± 9 0.11 
ICAM-1          
AUC (μg/mL x 420 min)  38 ± 4 35 ± 3 -2 ± 1  36 ± 4 37 ± 3 1 ± 2 0.22 
iAUC (μg/mL x 420 min)  1 ± 2 0.4 ± 2 -0.6 ± 3  1 ± 2 -1 ± 72 -2 ± 3 0.15 
E-selectin          
AUC (μg/mL x 420 min)  10 ± 1 10 ± 1 0 ± 0  10 ± 1 11 ± 1 1 ± 0 0.68 
iAUC (μg/mL x 420 min)  -0.3 ± 0.2 -0.4 ± 0.3 -0.1 ± 0.3  -0.3 ± 0.2 -0.1 ± 0.3 0.2 ± 0.3 0.25 
P-selectin          
AUC (μg/mL x 420 min)  11 ± 1 11 ± 1 0 ± 0  11 ± 1 11 ± 1 0 ± 0 0.66 
iAUC (μg/mL x 420 min)  -0.1 ± 0.2 -0.4 ± 0.3 -0.3 ± 0.4  -0.6 ± 0.2 -0.1 ± 0.2 0.5 ± 0.3 0.32 
LPS-stimulated cytokines          
TNFα          
AUC (x 420 min)  4847 ± 328 5393 ± 303 536 ± 228  4904 ± 290 5447 ± 295 543 ± 341 0.85 
iAUC (x 420 min)  -267 ± 213 -216 ± 213 51 ± 306  169 ± 239 -305 ± 164 475 ± 258 0.70 
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IL-6 
AUC (x 420 min) 
 32034 ± 1675 35199 ± 1983 3165 ± 1119  32835 ± 1709 34972 ± 1765 2138 ± 1596 0.43 
iAUC (x 420 min)  -2879 ± 1086 -2347 ± 1094 532 ± 1752  285 ± 1337 -2660 ± 213 2944 ± 1474 0.57 
IL-1β          
AUC (x 420 min)  11577 ± 562 11914 ± 570 337 ± 404  12222 ± 606 13489 ± 700 1266 ± 631 0.10 
iAUC (x 420 min)  60 ± 381 449 ± 329  388 ±533  1442 ± 400 1242 ± 406 -200 ± 578 0.63 
IL-8          
AUC (x 420 min)  48211 ± 3795 53918 ± 5429 5707± 3279  51440 ± 5533 49782 ± 5604 -1659 ± 4031 0.15 
iAUC (x 420 min)  -2698 ± 2841 -1320 ± 4144 1378 ± 4717  -839 ± 4374 -4881 ± 3504 -4041 ± 3850 0.91 
IL-10          
AUC (x 420 min)  288 ± 23 302 ± 26 14 ± 23  356 ± 34 321 ± 30 -44 ± 29 0.34 
iAUC (x 420 min)   -61 ± 22 -65 ± 24 -4 ± 33   -19 ± 25 -84 ± 20 -65 ± 34 0.76 
 
 
1Values are means ± SEMs. All LPS-stimulated cytokines are expressed as μg x 103 monocytes. For all variable, n = 50; except TNF-α, IL-1β, IL-6, 
IL-10, n = 49 and IL-8, n = 47. Data not normally distributed was log transformed. AUC, area under the curve; iAUC, incremental AUC; ICAM-1, 
intercellular adhesion molecule-1; TNFα, tumor necrosis factor alpha; VCAM-1, vascular adhesion molecule 1; Δ, change-from-baseline (pre-
intervention visit).  
 
2 Mixed model analyses were used to calculate overall treatment effect based on change in postprandial summary measures from the pre-intervention to 
the post-intervention study visit, with adjustments made for fixed effects of baseline values of the assessed variable, period, treatment sequence, gender, 
age and BMI. Participant was included as a random effect. For all outcome measures, P ≤ 0.01 was deemed as significant. 
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Table 4.5 Postprandial iAUC summary measures of plasma total lipid fatty acid responses after the modified and control postprandial test meals at 
baseline and following the 12-wk dietary interventions (post)1 
                            
 Modified diet   Control diet   
              
FA (g/100g x 420 min) Baseline   Post   Δ  Baseline   Post   Δ  P
2 
SFAs              
14:00 72 ± 20  19 ± 20  -53 ± 22  96 ± 30  94 ± 30  -3 ± 30  0.02 
15:0  23 ± 2  20 ± 2  -3 ± 2  38 ± 3  39 ± 3  0 ± 3  <0.0001 
15:0 antiso  5 ± 1  3 ± 1  -3 ± 1  6 ± 2  5 ± 1  -1 ± 1  0.03 
16:0 -115 ± 59  -375 ± 142  -260 ± 157  -33 ± 120  196 ± 204  229 ± 250  0.02 
17:0  2 ± 3  0.1 ± 3  -2 ± 3  12 ± 4  11 ± 4  -1 ± 4  0.06 
17:0 iso  -1 ± 3  -5 ± 4  -4 ± 5  0.1 ± 3  0 ± 5  -0.1 ± 5  0.34 
18:0 99 ± 33  -94 ± 69  -192 ± 72  -35 ± 57  122 ± 66  157 ± 92  0.01 
Total SFA 827 ± 250  497 ± 160  -330 ± 285  1566 ± 293  1704 ± 262  138 ± 378  <0.0001 
MUFAs              
14:1 trans 9 2 ± 1  0 ± 1  -2 ± 1  4 ± 1  3 ± 1  -1 ± 1  0.01 
18:1 742 ± 174  391 ± 133  -350 ± 214  -181 ± 192  24 ± 170  205 ± 258  0.16 
18:1 cis  326 ± 167  -10 ± 117  -336 ± 204  -293 ± 189  -80 ± 165  -213 ± 253  0.81 
18:1 trans 416 ± 23  402 ± 28  -14 ± 22  112 ± 14  104 ± 12  -8 ± 13  0.02 
18:1 cis 9 329 ± 200  -8 ± 139  -336 ± 234  -421 ± 102  -140 ± 220  -413 ± 176  0.60 
18:1 trans 6-8  35 ± 4  11 ± 4  -25 ± 5  6 ± 2  7 ± 1  1 ± 2  0.04 
18:1 trans 9  19 ± 3  4 ± 4  -14 ± 4  1 ± 4  6 ± 3  5 ± 5  0.31 
18:1 trans 10   74 ± 10  24 ± 10  -50 ± 10  5 ± 4  8 ± 3  3 ± 4  0.04 
Total cis-MUFA  399 ± 179  55 ± 127  -343 ± 219  -182 ± 202  57 ± 177  239 ± 272  0.94 
Total trans-MUFA   419 ± 24  402 ± 29  -17 ± 25  116 ± 16  112 ± 15  -3 ± 17  0.009 
CLAs              
CLA cis9, trans11 20 ± 2  5 ± 3  -15 ± 3  12 ± 2  7 ± 3  -4 ± 3  0.42 
Total CLA  39 ± 3  33 ± 3  -6 ± 3  25 ± 3  22 ± 2  -2 ± 3  0.40 
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Total trans   439 ± 26  418 ± 31  -21 ± 28  124 ± 18  122 ± 18  -3 ± 21  0.008 
PUFAs              
n-3  -84 ± 36  -182 ± 15  -97 ± 38  -120 ± 53  -79 ± 36  41 ± 64  0.0023 
n-6  -1035 ± 284  -1744 ± 174  -709 ± 290  -1200 ± 280  345 ± 414  -182 ± 20  0.001 
Total PUFA  -1064 ± 313   -1880 ± 184   -817 ± 319   -1287 ± 327   -925 ± 353   362 ± 472   0.0013 
 
 
1Values are means ± SEMs.  For all variables, n = 49. Data not normally distributed was log transformed. CLA, conjugated linoleic acid; iAUC, 
incremental area under the curve; Δ, change-from-baseline. 
2 Linear mixed model analyses were used to calculate overall treatment effect based on change in postprandial summary measures from the pre-
intervention to the post-intervention study visit, with adjustments made for fixed effects of baseline values of the assessed variable, period, treatment 
sequence, gender, age and BMI. Participant was included as a random effect. For all outcome measures, P ≤ 0.01 was deemed as significant. 
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Supplemental Figure 4.1 RESET participant flowchart for the acute-within-chronic study 
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Supplemental Figures 
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e) 
 
 
 
Postprandial time response curve of: a) apolipoprotein B (apoB); b) triacylglycerols (TAG); 
c), non-esterified fatty acids (NEFA); d) insulin and e) glucose following 12-week intake of 
the FA-modified dairy diets and two meal challenge. Values are ± SEMs. Con, control diet; 
Mod, modified diet; Pre, relates to postprandial investigation study prior to the assigned 12-
week dairy diet; Post, relates to the postprandial investigation at the end of each assigned 12-
week dairy diet 
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5.1 Abstract 
 
Scope: To determine whether apolipoprotein (APO)E genotype influences fasting and 
postprandial responses to long term consumption of saturated fatty acid (SFA)-reduced, 
monounsaturated fatty acid (MUFA)-enriched dairy products (modified) compared to 
conventional dairy products (control).  
Methods and results: Adults (52 ± 2 y) at 1.5-fold higher CVD risk, retrospectively genotyped 
for APOE (n = 31 E3/E3, n = 16 E4 carriers), were assigned to a high dairy, iso-energetic daily 
dietary exchange with varying fatty acid composition (38% total energy (%TE) from total fat; 
dietary targets: modified, 16%TE SFA, 14%TE MUFA; control, 19%TE SFA, 11%TE MUFA) 
in a random order, with an 8 week wash out between diets. At the beginning and end of each 
12-wk dietary period, a postprandial investigation was conducted using dairy products from the 
assigned intervention diet. At baseline, high-density lipoprotein cholesterol (HDL-C) and non-
esterified fatty acids (NEFA) concentrations were higher in E4 carriers, with a greater 
proportion of small and medium sized HDL particles compared to the E3/E3 genotype group 
(P < 0.05). No genotype x treatment interactions were observed for the postprandial CVD risk 
biomarkers. 
Conclusion: APOE genotype only influenced baseline fasted lipids, with little impact on the 
fasting and postprandial CVD risk markers in response to the dairy intervention diets and test 
meals of varying fat composition.  
 
Key words: Dairy fat, APOE genotype, dietary fat manipulation, saturated fatty acids, 
monounsaturated fatty acids 
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5.2 Introduction 
 
Genetic factors are known to play a key role in the progression of cardiovascular diseases 
(CVD) (116). Common genetic variants of the apolipoprotein E (APOE) gene have been 
extensively investigated in association with CVD risk, which accounts for up to 7% variance 
observed in the fasting total (TC) and low-density lipoprotein cholesterol (LDL-C) 
concentrations (111, 119, 253). Of particular interest are carriers of the APOE4 allele, 
representing just over 30% of the UK population (254), associated with a higher CVD risk 
relative to the wild type variant E3/E3, partially due to increased fasted LDL-C concentrations, 
and a potentially more pro-oxidative and pro-inflammatory phenotype (116, 255).  
A greater responsiveness to dietary fatty acid (FA) composition has also been reported 
in E4 carriers compared to the wild type E3/E3 variant (116, 256). However, studies which have 
investigated the impact of APOE genotype following dietary fat manipulation have primarily 
focused on lipid responses in the fasted state (116, 119, 256, 257). Fewer studies have 
investigated responses to meal FA composition in the postprandial state, particularly when 
comparing meals rich in monounsaturated (MUFA) and saturated fatty acids (SFA) (258-260). 
Current evidence suggests a modest beneficial impact on the lipid profile following a 
replacement of SFA with unsaturated fatty acids, although most studies have primarily focused 
on long chain n-3 FAs (116, 119). Additionally, limited studies have investigated the impact of 
APOE genotype on novel risk markers, such as biomarkers of endothelial function and 
inflammation, which may also be modulated by dietary and meal FA composition (102, 261, 
262).  
Current UK dietary recommendations advocate for a reduction of total SFA intake to 
≤10% of total energy intake, a target which is still exceeded by 27% of the adult population 
(10, 263). Therefore, reducing SFA entry into the food chain and the subsequent impact on 
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CVD risk markers is an important public health strategy aimed at reducing the prevalence of 
CVD in the population. The RESET trial (NCT02089035), examined the effects of partially 
replacing the SFA content of milk and dairy products with unsaturated FAs, predominantly in 
the form of MUFA, through supplementation of the dairy cow diet (203) on traditional and 
novel CVD risk factors in the fasted and fed (postprandial) state (201, 238, 264). To the best of 
our knowledge, no other study has investigated the impact of the APOE genotype on CVD risk 
biomarkers responses to long-term consumption of the FA modified dairy products, produced 
as a result of supplementation of the dairy cow feed with plant oils. The current paper is a 
secondary analysis which aimed to explore the potential role of the APOE genotype on the 
fasting and postprandial risk markers following two iso-energetic, high dairy diets with a 
differential fatty acid profile. We hypothesised that fasted and postprandial risk markers of 
CVD would be significantly impacted in the E4 carriers group following the two dairy diets 
and compared to the wild type E3/E3 participants. 
 
5.3 Materials and methods 
 
5.3.1 Study design and subjects 
The RESET study was a 12-wk double-blind, randomized, controlled crossover 
intervention study conducted with an 8-wk washout period between the two dietary treatments.  
The intervention trial was conducted at the Hugh Sinclair Unit of Human Nutrition (University 
of Reading, UK), between February 2014 and April 2016 in accordance with the Declaration 
of Helsinki and was given a favourable ethical opinion by the University of Reading Research 
Ethics Committee (Project reference 13/14). All participants gave their written informed 
consent before starting the intervention.  
A total of 54 participants (31 males; 23 females), were screened for fasting and 
anthropometric parameters and a scoring system was used, based on the modified Framingham 
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risk score, to recruit participants with a 1.5-fold higher CVD risk (164, 201). A flexible food-
exchange model (201) was developed to implement two separate iso-energetic high dairy diets 
(38% of total energy intake (%TE) from total fat): modified (dietary target: 16%TE SFA, 
14%TE MUFA) and control (19%TE SFA, 11%TE MUFA) which were consumed in a 
randomised cross-over design, separated by an 8-wk washout period. 
Before each study visit at weeks 0, 12, 20 and 32, participants refrained from alcohol 
and aerobic exercise for 24 h and fasted for 12 h, after consuming a low fat standard meal (< 
1.46 MJ; < 7 g total fat), drinking only low nitrate mineral water during this time. Prior to 
fasting blood sampling and vascular function measurement, participants were cannulated in the 
antecubital vein of the forearm, to allow multiple blood samples to be collected throughout the 
day. Of the 54 participants, only 52 completed the postprandial intervention study following 
fasted measurements, with test meals containing dairy products with a FA composition 
representative of the assigned dietary intervention. The breakfast test meal (50 g total fat) was 
provided at 0 min and consisted of a toasted sandwich with study cheese and butter, UHT study 
milk with cornflakes and milkshake prepared with study UHT milk and strawberry syrup. At 
330 min, the lunch test meal (30 g total fat) was provided, consisting of a toasted study cheese 
and butter sandwich and strawberry UHT study milkshake drink. A total of 13 blood samples 
were collected at regular intervals until 480 min after the breakfast meal (264) (see 
Supplemental Table 5.1 for test meal composition). 
5.3.2 Biochemical analyses 
Serum lipids (total cholesterol, TC (fasting only); HDL-cholesterol (HDL-C; fasting 
only); and triacylglycerol, TAG), glucose, apolipoprotein (apo)B, C-reactive protein (fasting 
only) and non-esterified fatty acids (NEFA) were measured using an autoanalyzer (reagents and 
analyzer: Instrumentation Laboratory Ltd. ILAB600, Werfen,UK); apoB reagent: Randox 
Laborarories Ltd; non-esterified fatty acid reagent: Alpha Laboratories Ltd.). The Friedewald 
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equation was used to estimate fasting LDL-C (49). ELISA kits were used to analyze circulating 
serum insulin (Dako UK Ltd.).  
5.3.3 NMR metabolomics 
Quantification of the particle size distribution of the LDL and HDL subclasses in the 
fasted state, was performed through a high-throughput nuclear magnetic resonance (1H-NMR) 
metabolomics platform (Nightingale Health Ltd., Finland) as previously described (215). 
Change from the pre-intervention visit (baseline) following each intervention diet for the 
number of LDL-particle (LDL-P; classified by their mean diameter size as small, (18.7 nm), 
medium (23 nm) and large (25.5 nm)) and HDL-particle (HDL-P; classified as small (8.7 nm), 
medium (10.9 nm), large (12.1 nm) and very large (14.3 nm) within each subclass distribution 
will be presented. 
5.3.4 Stimulation of whole blood cultures 
LPS-stimulated cytokine production from whole blood samples were determined as 
previously described (262). Briefly, K2EDTA whole blood cultures (WBC), diluted 1:9 in 
RPMI medium (Sigma, UK) were cultured in 12-well plates (Greiner bio-one, UK) with 0.5 
μg/ml of bacterial lipopolyssacharide (LPS; E. coli 026:B6, Sigma, UK), with the addition of 
1% antibiotics, 1% L-glutamine and 1% non-essential amino acids (Bioscience, UK). 
Following 24 h incubation at 37 °C, cultures were centrifuged at 700 x g (1000 rpm) and the 
supernatant stored at -20 °C. Measurement of the monocyte count of each sample was 
performed by the Pathology Department at the Royal Berkshire Hospital (Reading, UK). A 
human cytokine premixed 5-Plex Panel (IL-6, IL-8, IL-1β, TNF-α; R&D Systems Europe Ltd) 
and Luminex 200 with xPONENT software was used to measure the concentrations of 
cytokines in the WBC supernatant (1:2 dilution). Cytokine production was corrected for the 
number of monocytes in the whole blood sample. 
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5.3.5 Genotyping 
 The Qiagen DNA Blood Mini Kit (Qiagen Ltd., Crawley, UK) was used to extract DNA 
from the buffy coat samples, collected into K3EDTA-coated tubes at week 0. APOE genotyping 
was performed retrospectively using “Assay-on-Demand” single nucleotide polymorphism 
genotyping assays (rs7412 and rs429358) (Life Technologies, UK).  
5.3.6 Statistical analysis 
 
All data were checked for normality and log transformed where necessary prior to 
statistical analysis. The genotype distribution of the two SNPs at the APOE genes were in 
Hardy-Weinberg equilibrium (p > 0.05). Differences in participant baseline characteristics 
(prior to starting the dietary interventions) according to APOE genotype, were assessed by 
independent t-test. For fasted outcome measures, differences from baseline (Δ; wk-12 – wk-0 
and wk-32 – wk-20) were calculated. Summary measures of change in postprandial responses 
were calculated using the trapezoidal rule for area under the curve (AUC) and, by subtracting 
the fasted value, the incremental AUC (iAUC). Percentage NEFA suppression was also 
calculated to represent an initial drop in NEFA concentration following the breakfast meal (0 – 
120 min). Therefore, the postprandial summary measures of NEFA AUC and iAUC were 
calculated from 120 min to the end of the postprandial period (480 min). Maximum 
concentration (CMax) and time to reach maximum concentration (TTMax) were calculated for 
variables with 10 (apoB) and 13 (TAG, NEFA, glucose and insulin) time points only. Genotype 
x treatment effects were evaluated for E3/E3 and E4 carriers, using a linear mixed-model run 
through the SAS 9.4 University edition statistical software (SAS Institute Inc., Cary, NC, USA). 
Differences in fasted baseline values and summary measures of change of postprandial 
responses were inputted as the dependent variable, adjusted for fixed effects of baseline values 
of the assessed variable, period, sequence, treatment, age, gender, BMI and genotype. 
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Participant was included as a random effect. No genotype effects were observed for any of the 
fasting outcome measures or postprandial summary responses. Data are presented in the tables 
as the mean change ± SEM. Values of P ≤ 0.05 were taken as significant.  
5.4 Results 
 
Genotyping for APOE resulted in the following frequencies: 57% E3/E3 (n = 31; 19 
males and 12 females); 30% E4 carriers (n = 15 E3/E4; n = 1 E4/E4; 6 males and 10 females) 
and 13% E2 carriers (n = 7; 6 males and 1 female). Due to the low numbers of E2 carriers, this 
group of participants was excluded from the data analyses, resulting in a total of 47 participants 
in this genotyping dataset. Additionally, E3/E4 and E4/E4 carriers were combined for the 
analysis. 
Subject characteristics for the complete genotyping dataset (n = 47) and by E3/E3 (n = 
31) and E4 carriers (n = 16) are presented in Table 5.1. There was a significant difference 
between the two genotype groups in fasting concentrations of HDL-C, which was 16% higher 
in the E4 carriers compared to the E3/E3 group (P = 0.03). Additionally, fasting small and 
medium sized HDL particle (HDL-P) concentrations were 5% and 14% higher in the E4 
carriers, compared to E3/E3 (P = 0.03 and P = 0.04 respectively). Fasting NEFA concentrations 
were also 28% higher in the E4 carriers compared to the wild type genotype group (P = 0.04). 
There were no other significant differences observed for any of the other baseline characteristics 
according to APOE genotype.  
There were no genotype or treatment effects and no genotype x treatment interactions 
on the fasting concentrations or postprandial summary measures of CVD risk biomarkers, as 
measured by AUC, iAUC, CMax and TTMax (Tables 5.2 and 5.3). Similarly, genotype and 
treatment effects and genotype x treatment interactions were not observed for the postprandial 
WBC LPS-stimulated cytokine production (IL-1β, IL-6, IL-8, IL-10 and TNFα), following the 
two dietary interventions (Table 5.4). 
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5.5 Discussion 
 
As far as the authors are aware, this is the first study to determine the effects of APOE 
genotype on the lipid responses following manipulation of the dairy fat composition. Significant 
differences in certain pre-intervention (baseline) parameters between E4 carriers and E3/E3 
groups were observed. Yet, although APOE genotype has been shown to influence the lipid 
response to dietary intervention and meal intake, our study found no effect following 
consumption of dairy products in which SFA was partially replaced by MUFA. 
We observed higher baseline fasting NEFA concentrations in the E4 carriers, compared 
to E3/E3 which is in line with previous observations and have been recognized as a CVD risk 
marker (112, 113, 119, 265). We also observed higher baseline fasted HDL-C concentrations 
in the E4 carriers, compared to the wild type E3, which is in contrast to previously published 
studies (266, 267). Interestingly, this difference appears to be reflected in a higher proportion 
of small and medium sized HDL-P in the E4 carrier group. The heterogeneity of the HDL-P, in 
terms of size, density and functionality is well recognized (268). The association of each HDL-
P sub-class to CVD risk is unclear, with some studies suggesting that larger, more buoyant 
HDL-P present a stronger inverse association with CVD risk compared to smaller, dense HDL-
P (269). If true, this would imply that the E4 carriers in our study may be at higher CVD risk. 
However, our observed baseline differences should be interpreted with caution, due to 
retrospective genotyping and small number of E4 participants and would need confirmation in 
further studies.  
Although a limited number of studies have investigated the impact of replacing SFA 
with MUFA on fasted or postprandial CVD risk markers according to APOE genotype, the 
majority have used commercially available foods, such as spreads, snacks and oils 
(predominantly olive oil) to implement the dietary fat manipulation (270). In the LIPGENE 
study, individuals with the metabolic syndrome (n = 416) were randomized to one of four iso-
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energetic dietary interventions (high SFA, high MUFA, two low fat, high complex carbohydrate 
supplemented with 1g long chain n-3 FA (EPA and DHA) or placebo oil) (271). No interaction 
between APOE genotype was observed when comparing the high SFA diet (38%TE total fat; 
16%TE SFA, 12%TE MUFA) to the high MUFA diet (38%TE total fat; 20%TE MUFA; 8%TE 
SFA) (119, 271). Furthermore, the SATgene study (n = 88), which investigated the impact of 
APOE genotype following a low fat (24% E total fat, 8% as SFA, 59% CHO), high SFA (HSF; 
38% total fat, 18% SFA, 45% CHO) and high SFA with added 3 g/d DHA diets in prospectively 
genotyped normolipidaemic adults, found a modest impact on TAG and C-reactive, suggesting 
a greater sensitivity to dietary fat composition in E4 carriers (118, 257, 258). Similar to our 
study design, the SATgene postprandial study also used test meals representative of the 
macronutrient content of the dietary intervention (258). A variable postprandial TAG response 
was reported according to genotype and following the HSF-DHA diet compared to the other 
three diets, whereby E4 carriers exhibited a greater TAG-lowering effect (258). In a further 
postprandial study, which explored the responses to SFA-rich, MUFA-rich (both from 
vegetable oil sources) and SFA with fish oil in mixed meals, no significant differences in 
outcome measures were observed, when comparing E4 carriers to the E3/E3 group (260). 
However, both postprandial studies were carried out in healthy men, which is in contrast to our 
study cohort. 
Dietary fat manipulation may impact inflammatory responses, with evidence suggesting 
that the APOE genotype affects macrophage cytokine secretion and fasted CRP concentrations 
(116, 118, 255). In our study, we observed no differences in baseline concentrations of ex vivo 
LPS-stimulated cytokines. This is in contrast to in vitro and the small number of human studies 
which report higher concentrations of pro-inflammatory cytokines and lower concentrations of 
anti-inflammatory cytokines in E4 carriers, compared to E3 homozygotes (255). This may be 
explained in part by the small number of E4 carriers in our cohort, which was lower than the 
E3/E3 group. Additionally, few studies have investigated the interaction of genotype on 
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modulation of the inflammatory response following dietary fat manipulation. In agreement with 
our results, a subset of the SATgene study which investigated ex vivo LPS-stimulated cytokine 
production in whole blood cultures, did not observe an interaction of APOE genotype following 
the sequential dietary fat interventions (262). The authors concluded that dietary fat 
composition, rather than APOE genotype, influenced ex vivo cytokine production (262). Taking 
into account that inflammatory markers are also affected by other factors, such as age and 
gender, more studies are needed to investigate the impact of APOE genotype on fasting and 
postprandial inflammatory markers following dietary fat modification. 
A strength of the current study is the investigation of a genotype effect in a chronic and 
acute-within-chronic design. Additionally, the test meals incorporated dairy with a FA 
composition representative of the dietary interventions. Furthermore, the ex vivo production of 
LPS-stimulated cytokines used whole blood cultures, considered more physiologically 
informative for the assessment of low grade inflammation, compared to measurement of 
circulating plasma cytokines (272). Lastly, the genotype frequency in our sub-cohort appears 
in line with data from the literature for the UK population (254).However, a limitation of the 
current hypothesis generating study was the use of a retrospective genotype approach, which 
resulted in unequal group sizes and gender distribution of E3/E3 homozygotes and E4 carriers. 
Due to this approach, the number of participants was relatively small compared to studies which 
have previously investigated dietary fat manipulation and APOE genotype.  
In conclusion, this study investigated the interaction of APOE genotype on fasting and 
postprandial CVD risk markers following long-term consumption of dairy products with a 
differential fatty acid composition. The observed baseline differences in HDL particle size 
number between the two genotype groups is a novel finding worth exploring in future studies. 
No outcome measures were significantly modulated by APOE genotype. However, there is 
considerable interest to determine sensitivity of APOE polymorphisms to dietary SFA 
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replacement with unsaturated FAs, as UK dietary recommendations advocate for a reduction of 
current SFA intakes for CVD risk reduction (10). Future studies are therefore needed to evaluate 
this interaction in larger, prospectively recruited cohorts.  
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Table 5.1 Pre-intervention baseline characteristics of the group as a whole and according to APOE genotype 
          
  All  E3/E3 carriers  E4 carriers  p1 
n (M/F) 47 (25/22) 31 (19/12) 16 (6/10)  
Age (years) 52 ± 2 51 ± 2 55 ± 3 0.35 
BMI (kg/m2) 26 ± 0 26 ± 1 25 ± 1 0.27 
Systolic BP (mm Hg) 121 ± 2 121 ± 3 122 ± 2 0.76 
Diastolic BP (mm Hg) 70 ± 1 70 ± 2 72 ± 1 0.30 
TC (mmol/L) 5.58 ± 0.13 5.46 ± 0.16 5.79 ± 0.19 0.23 
LDL-C (mmol/L) 3.54 ± 0.11 3.48 ± 0.14 3.67 ± 0.17 0.43 
HDL-C (mmol/L) 1.50 ± 0.05 1.42 ± 0.05 1.65 ± 0.09 0.03 
TC:HDL-C ratio 3.85 ± 0.12 3.97 ± 0.16 3.61 ± 0.17 0.17 
TAG (mmol/L) 1.18 ± 0.07 1.25 ± 0.10 1.04 ± 0.08 0.19 
ApoB (g/L) 1.02 ± 0.03 1.02 ± 0.04 1.02 ± 0.05 0.94 
NEFA (μmol/L) 602 ± 30 551 ± 28 703 ± 62 0.04 
Glucose (mmol/L) 5.38 ± 0.11 5.47 ± 0.16 5.20 ± 0.08 0.13 
Insulin  36.2 ± 2.8 34.8 ± 3.4 38.7 ±4.9 0.53 
HOMA-IR 1.42 ± 0.12 1.39 ± 0.15 1.50 ± 0.20 0.67 
CRP (mg/L) 1.64 ± 0.40 1.60 ± 0.44 1.73 ± 0.81 0.89 
Particle distribution     
LDL-P (nmol/L)     
Small 173 ± 4 170 ± 6 179 ± 4 0.31 
Medium 280 ± 8 275 ± 1 290 ± 13 0.40 
Large 579 ± 16 562 ± 20 611 ± 24 0.15 
HDL-P (nmol/L)     
Small 9966 ± 117 9782 ± 141 10310 ± 177 0.03 
Medium 3969 ± 114 3783 ± 123 4318 ± 205 0.02 
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Large 
Very Large 
1647 ± 114 
235 ± 13 
1518 ± 131 
224 ± 16 
1889 ± 206 
256 ± 24 
0.13 
0.27 
LPS-stimulated cytokines     
IL-6 (μg x 10³ monocytes) 77 ± 4 78 ± 5 74 ± 4 0.53 
IL-8 (μg x 10³ monocytes) 140 ± 15 123 ± 15 178 ± 31 0.14 
IL-1β (μg x 10³ monocytes) 27 ± 1 27 ± 2 28 ± 3 0.87 
IL-10 (μg x 10³ monocytes) 29 ± 3 27 ± 3 33 ± 2 0.07 
TNF-α (μg x 10³ monocytes) 11 ± 1 11 ± 1 10 ± 1 0.22 
Risk score     
CVD risk score2 3.1 ± 0.2 3.0 ± 0.2 3.2 ± 0.3 0.88 
 
Values are mean ± SEM. ApoB, apolipoprotein B; BP, blood pressure; CRP, C-reactive protein; HDL-C, HDL-cholesterol;  
HDL-P, HDL particle size; LDL-C, LDL-cholesterol; LDL-P, LDL particle size; NEFA, non-esterified fatty acids; TC, total cholesterol; TAG, 
triacylglycerol.  
1 Independent t test was used to assess differences between fasting baseline characteristic of the genotype groups. 
2 Assessed with the use of a modified Framingham risk score, where a score of ≥ 2 points relates to a 1.5-fold higher risk of CVD than the population 
mean (164, 165, 201). 
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Table 5.2 Change in fasting lipid profile, particle size distribution, glucose, insulin and C-reactive protein following the modified and control diet and 
according to genotype1 
                       
   Modified diet   Control diet   p² 
  
E3/E3  
 
E4 carriers  
 
E3/E3  
  
E4 carriers  
 
Treatment Genotype Genotype x treatment          
TC (mmol/L)  0.24 ± 0.09  0.15 ± 0.14  0.23 ± 0.12  0.26 ± 0.08  0.11 0.91 0.47 
LDL-C (mmol/L)  -0.05 ± 0.08  0.08 ± 0.12  0.17 ± 0.07  0.21 ± 0.08  0.07 0.44 0.65 
HDL-C (mmol/L)  0.05 ± 0.03  -0.01 ± 0.04  0.08 ± 0.03  0.07 ± 0.05  0.34 0.25 0.81 
TC:HDL-C ratio  -0.07 ± 0.06  0.10 ± 0.09  0.03 ± 0.05  0.04 ± 0.09  0.76 0.14 0.34 
TAG (mmol/L)  0.16 ± 0.10  0.18 ± 0.09  0.12 ± 0.07  -0.11 ± 0.08  0.08 0.45 0.10 
ApoB (g/L)  4 ± 18  52 ± 30  39 ± 17  34 ± 22  0.86 0.53 0.35 
NEFA (μmol/L)  -47 ± 29  -92 ± 59  -31 ± 28  -82 ± 59  0.62 0.25 0.60 
Glucose (mmol/L)  0.02 ± 0.08  -0.02 ± 0.06  0.11 ± 0.10  -0.09 ± 0.21  0.16 0.17 0.61 
Insulin (pmol/L)  -2 ± 2.4  -4.5 ± 4.5  11.5 ± 6.4  1.1 ± 3.3  0.75 0.21 0.68 
HOMA-IR  0.02 ± 0.07  -0.20 ± 0.19  0.35 ± 0.25  0.13 ± 0.23 
 0.16 0.61 0.68 
CRP (mg/L)  0.14 ± 0.42  -0.08 ± 0.25  0.09 ± 0.23  -0.64 ± 0.57  0.73 0.21 0.42 
Particle distribution           
 
 
LDL-P (nmol/L)           
 
 
 Small  2.2 ± 3.2  6.2 ± 3.2  6.2 ± 2.3  4.8 ± 3.6 
 0.74 0.45 0.31 
 Medium  0.7 ± 4.7  12.7 ± 6.0  9.2 ± 4.1  7.6 ± 6.4 
 0.76 0.82 0.21 
 Large  -3.0 ± 11.4  30.1 ± 13.6  46.2 ± 30.3  24.0 ± 14.2 
 0.50 0.21 0.29 
HDL-P (nmol/L)           
 
 
 Small  241.5 ± 151.0  165.8 ± 136.6  385.0 ± 140.8  19.3 ± 227.8 
 0.85 0.21 0.56 
 Medium  136.0 ± 81.0  49.4 ± 62.7  276.4 ± 149.1  27.7 ± 117.0 
 0.83 0.49 0.64 
 Large  95.5 ± 63.1  -79.2 ± 111.6  85.5 ± 63.1  36.2 ± 67.9 
 0.98 0.64 0.46 
 Very Large   10.1 ± 8.3   14.2 ± 21.6   12.6 ± 9.5   17.7 ± 11.5   0.69 0.10 0.64 
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1 Values represent change-from-baseline in fasted parameters following the modified and control diets ± SEM. n = 31 E3/E3; n = 16 E4 carriers. ApoB, 
apolipoprotein B; CRP, C-reactive protein; HDL-C, HDL cholesterol; HDL-P, HDL particles; HOMA-IR, homeostatic model assessment of insulin 
resistance; LDL-C, LDL cholesterol; LDL-P, LDL particles; NEFA, non-esterified fatty acids; TAG, triacylglycerol; TC, total cholesterol. 
2 Mixed model analyses were used to calculate overall effect of genotype x treatment based on change-from-baseline values, with adjustments made for 
fixed effects of baseline values of the assessed variable, period, treatment sequence, gender, age, BMI and genotype. Participant was included as a random 
effect. 
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Table 5.3. Change in postprandial summary response measures of lipids, glucose and insulin following consumption of the modified and control test 
meals, according to genotype1 
                         
  Modified diet  Control diet 
 p² 
    E3/E3   E4 carriers   E3/E3   E4 carriers   Genotype Treatment 
Genotype x 
treatment 
TAG           
 
 
 
AUC (mmol/l x 480min)  117 ± 76  121 ± 88  91 ± 59  -23 ± 59  0.79 0.74 0.56 
iAUC (mmol/l x 480min)  38 ± 35  48 ± 48  -8 ± 36  40 ± 36  0.90 0.14 0.30 
Cmax (mmol/l)  0.2 ± 0.2  0.3 ± 0.3  0.1 ± 0.2  -0.1 ± 0.2 
 0.83 0.72 0.28 
TTmax (min)  -22 ± 15  -13 ± 22  -14 ± 20  -10 ± 28 
 0.72 0.77 0.53 
NEFA             
 
 % suppression (120min)  52 ± 31  42 ± 51  13 ± 33  8 ± 61  0.85 0.89 0.83 
AUC (mmol/l 120-480min)  -0.4 ± 0.1  11 ± 11  -0.5 ± 4.2  0.8 ± 9.3 
 0.70 0.97 0.76 
iAUC (mmol/l 120-480min)  10 ± 13  20 ± 16  14 ± 11  23 ± 29  0.99 0.68 0.76 
Cmax (mmol/l)  -0.73 ± 0.32  -0.04 ± 0.64  0.2 ± 0.32  -0.53 ± 0.62 
 0.31 0.16 0.47 
TTmax (min)  7 ± 43  3 ± 41  -70 ± 31  -16 ± 61 
 0.97 0.25 0.96 
ApoB            
 
AUC (mg/l x 420min)  -3 ± 9  15 ± 14  18 ± 7  21 ± 10  0.33 0.18 0.71 
iAUC (mg/l x 420min)  -4 ± 4  1 ± 7  4 ± 4  6 ± 8  0.58 0.09 0.57 
Cmax (mg/l)  10 ± 22  37 ± 37  40 ± 22  55 ± 26  0.34 0.36 0.92 
TTmax (min)  -1 ± 42  72 ± 44  0 ± 48  46 ± 48  0.74 0.49 0.10 
Glucose            
 
AUC (mmol/l x 480min)  -15 ± 36  27 ± 64  137 ± 58  -86 ± 45  0.13 0.44 0.11 
iAUC (mmol/l x 480min)  -34 ± 51  18 ± 56  35 ± 43  -36 ± 48  0.49 0.59 0.97 
Cmax (mmol/l)  -0.1 ± 0.2  0.3 ± 0.3  0.1 ± 0.4  -0.5 ± 0.2 
 0.35 0.5 0.27 
TTmax (min)  41 ± 36  30 ± 52  -6 ± 31  63 ± 59 
 0.75 0.96 0.51 
Insulin             
 
AUC (pmol/l x 480min)  -2 ± 5  13 ± 16  2 ± 4  -8 ± 8  0.54 0.73 0.44 
iAUC (pmol/l x 480min)  -7 ± 7  15 ± 18  -9 ± 7  -7 ± 7  0.38 0.82 0.83 
Cmax (pmol/l)  29 ± 27  94 ± 69  2 ± 30  -105 ± 71 
 0.19 0.14 0.15 
TTmax (min)   7 ± 43   55 ± 11   -67 ± 30   -39 ± 64   0.81 0.67 0.67 
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1 Values represent post-intervention change from the pre-intervention visit following the sequential test meals of the modified and control diets ± SEM. 
n = 31 E3/E3; n = 16 E4 carriers. ApoB, apolipoprotein B; AUC, area under the curve; Cmax, maximum concentration; iAUC, incremental area under 
the curve; NEFA, non-esterified fatty acids; TAG, triacylglycerol; TTMax, time to reach maximum concentration. 
2 Mixed model analyses were used to calculate overall effect of genotype and genotype x treatment effect based on change-from-baseline values, with 
adjustments made for fixed effects of baseline values of the assessed variable, period, treatment sequence, gender, age, BMI and genotype. Participant 
was included as a random effect. 
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Table 5.4 Change in fasting and postprandial summary response measures of LPS-stimulated cytokine production in whole blood cultures following the 
modified and control test meals, according to genotype1 
                  
    Modified  Control  p² 
    APOE3/E3    APOE4 carriers   APOE3/E3  APOE4 carriers   Genotype Treatment Genotype x treatment 
IL-6             
fasting   10 ± 6  -3 ± 9 
 9 ± 6 -0.4 ± 7  0.69 0.26 0.31 
AUC (x 420 min)  3857 ± 1613  3439 ± 2100  2420 ± 2170 755 ± 2181 
 
0.26 0.25 0.68 
iAUC (x 420 min)  -739 ± 2454  -582 ± 1974  -2450 ± 2097 -2790 ± 2438 
 
0.40 0.62 0.27 
IL-8            
fasting   45 ± 38  10 ± 18  2 ± 20 4 ± 23  0.90 0.54 0.98 
AUC (x 420 min)  7201 ± 3430  2549 ± 8448   -5476 ± 4506 3467 ± 11069  0.84 0.12 0.23 
iAUC (x 420 min)  268 ± 6709  -1645 ± 6226  -4475 ± 5677 -429 ± 6096  0.74 0.44 0.18 
TNFα             
fasting   2 ± 2 
 2 ± 2  2 ± 2 2 ± 2  0.19 0.99 0.95 
AUC (x 420 min)  457 ± 329  598 ± 427  591 ± 464 127 ± 468  0.29 0.73 0.38 
iAUC (x 420 min)  10 ± 445  403 ± 537  -382 ± 386 -510 ± 372  0.63 0.74 0.52 
IL-1β            
fasting   0 ± 2 
 -2 ± 2  3 ± 2 4 ± 4  0.88 0.42 0.47 
AUC (x 420 min)  564 ± 611  -84 ± 609  1149 ± 869 1670 ± 1130  0.94 0.13 0.86 
iAUC (x 420 min)  21 ± 733  721 ± 1018  -130 ± 771 318 ± 1047  0.77 0.19 0.96 
IL-10            
fasting   0.0 ± 0.1  0.0 ± 0.2  0.0 ± 0.1 0.0 ± 0.3  0.82 0.45 0.32 
AUC (x 420 min)  9 ± 34  -9 ± 36  -34 ± 36 -99 ± 58  0.71 0.18 0.38 
iAUC (x 420 min)   -4 ± 41   -2 ± 79   -52 ± 29 -85 ± 98   0.21 0.97 0.87 
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1 Values represent change in fasting values and change in postprandial summary response measures following the modified and control diets ± SEM. All 
cytokines are expressed in μg x 103 monocytes. For fasted parameters: n = 30 APOE3/E3; n = 15 APOE4 carriers. For postprandial parameters: n = 28 
APOE3/E3; n = 14 APOE4 carriers (IL-6, TNFα, IL-1β, IL-10); n = 28 APOE3/E3; n = 12 APOE4 carriers (IL-8). AUC, area under the curve; iAUC, 
incremental area under the curve. 
2 Mixed model analyses were used to calculate overall effect of genotype x treatment effect based on change-from-baseline values, with adjustments 
made for fixed effects of baseline values of the assessed variable, period, treatment sequence, gender, age, BMI and genotype. Participant was included 
as a random effect. 
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Supplemental Table 5.1 Macronutrient composition of the breakfast and lunch test meals consumed by participants at baseline (wk-0) and post-
intervention (wk-12) of the modified and control diets. 
                  
 Energy Protein CHO Fat SFA MUFA PUFA trans MUFA 
  MJ g g g g g g g 
Breakfast (0 min)         
Modified diet 4.3 36.1 105.9 50.6 24.5 20.0 2.9 3.9 
        Control diet 4.1 39.7 101.4 49.9 31.7 12.3 2.8 2.2 
Lunch (330 min)         
Modified diet 2.6 20.9 64.6 30.6 14.8 12.1 1.8 2.6 
        Control diet 2.5 19.6 63.3 30.3 19.1 7.4 1.8 1.4 
 
CHO, carbohydrates. Adapted from Vasilopoulou et al (264). 
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Chapter VI: General discussion and future perspectives 
 
The following chapter summarises the studies presented in this thesis, providing an overview 
and concluding remarks of the findings to date. Additionally, recommendations for future 
research are presented. 
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6.1 General discussion 
 
Milk and dairy products are a widely consumed food group and a source of several important 
nutrients in the diet. The impact of dairy products on human health remains of significant 
importance, considering their use in a wide variety of composite foods, ranging from pastries 
to ready meals. Cardiovascular disease (CVD) remains one of the major causes of death and 
morbidity worldwide, despite declining rates in mortality following prevention strategies and 
improved treatments (5). In the UK, CVD represents the second most common cause of 
mortality, responsible for almost a third of all deaths (4). High intakes of dietary saturated 
fatty acids are regarded as one of the key risk factors associated with the development and 
progression of CVD, mediated by increased levels of circulating LDL-cholesterol (LDL-C) 
(9). Therefore, most national dietary guidelines advocate for a reduction of total SFA intake. 
In the UK, current recommendations aim for a reduction of SFA to <10% total energy intake, 
a target which is still exceeded by the majority of the adult population (10). Milk and dairy 
products (including butter) contribute on average up to 35% of total dietary SFA in the UK 
and are regarded as the greatest contributor to dietary SFA intake (10). Dietary 
recommendations for dairy products advise for a limitation of total dairy product consumption 
and a preference for low-fat alternatives, compared to full-fat counterparts (263). These 
recommendations were also described in the UK’s former Eatwell Plate, which advised for 
dairy consumption to contribute up to 15% of the overall diet. In 2016, the new Eatwell Guide 
replaced the Eatwell Plate and presented a reduced target of dairy consumption of up to 8% of 
the overall diet, which includes dairy alternatives such as soya drinks (273). As presented in 
the literature review (Chapter 1), these dietary recommendations do not seem to be in 
accordance with current evidence from prospective cohort studies and RCTs, which have not 
shown a detrimental effect of dairy consumption on CVD risk, with the exception of butter 
intake (36, 48, 150). In contrast to current UK advice on dairy intake, other countries such as 
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Denmark and USA, advocate for the consumption of at least 3 portions of dairy products per 
day. As described in Chapter 1, a number of potential mechanisms have been proposed to 
explain the beneficial impact of milk and specific dairy product consumption on CVD risk 
(68). Specifically, bioactive compounds such as dairy proteins, amino acids and 
micronutrients may, beneficially impact on CVD risk markers. Furthermore, increasing 
evidence suggests that focus should shift toward investigating the food matrix of dairy 
products (the sum of dairy nutrients within the specific dairy food structure), rather than 
single nutrients, to evaluate their impact on health (21, 25). 
Recently, three meta-analyses of prospective studies reported no association between 
dietary SFA intake and CVD risk, raising doubts on the detrimental effects of high SFA 
intake and questioning current dietary recommendations (18-20). However, these meta-
analyses have been criticised for not taking into account the importance of dietary 
replacement of SFA with a suitable macronutrient to assess disease risk associations. 
Moreover, the meta-analysis of Hooper et al reported a 17% reduction in CVD events 
following a reduction in SFA intake, although recognised that effects on myocardial infarction 
and stroke were less clear (199). Additionally, the association between high SFA intake and 
CVD risk is an indirect one, mediated primarily by the observed increases in LDL-C an 
independent CVD risk marker, with additional mechanisms such as an impact on vascular 
function and glycaemia (15, 53). Studies which have investigated an iso-energetic SFA 
replacement with unsaturated fats (UFA) have contributed towards accumulating evidence 
supporting a beneficial impact on CVD (23). As described in Chapter 1, taking into 
consideration the beneficial effects of certain dairy products on CVD risk and the importance 
of replacing high SFA intake with a suitable UFA, partial replacement of SFA in dairy fat 
with UFAs provides an alternative strategy to simply reducing total dairy intake or advocating 
for low-fat products. Supplementation of the dairy cow diet with plant oils or oil seeds leads 
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to the production of milk with a modified FA profile (122). Although such an approach would 
allow consumers to maintain the beneficial aspects of dairy consumption while limiting SFA 
intake into the food chain, only a small number of RCTs have investigated the impact of 
consuming FA-modified dairy products on human health (Chapter 1). Of these studies, four 
observed a reduction in TC and LDL-C following chronic consumption of FA-modified dairy 
products in which total dairy SFA was partially replaced by MUFA. However, these studies 
presented heterogeneity in methodological approaches, from the supplementation strategy of 
the dairy cows to study populations and estimations of CVD risk. Considering the 
methodological variations of these studies and the apparent beneficial impact on CVD lipid 
risk markers (primarily TC and LDL-C), further research combining multiple risk markers 
would provide a more informative understanding of the effects associated with replacing SFA 
with UFAs in dairy products. 
To address this evidence gap and to gain a better insight of the replacement of SFA 
with MUFA within a dairy background, a novel RCT was conducted and presented in 
Chapters 2, 3 and 4. The RESET trial investigated both the chronic and acute-within-chronic 
effects of SFA-reduced, MUFA-enriched dairy products (FA-modified), compared to control 
matched conventional products, on traditional and novel risk markers of CVD. 
Supplementation of the dairy cow feed with high-oleic sunflower oil led to partial 
replacement of total SFA and a parallel increase of total MUFA in milk fat, as described in 
detail in Appendix II. The development of the food exchange model, described in Chapter 2, 
aimed to implement specific dairy fat manipulation, without changing other components of 
the participants’ diets. Furthermore, it underlined the importance of evaluating the efficacy 
and adherence of the food-exchange strategy within the dietary interventions. This was 
achieved by comparing post-intervention change of the two dairy diets from both the 4 day 
weighed diet diaries and data obtained from the analysis of the plasma phospholipid FA (PL-
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FA) fraction of the participants. The weighed dietary records confirmed that overall, the FA-
modified diet let to a reduction in SFA intake by 2.5% of total energy (%TE), with a parallel 
increase in MUFA of 3.5%TE, compared to the control diet. Comparatively, the analysis of 
the PL-FA data showed a modest decrease in the abundance of total SFAs and a concomitant 
increase in total cis-MUFAs. It is worth noting the potential limitation of circulating SFA as 
direct indicators of dietary intake, as some FA, particularly palmitic acid, can be 
endogenously synthesized from other FA and dietary carbohydrate (163, 274). Results from 
both the 4 day weighed food diaries and PL-FA analysis also highlighted the observed 
increase in trans ruminant FA (rTFA) intake following the modified diet and compared to the 
control diet. This is consistent with previous dairy cow supplementation studies, which have 
observed increased levels of ruminant TFA (rTFA) in the milk and derived dairy products, a 
result of ruminal biohydrogenation of UFAs (122, 203). Current evidence appears to suggest 
that rTFA do not detrimentally impact on human health, unlike industrial counterparts (220). 
The observed results from the RESET study have added to the evidence base of the impact of 
specifically increasing rTFA on CVD. However, further work is needed to explore the 
association of consuming rTFA present in FA-modified dairy products on human health.  
The intervention study presented in Chapter 3 and 4, add further insight into the 
impact of three types of FA-modified dairy products (UHT milk, Cheddar cheese and butter) 
on both traditional (fasted circulating lipid markers, blood pressure, arterial stiffness) and 
novel (vascular function, inflammatory and endothelial risk markers, size distribution of LDL 
and HDL particles) risk markers of CVD. The nature of the chronic and acute-within-chronic 
design addressed important aspects of dietary intervention studies. Firstly, investigating the 
long-term impact of replacing habitually consumed dairy products with FA-modified study 
products, provided the means to evaluate potential improvements in CVD risk markers, in a 
population at moderate CVD risk. The observed attenuation in the rise of fasted LDL-C 
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concentrations from baseline values, following consumption of the FA-modified diet and 
compared to the control diet, confirms the importance of considering not only the 
macronutrient replacing dietary SFA, but also the potential impact of the dairy food matrix. 
Additionally, the observed increase in fasted circulating LDL-C from baseline values 
following intake of conventional dairy products supports the detrimental effect of total SFA 
on LDL-C.  
One of the aims of the present intervention study was to investigate the impact of FA-
modified dairy products on novel risk markers of CVD, in parallel to traditional ones. The 
observed increase in fasted plasma nitrite concentrations as a result of 12-week consumption 
of the FA-modified dairy diet is indicative of a potentially beneficial impact on endothelial 
function, which may further be supported by the results of the FMD response. However, it 
remains unanswered whether the lack of an impact on other fasted markers of CVD risk 
(Chapter 3) was due to the two dairy diets having similar amounts of protein and other 
micronutrients, such as calcium, which have been observed to mediate effects on blood 
pressure and arterial stiffness (69). 
Given that many individuals consume frequent meals throughout the day, investigating 
the postprandial state and assessing potentially modulatory effects on both circulating lipid 
markers and vascular function following dietary interventions remains of great public health 
importance. The acute-within-chronic study (Chapter 4) aimed to assess whether long-term 
intake of FA-modified dairy products would beneficially impact on postprandial markers of 
CVD risk. The novel design of the acute-within-chronic study assessed postprandial risk 
markers both pre and post chronic consumption of the two dairy diets by implementing a two 
meal challenge, with study test meals representative of the dairy products of each intervention 
arm.   The observed lower postprandial response in the incremental area under the curve 
(iAUC) of apolipoprotein B (apoB), following consumption of the FA-modified diet and test 
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meals, is indicative of an effect on triglyceride-rich lipoprotein (TRL) metabolism. This is in 
agreement with other studies (232, 233) which have investigated a replacement of SFA with 
MUFA-rich diets and suggests an overall influence on the number and size of TRLs, which 
may therefore lead to an increased rate of clearance in the circulation. Similarly to the chronic 
study in Chapter 3, the FA-modified diet appears to also modulate the response of plasma 
nitrite in the postprandial state. However, as it was a non-significant change, this finding 
remains to be compared with the FMD response in the fasted and postprandial state, as 
evidence suggests that FMD response may be in part mediated by production of nitric oxide in 
healthy adults and to a lesser degree in adults at CVD risk (275). 
The observed increase in TFA intake in the FA-modified diet compared to the control 
requires further investigation. Although, as has been mentioned in this thesis, the impact of 
rTFA may not as detrimental as iTFA, further studies are still needed to elucidate potential 
mechanisms on risk markers of CVD. Limited evidence suggests that specific rTFA, such as 
vaccenic acid, may increase both LDL-C and HDL-C (132, 220). This mechanism may have 
impacted the observed results in the present intervention. However, the specific effect of the 
rTFA present in the FA-modified dairy products could not be adequately investigated. Future 
studies on FA-modified dairy products may incorporate analyses that would elucidate 
potential mechanisms of rTFA on risk markers. 
Response to dietary manipulation has been shown to be highly heterogenous, based on 
a number of factors including genetic polymorphisms. In Chapter 5, the response to the 
dietary intervention according to the participants’ APOE genotype was explored. Evidence 
suggests that the APOE4 allele is associated with an observed greater LDL-C elevation in 
response to dietary SFA and individuals with this allele may benefit from a reduced SFA 
intake and a parallel replacement of a suitable macronutrient (260). However, only E4 carriers 
and the E3/E3 wild type variant were analysed retrospectively, resulting in unequal participant 
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numbers and gender distribution for each group and no significant interaction observed 
following consumption of the two dairy diets. However, the pre-intervention observed 
baseline differences in NEFA, HDL-C and HDL particle size are of interest, primarily as it 
highlights the importance of not only exploring the association between genotype and dietary 
manipulation in larger studies, but how these findings may be translated in a wider context for 
populations at risk. Dietary recommendations may in future be tailored to specific population 
groups, such as those at higher CVD risk based on existing non-modifiable risk factors such 
as genetic polymorphisms. 
Overall, findings from the chronic and acute-within-chronic study suggest that consumption 
of FA-modified dairy products leads to a modest beneficial impact on aspects of circulating 
LDL-C metabolism and nitrite bioavailability. As mentioned in the research chapters, the 
difference in total SFA and cis-MUFA content between the two dairy diets, although 
significant, may be regarded as modest, which may explain why no further changes in the 
other CVD risk markers were observed. However, these are aspects that may be investigated 
in future studies. 
It is of interest to note that although recent UK dietary guidelines have advised a 
further reduction in total dairy intake, there is no actual recommendation for dairy intake. In 
contrast, other countries such as France, advise up to 3 servings of dairy a day (for example, 
one serving represents 250ml milk, 40 g hard cheese, 200 g yoghurt) (276). This 
recommendation was recently adopted in the UK by the dairy sector (277), as a way to 
campaign for transparency for the role of milk and dairy, and promote their consumption as 
part of a healthy diet. It remains to be seen therefore, whether dietary recommendations in the 
UK will also change in light of the current evidence of dairy consumption on CVD risk. 
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6.2 Conclusions 
 
In conclusion, the data presented in this thesis add novel insight into the impact of FA-
modified dairy products on fasted and postprandial risk markers of CVD. Development and 
implementation of the food-exchange model was successful, as shown by data obtained from 
the 4 day weighed food diaries and PL-FA. Our findings show that in adults at moderate CVD 
risk, long-term consumption of high quantities of FA-modified dairy products (38% total 
energy intake) led to an attenuation in the fasted concentrations of LDL-C, compared to both 
baseline values and consumption of matched control dairy products. Additionally, a 
postprandial investigation with test meals representative of the dietary intervention products 
resulted in observed decreases in postprandial apoB response following the FA-modified test 
meals are indicative of a potential impact on TRL metabolism. A further aim was to 
determine whether APOE polymorphisms would result in an additional impact on fasted and 
postprandial response, following dietary fat manipulation and consumption of the dairy study 
products. No outcome measures were significantly modulated by the APOE genotype of the 
participants, however baseline differences in NEFA, HDL-C and HDL particle size were 
observed. The findings of the present PhD research have added new and valuable data on the 
impact of FA-modified dairy products on established and novel CVD risk markers. At the 
same time, several aspects of the impact of FA-modified dairy products on CVD risk require 
further research. 
6.3 Future perspectives 
 
The studies presented in this thesis have addressed a number of important questions, while 
generating new insights into potential mechanisms of the role of dairy fat on CVD risk 
markers, which may form the basis for future research opportunities, some of which have 
been proposed in previous sections of the thesis. Findings from the RCT demonstrate a 
modest beneficial impact on specific CVD risk markers following consumption of high 
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intakes of FA-modified dairy products compared with conventional dairy foods, in both the 
fasted and postprandial state. The observed beneficial effect of specific dairy products on 
fasted LDL-C concentrations and blood pressure may represent the nature of the dairy food 
structure and nutritional composition. Nutrient digestion and absorption are determined by the 
nature of the food structure and nutritional composition. In the case of dairy foods, it has been 
suggested that the detrimental effect of SFA on blood lipids is attenuated following 
consumption of specific products, such as milk, cheese or yogurt (21, 64, 77). The 
combination of dairy bioactive peptides, minerals and fatty acids in certain dairy products 
may exert beneficial effects on CVD risk marker, as suggested by increasing evidence from 
intervention studies. In particular, studies which have compared iso-energetic quantities of 
cheese and butter provide support of a food matrix effect on observed changes in circulating 
blood lipids (61). Previous studies on dairy fat consumption have suggested that the observed 
attenuation in blood lipid response may be explained by a decrease in intestinal fat absorption 
and bile-acid recycling, modulation of the gut microbiota or the alteration of gene expression 
(21). Moreover, there is a wealth of evidence to indicate that the beneficial effects of certain 
dairy products are due to calcium content. In particular, it has been observed that an increased 
intake of calcium from certain dairy products, such as cheese, leads to increased faecal fat and 
bile acid excretion following consumption of both low- and high-fat diets. It has been 
proposed that the effect of calcium on faecal fat and bile excretion is probably due to a 
combination of a formation of insoluble calcium-fatty acid soaps, and hydrophobic 
aggregations with phosphorus and bile acids (21, 25, 278). In support of this concept, a study 
which compared isocaloric quantities of milk, cheese and butter observed that both milk and 
cheese attenuated the increase in LDL-C compared to butter (279). The three diets were 
matched not only for energy content, but also total fat and protein; calcium content was 
similar for cheese and milk but not matched in butter (279). Although this was a short-term 
intervention study in healthy men, it provides further evidence for an impact of calcium 
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content in specific dairy product on circulating LDL-C. Considering the effect on fasted LDL-
C and iAUC of apoB following consumption of FA-modified dairy products presented in this 
thesis, this is an area of research that needs further intervention-based evidence, which would 
include investigation into changes of the composition of gut microbiota, the role of calcium 
present in specific dairy products in reduced fat digestion and whether there is a dose 
dependent response effect which would impact on bile acid excretion.  
The RCT presented in this thesis also highlights the need for mechanistic in vitro 
studies to further understand and assess the effect of the FA-modified dairy products on risk 
markers of disease. Specifically, the impact on TRL metabolism observed in the postprandial 
study may be further examined with the use of hepatocyte (HepG2) cell model uptake studies 
to investigate potential pathways of TRL production and clearance. Potential in vitro research 
using human aortic endothelial cells (HAEC) may also provide a platform to conduct 
investigations in physiological concentrations of dairy FA mixtures. A previous study which 
examined the effect of individual dairy FA and FA mixtures on both healthy and type II 
diabetic HAEC, observed that the alteration of dairy FA composition did not significantly 
affect endothelial markers of CVD, although there was a differential effect of individual dairy 
FA on production of NO and sE-selectin (280). Considering that few in vitro studies have 
investigated dairy FA mixtures in cell lines, the use of better cell models, such as co-culture 
of endothelial cells with vascular smooth muscle cells, remains a research area of great 
interest. 
The genetic analysis presented in Chapter 5 does not allow definite conclusions to be 
drawn due to the small population size, uneven numbers of the two groups and retrospective 
genotype analysis. However, there is considerable interest to further explore lipid-associated 
SNPs in response to dietary fat manipulation and future studies could reduce the limitations 
mentioned above by including an increased number of participants and a prospective 
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genotype analysis. In addition to APOE, other SNPs, such as polymorphisms of lipoprotein 
lipase (LPL) are of interest. Two LPL SNP (rs320 and rs328), have been linked as genetic 
determinants which may explain the inter-individual variability of TAG and HDL-C 
concentrations in both the fasted and postprandial state following dietary fatty acid 
replacement (281-283). LPL plays a role in lipid metabolism by both hydrolysing TRL, 
affecting HDL-C concentrations and binding TRL to hepatic LDL receptors, mediating the 
clearance of these particles in the circulation (284). Considering the observed increased 
content of rTFA in the FA-modified dairy products and the impact of total TFA intake on 
HDL-C, investigation into LPL polymorphisms may add further evidence in understanding 
the impact of rTFA on risk markers. 
 Considerable research from previous studies has demonstrated that milk FA 
composition can be modified by supplementing the bovine feed with plant seeds or oils (200), 
as has been illustrated in Chapters 1 and 2 and Appendix II. The challenging aspect of 
partially replacing SFA with cis-MUFA in milk fat is the increase in rTFA. Although these 
FA are distinct from industrially derived TFA, further research is needed in order to fully 
understand their impact on health. Protection of oils/oilseeds from ruminal biohydrogenation 
remains an area to explore further. To date, a number of studies have looked at different 
methodologies, such as extrusion and saponification, as a way to minimise the increases in 
rTFA with varying degrees of success (122). Larger scale trials are still needed to confirm 
existing findings or to explore novel strategies, such as whey-gel protection of the supplement 
(122). However, the implementation of oil/oilseed supplementation strategies on a larger 
scale, aimed for a consumer market, would incur additional costs on dairy farmers. Although 
the financial costs of producing FA-modified dairy products was not part of the scope of the 
present thesis, it does represent an aspect which may affect potential future directions. 
According to data available from the Agriculture and Horticulture Development Board 
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(AHDB), purchased feed in November 2017 averaged £210 per tonne in the UK, representing 
a 6.4% increase from the previous year (285). With feed and forage costs representing 30-
40% of the total cost of dairy farm production and farmgate prices for liquid milk declining 
since 2015 (285), any additional production costs would need to either be subsidised or 
covered by the consumer. Considering the decline in demand for dairy products and the 
parallel increase in market competition from plant-based alternatives, FA-modified dairy 
products may, at least initially, represent a niche market for dairy products valued by 
consumers willing to pay a premium for healthy dairy product alternatives. 
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Dairy and cardiovascular health:
Friend or foe?
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University of Reading, UK;
†Food Production and Quality Research Division, School of Agriculture, Policy and Development, Faculty of Life Sciences, University of Reading, UK
Abstract Cardiovascular disease (CVD) prevalence at a global level is predicted to increase
substantially over the next decade due to the increasing ageing population and
incidence of obesity. Hence, there is an urgent requirement to focus on modifiable
contributors to CVD risk, including a high dietary intake of saturated fatty acids
(SFA). As an important source of SFA in the UK diet, milk and dairy products are
often targeted for SFA reduction. The current paper acknowledges that milk is a
complex food and that simply focusing on the link between SFA and CVD risk
overlooks the other beneficial nutrients of dairy foods. The body of existing pro-
spective evidence exploring the impact of milk and dairy consumption on risk
factors for CVD is reviewed. The current paper highlights that high milk consump-
tion may be beneficial to cardiovascular health, while illustrating that the evidence
is less clear for cheese and butter intake. The option of manipulating the fatty acid
profile of ruminant milk is discussed as a potential dietary strategy for lowering SFA
intake at a population level. The review highlights that there is a necessity to
perform more well-controlled human intervention-based research that provides a
more holistic evaluation of fat-reduced and fat-modified dairy consumption on
CVD risk factors including vascular function, arterial stiffness, postprandial
lipaemia and markers of inflammation. Additionally, further research is required to
investigate the impact of different dairy products and the effect of the specific food
matrix on CVD development.
Keywords: arterial stiffness, blood pressure, cardiovascular disease, dairy products, milk,
saturated fatty acids
Introduction
Althoughmortality from cardiovascular disease (CVD) is
now falling in most European countries, CVD is ranked
as the leading cause of mortality in the UK and world-
wide (BHF 2010; WHO 2011; Nichols et al. 2012). It is
envisaged that the global prevalence of CVD will con-
tinue to increase and is expected to be responsible for
more than 23.6 million deaths by 2030 (Smith et al.
2012), a figure that is largely attributable to today’s
dramatic demographic changes with increasing propor-
tions of ageing and obese groups. The outcome of today’s
obesity and ageing trendsmay, if not moderated, result in
unsustainable costs to global society. Currently, CVD
costs the European Union (EU) economy approximately
€196 billion per annum in direct and indirect charges,
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with the cost per person in the UK exceeding the EU
average (Nichols et al. 2012). There is growing pressure
to reduce risk factors for CVD at a population level. An
atherogenic diet, characterised by a high intake of dietary
saturated fatty acids (SFA), is a key modifiable risk factor
for CVD. While the effects of the amount and type of
dietary fat have been examined in relation to CVD, less
focus has been placed on the role of animal-derived staple
foods such as milk and dairy products, which are signifi-
cant dietary sources of SFA.
Saturated fat consumption
In order to reduce the population health burden of
CVD, a number of strategies can be addressed; these
include increasing physical activity, improving weight
profiles and reducing tobacco and alcohol intake.
However, this paper will focus on strategies for combat-
ting the overconsumption of dietary SFA.
The adverse effect of SFA on CVD risk is well estab-
lished; this is primarily mediated via increases in serum
lipids, particularly low-density lipoprotein (LDL)-
cholesterol (Mensink et al. 2003). Current dietary rec-
ommendations include an intake of dietary SFA of less
than 10% of total energy (DH 1991; WHO 2008). The
current rolling National Diet and Nutrition Survey
(NDNS), as outlined in Table 1, highlights that this
dietary target is exceeded by the majority of men,
women and children in the UK (DH 2012).
Substitution of dietary saturated fat with
carbohydrate or unsaturated fatty acids
The question of whether replacement of dietary SFA
with carbohydrate (CHO), cis-polyunsaturated fatty
acids (cis-PUFA) or cis-monounsaturated fatty acids
(cis-MUFA) can have beneficial effects on CVD mortal-
ity and risk has received considerable attention (Astrup
et al. 2011; Hooper et al. 2012; Vafeiadou et al. 2012).
There would seem to be no clear evidence for a benefit
of substituting CHO for SFA in the prevention of CVD
(Astrup et al. 2011; Hooper et al. 2012) but there is
some recent evidence for the benefit of replacing SFA
with unsaturated fatty acids (Jakobsen et al. 2009;
Micha &Mozaffarian 2010; Hooper et al. 2012). There
is good evidence that replacing SFA with cis-PUFA will
reduce CVD mortality and risk markers, although there
is less information on the effects of replacing SFA with
cis-MUFA, mainly because few relevant randomised
controlled trials have been performed (Mozaffarian
et al. 2010). Overall, the Cochrane meta-analysis of
Hooper et al. (2012) identified that a reduction of
dietary SFA intake (where it is replaced by unsaturated
fat) and/or reduction of total dietary fat lowered the risk
of cardiovascular events by 14% [relative risk (RR)
0.86; 95% confidence interval (CI) 0.77–0.96] but had
no effect on total mortality.
The contribution of dairy products to
saturated fat intake
Milk and dairy products are one of the most significant
contributors to SFA intake in the UK diet. In the context
of this review, we are defining dairy as cows’ milk or any
food product derived from cows’ milk. However, it
should be noted that some dairy products (including
butter and cream) do not fall into the ‘milk and dairy’
section of the eatwell plate because they are predomi-
nantly viewed as significant sources of fat (FSA 2011).
Recent NDNS data (Table 2) suggest that milk and
dairy products are responsible for 22–25% of SFA con-
sumption in adults (DH 2011); however, it should be
noted that this analysis failed to take into account the
intake of composite dairy dishes (e.g. pizza and lasagne)
as well as butter consumption, the latter contributing
around 5% to daily average saturated fat intakes; thus
SFA intake from milk and dairy product consumption
may be underestimated.
Table 1 Average intake of saturated fatty acids in absolute terms and as a percentage of food/total energy, by age and gender (NDNS
2008/2009–2010/2011)
Boys/Men Girls/Women
4–18 years 19–64 years ≥65 years 4–18 years 19–64 years ≥65 years
SFA (g/day) 25.8 ± 8.6 28.8 ± 12.1 29.3 ± 10.7 22.7 ± 8.1 22.0 ± 9.8 23.2 ± 9.0
% food energy 12.9 ± 2.6 12.8 ± 3.3 14.4 ± 3.5 12.9 ± 2.7 12.6 ± 3.4 14.0 ± 3.7
% total energy 12.9 ± 2.6 12.0 ± 3.4 13.6 ± 3.4 12.9 ± 2.8 12.0 ± 3.3 13.7 ± 3.3
Source: DH (2012).
Mean ± SD. NDNS, National Diet and Nutrition Survey; SFA, saturated fatty acids.
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Effects of saturated fat in dairy products on plasma
lipids and lipoproteins
A detailed review by Huth and Park (2012) revealed
that diets higher in SFA from whole milk and butter
increase LDL-cholesterol but may also have a beneficial
impact on high-density lipoprotein (HDL)-cholesterol
concentrations, resulting in a neutral or beneficial effect
on the total cholesterol:HDL-cholesterol ratio. Fer-
mented dairy products including cheese and yogurt
appear to have a different impact on circulating levels of
plasma lipid and lipoproteins. For example, compared
to butter matched for milk fat intake, consumption of
hard cheese for a 6-week period led to significantly
lower concentrations of total cholesterol, LDL-
cholesterol and HDL-cholesterol (Hjerpsted et al.
2011). However, it should be noted that butter is not
necessarily a good comparator. There are a number of
confounding variables that negate the drawing of firm
conclusions in relation to cheese and CVD risk due to
the differential effect of individual cheese varieties that
differ in macronutrient content, degree of fermentation
and food matrix (Huth & Park 2012). Furthermore, it
highlights that the impact of dairy products on CVD
risk factors may be dependent on the specific dairy food,
even when supplying the same mass of dairy fat.
However, further long-term studies are necessary before
firmer conclusions can be drawn on the relative impact
of milk and milk-derived food consumption on plasma
lipids and lipoproteins.
The consumption of milk and milk-derived
products and cardiovascular disease
Potential benefits of milk and dairy consumption
Dairy fats are high in SFA; however, ruminant milk is a
complex food and there is much debate as to whether
nutrients within dairy foods act independently or syner-
gistically in relation to chronic disease development. The
association of SFA with CVD development may be
dependent on other nutrients/macronutrients in the
matrix of the SFA-containing food (de Oliveira Otto
et al. 2012). Milk is a significant source of a number of
essential micronutrients including calcium, potassium
and iodine. Calcium, for example, has a higher
bioavailability in milk compared with that present in
some other foods (Weaver et al. 1999). Furthermore,
mineral bioavailability is enhanced by the lack of inhibi-
tors present in milk, including phytates and oxalates,
and by the presence of lactose and certain amino acids
that may promote mineral absorption (FAO 2013).
Moreover, lipids mediate the delivery of essential fat-
soluble vitamins, including vitamins D and A, and fatty
acids associated with dairy products, namely conjugated
linoleic acids, may also have cardio-protective proper-
ties, although the data are inconsistent and require con-
firmation in further human studies (Dilzer & Park
2012). Furthermore, emerging evidence suggests that
plasma phospholipid trans-palmitoleic acid (trans 16:1
n-7), a circulating fatty acid biomarker positively corre-
Table 2 Percentage contribution of food groups to average daily total saturated fatty acid intake, by age and gender (NDNS 2008/2009–
2009/10)
Food groups (%)
Boys/Men Girls/Women
4–18 years 19–64 years ≥65 years 4–18 years 19–64 years ≥65 years
Cereals and cereal products 25 18 17 24 20 18
Milk and milk products 25 22 28 27 22 24
Eggs and egg dishes 2 3 3 2 4 4
Fat spreads 9 10 13 8 10 16
Meat and meat products 22 27 22 20 23 19
Fish and fish dishes 2 3 4 1 3 5
Vegetables and potatoes 5 7 5 6 7 6
Savoury snacks 2 1 0 2 1 0
Nuts/seeds/fruits 0 1 1 0 2 0
Sugars/preserves/confectionary 7 4 2 7 5 3
Drinks 0 1 1 0 1 0
Miscellaneous 2 3 3 2 4 3
Source: DH (2011).
NDNS, National Diet and Nutrition Survey.
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lated with self-reported intakes of dairy fat intake
(whole-fat dairy products and butter), is associated with
a more favourable metabolic profile and incident diabe-
tes rate (Micha & Mozaffarian 2010; Mozaffarian et al.
2013). However, the aforementioned findings regarding
trans 16:1 n-7 should be interpreted with caution as they
do not necessarily prove cause and effect; thus, oversim-
plifying the relationship between dairy product intake
(in terms of SFA content) and CVD risk may be mislead-
ing (Givens 2012).
Changing trends in dairy consumption
UK trends in dairy product consumption have changed
markedly over recent years; this could be partly due to
the negative connotations surrounding dairy products
and SFA content. Family Food statistics published by the
Department for Environment, Food and Rural Affairs
(Defra) over the past 20 years show a decline in total
liquid milk consumption, largely brought about by a
decrease in whole milk consumption, which now
accounts for around 20% of milk consumed in the UK
today. Butter consumption has decreased markedly
from the 1970s by about 70%, and fell around 2%
lower in the decade between 2001 and 2011, while
cheese and yogurt consumption increased by around
5% and 30%, respectively, over the same time period
(AHDB-DairyCo 2012).
Dietary patterns associated with milk and dairy
product consumption
Analysis of dietary patterns is recognised as an alternate
and complementary strategy for investigating the asso-
ciation between diet and disease risk. As dietary patterns
are more representative of overall food consumption,
they may facilitate a more valid prediction of CVD risk
compared with assessment of an individual nutrient or
food (Hu 2002). Prospective data from 88 517 middle-
aged women indicated that adherence to the Dietary
Approaches to Stop Hypertension (DASH) diet, charac-
terised by a moderate intake of low-fat dairy, legumes
and nut products, high intake of fruit, vegetables and
wholegrains, and low intake of red meat, was inversely
associated with risk of coronary heart disease (CHD)
and stroke during a 24-year follow-up period (Fung
et al. 2008). This finding was in agreement with the
Atherosclerosis Risk in Communities Study which illus-
trated that a dietary pattern rich in dairy and nut prod-
ucts, but less meat, is associated with a lower risk of
incident hypertension in middle-aged adults (Weng
et al. 2013). However, many international and national
dietary guidelines recommend the reduced intake of full-
fat dairy products as one aspect of a dietary pattern
linked to reducing risk of CHD (Erlinger & Appel
2005).
Dairy consumption and cardiovascular disease risk:
Prospective evidence
A number of studies have investigated the effect of milk
and dairy products on different CVD events. As previ-
ously mentioned, there is a lack of robust evidence on the
potential differential effects of individual dairy foods on
CVD risk as most observational studies combine dairy
products as a single food group, although milk is better
studied. A meta-analysis of prospective cohort studies
reported that, overall, high milk consumption does not
increase the RR of CHD (Elwood et al. 2008). A second
meta-analysis, which combined prospective cohort and
clinical studies, revealed that there was insufficient evi-
dence for an association between milk consumption and
CHD (RR 0.94; 95%CI 0.75–1.13) (Mente et al. 2009).
A later more extensive meta-analysis on milk and dairy
consumption and CVD events concluded that high con-
sumption of milk was related to a significant reduction in
risk of stroke development (Elwood et al. 2010). Table 3
is largely based on Elwood et al. (2010) but has been
updated by the addition of data from six recently pub-
lished studies (Bonthuis et al. 2010; Goldbohm et al.
2011; Sonestedt et al. 2011; Soedamah-Muthu et al.
2012; Avalos et al. 2013; van Aerde et al. 2013). A
recent study showed that compared with the lowest
quintile of dairy consumption, total dairy intake was
inversely related to myocardial infarction (MI) risk fol-
lowing an 11.6-year follow-up period (HR 0.77; 95%CI
0.63–0.95). Further analysis revealed that butter used on
bread was positively correlated with MI risk, while total
cheese intake had an inverse risk association (Patterson
et al. 2013). This evidence supports the hypothesis that
dairy products, excluding butter, are associated with no
detrimental effect, and in some cases a significant
reduced CVD risk.
Hypertension is one of the key risk factors for CVD
development and is influenced by gene polymorphisms,
nutrition, the environment and interactions between
these factors. Milk and milk-derived products provide
essential micronutrients (such as calcium, potassium
and iodine) and protein (whey, casein and specific
bioactive peptides), some of which have been associated
with beneficial hypotensive effects, either independently
or synergistically (Kris-Etherton et al. 2009). There are
a number of proposed mechanisms by which milk and
its components could reduce blood pressure (BP; for a
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detailed review, see Fekete et al. 2013). Bioactive
peptides present in casein and whey proteins have been
observed to play a role in controlling BP by inhibiting
the action of angiotensin-I-converting enzyme, resulting
in vasodilation (FitzGerald & Meisel 2000), by modu-
lating the release of endothelin-1 by endothelial cells
(Maes et al. 2004) and acting as opioid receptor ligands
increasing nitric oxide production which mediates arte-
rial tone (Kris-Etherton et al. 2009). An important con-
sideration is the potential impact of a threshold
dependency mechanism whereby benefit is conferred in
those at low nutrient status, such as calcium, whereas in
individuals with adequate baseline status, little effect is
observed (McCarron et al. 1991; Wennersberg et al.
2009; Park & Cifelli 2013). This has important consid-
erations in respect of public health advice on dairy con-
sumption within population groups with different
nutritional status. Although the Rotterdam Study found
an inverse association between low-fat dairy intake and
hypertension risk in older adults (Engberink et al.
2009), limited evidence exists as to the potential addi-
tional benefit of low-fat dairy foods and the type of
dairy products in relation to BP reduction. Low-fat
dairy is the product of choice in most trials, yet both
low- and high-fat alternatives appear to have an overall
beneficial effect in relation to BP (Ralston et al. 2012).
Fumeron et al. (2011) reported that consumption of
either a variety of dairy products excluding cheese, or
cheese alone, and the calcium density of the diet were
associated with a lower 9-year diastolic BP after analys-
ing data from the Epidemiological Study on the Insulin
Resistance Syndrome. Moreover, data from the Caer-
philly Prospective Study illustrated that when compared
to non-milk consumers, men who consumed >586 ml/
day had a 10.4 mmHg lower systolic BP after a 22.8-
year follow-up (Livingstone et al. 2013). Unsurprisingly,
greater hypotensive effects of dairy consumption are
observed in those with hypertension or who present
with calcium sensitivity. In normotensive subjects, dairy
consumption is often related to retaining BP homeosta-
sis rather than hypotensive effects (Park & Cifelli 2013).
Elasticity of the blood vessels can be influenced by
chronic dietary patterns (Kesse-Guyot et al. 2010). Car-
diovascular events and all-cause mortality are indepen-
dently predicted by carotid-femoral pulse wave velocity
(PWV), the gold standard measurement of arterial stiff-
ness (Vlachopoulos et al. 2010; Van Bortel et al. 2012).
Further evidence from the Caerphilly Prospective Study
highlighted that, with the exception of butter consump-
tion, dairy product intake does not impact negatively on
PWV (Livingstone et al. 2013). Furthermore, augmen-
tation index, another indicator of arterial stiffness, was
1.8% lower in men with the highest quartiles of dairy
food consumption (Livingstone et al. 2013). Similarly,
cross-sectional study findings illustrated that dairy food
intake was inversely correlated with PWV (Crichton
et al. 2012a).
A low-grade systemic inflammation is recognised as a
major factor contributing to the development and pro-
gression of a number of disorders related to CVD
(Labonte et al. 2013). Cross-sectional studies that have
investigated the relationship between dairy intake and
low-grade systemic inflammation have found an inverse
association (Salas-Salvado et al. 2008; Esmaillzadeh &
Azadbakht 2010). However, a review that grouped
several studies involving overweight or obese subjects
found a degree of heterogeneity which hinders any defi-
nite conclusions (Labonte et al. 2013). Although there is
evidence supporting a beneficial association between
dairy consumption and inflammation, the mechanisms
are still unclear and studies are either underpowered or
use more than one type of dairy product as an interven-
tion, making it difficult to distinguish between dairy
products (Labonte et al. 2013).
Table 3 Summary of the relative risk for milk and dairy consumption and CVD events
Disease outcome
Number of cohort studies
(number used in analyses)
Adjusted RR (95% CI) for
milk/dairy consumption*
Significance of heterogeneity
between studies
Ischaemic heart disease 22 (17) 0.92 (0.86, 0.99) P = 0.765
All strokes 12 0.79 (0.68, 0.91) P = 0.001
Haemorrhagic stroke 5 0.75 (0.60, 0.94) P = 0.014
Subarachnoid bleed 3 0.93 (0.84, 1.02) P = 0.004
All-cause mortality 12 (9) 0.91 (0.78, 1.05) P = 0.070
Source: Adapted from Givens et al. (2014).
*Estimate of the risk of each disease in individuals with the highest consumption of milk/dairy products compared to the risk in individuals with the lowest
consumption.
CI, confidence interval; CVD, cardiovascular disease; RR, relative risk.
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Dietary strategies for lowering consumption
of saturated fat and the implication
for cardiovascular disease
Low-fat milk and dairy products
When compared with low-fat alternatives, there is no
established nutritional benefit of whole-fat dairy con-
sumption, except in young children; therefore, the intake
of low-fat milk and milk-related products may be con-
sidered an effective strategy to lower SFA intake.
However, there is currently no consensus on whether
fat-reduced dairy foods are associatedwith a reduced risk
of CVD (Benatar et al. 2013).Observational studies have
indicated that low-fat dairy consumption is an effective
strategy to promote lower BP levels (Engberink et al.
2009; Toledo et al. 2009; van Meijl & Mensink 2011),
circulating markers of inflammation (Esmaillzadeh &
Azadbakht 2010), the ratio of total cholesterol:HDL-
cholesterol (Mensink et al. 2003) and LDL-cholesterol
concentration (Kai et al. 2013), as well as aid in weight
maintenance or reduction (Abargouei et al. 2012). The
Nurses’ Health Study cohort illustrated that the associ-
ated RR of CHD varied according to consumption of
high-fat (RR 1.12; 95% CI 1.05–1.20) or low-fat dairy
consumption (RR 0.80; 95% CI 0.73–0.87) (Hu et al.
1999). On the contrary, findings from a prospective
population-based cohort of 33 636 women suggested
there were no significant differences between consump-
tion of specific low-fat and high-fat dairy products and
MI risk (Patterson et al. 2013). Furthermore, findings
from a 12-month randomised crossover trial concluded
that inclusion of reduced-fat dairy products in the diets of
overweight adults had no impact on cardio-metabolic
outcomes, including blood lipids, BP and arterial com-
pliance (Crichton et al. 2012b).However, before it can be
clearly established whether or not removal of milk fat is
beneficial to overall cardio-metabolic health, further evi-
dence fromwell-controlled human intervention studies is
required.
Altering the dairy cow diet to manipulate the fatty
acid profile of milk
As an alternative to promoting low-fat dairy product
consumption, modification of the fatty acid profile of
bovine milk offers a strategy for lowering the popul-
ation’s intake of SFA, by removing SFA from the food
chain, while preserving the beneficial contributions that
dairy products make to the protein and micronutrient
content of the human diet (Shingfield et al. 2008). Over
100 studies have explored the potential of partially
replacing milk SFA with cis-MUFA or cis-PUFA through
supplementation of the bovine diet with plant oils or
oilseeds (Givens & Shingfield 2006; Glasser et al. 2008).
Through a reduced synthesis of short- and medium-
chain SFA by the mammary gland, this feeding strategy
enhances the long-chain (>C18) unsaturated fatty acid
concentration in the milk (Doreau et al. 1999). Inclu-
sion of 49 g/kg of dry matter of rapeseed oil in the
ruminant diet for a 28-day period increased cis-MUFA
from 20 to 33 g/100 g FA, while reducing SFA from 70
to 55–60 g/day FA (Givens et al. 2009). Although a
more substantial decrease in SFA (∼20 g/100 g of FA)
has been documented, the alteration to milk FA compo-
sition was adversely linked to voluntary bovine nutrient
intake and milk yield compared to the control diet
(Givens et al. 2003). In order for modification of the
composition of ruminant-derived foods to be recognised
as a sustainable strategy for reducing SFA intake at a
population level, it is essential to find an optimal
balance between maximising the unsaturated FA profile
of the milk and minimising the impact of the supple-
mentation on animal performance (Givens 2008).
Furthermore, it should be considered that ruminal bio-
hydrogenation of PUFA results in the formation of inter-
mediates including trans 18:1 and leads to small
increases in PUFA relative to MUFA concentrations and
therefore, it might be more feasible to supplement the
bovine diet with MUFA (Shingfield et al. 2013).
In addition to the reductions in SFA and increases in
cis-MUFA, inclusion of unsaturated fatty acids into the
bovine-feeding regimen can lead to increased concentra-
tions of naturally produced ruminant trans fatty acid
(rTFA), namely linoleic acid isomers and trans MUFA,
in the milk. The intake of trans fatty acids (TFA) from
industrially hydrogenated vegetable oils is known to
have a negative impact on cardiovascular health
(Mozaffarian et al. 2006; Brouwer et al. 2010) and,
accordingly, there has been a significant reduction in the
level of ‘industrial’ TFA (iTFA) in the food chain
(Hulshof et al. 1999). Conversely, the association
between rTFA and CVD remains inconclusive (Gebauer
et al. 2011; Brouwer et al. 2013) with some studies
showing a cardio-protective effect of ruminant sources
of trans fats (Mozaffarian et al. 2006; Jakobsen et al.
2008). In an attempt to resolve the conflicting reports, a
systematic review and meta-analysis was undertaken by
Bendsen et al. (2011). They reported that the RR for
high vs. low quintiles of total TFA intake (2.8 to
approximately 10 g/day) was 1.22 (95% CI 1.08–1.38;
P = 0.002) for CHD events and 1.24 (95% CI 1.07–
1.43; P = 0.003) for fatal CHD. rTFA intake (0.5–1.9 g/
day) was not significantly associated with CHD risk (RR
0.92; 95% CI 0.76–1.11; P = 0.36) although neither
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was iTFA. There was, however, a trend towards a posi-
tive association (RR 1.21; 95% CI 0.97–1.50; P = 0.09)
for iTFA intake. The authors concluded that while iTFA
may be positively related to CHD, rTFA is not, but the
limited number of studies available prevented a firm
conclusion concerning whether the source of TFA is
important. The lack of an association of rTFA with
CHD risk may be due to lower intake levels (Bendsen
et al. 2011). However, at levels currently consumed in
the UK diet, there is no evidence of risk from rTFA.
Over the past 10–15 years, the total TFA intake in the
UK diet has decreased substantially as a result of volun-
tary action by the UK food industry; this has led to a
greater proportion of the total dietary trans fats originat-
ing from rTFA (SACN 2007). However, while the pro-
portion of dietary rTFA has increased, the absolute
intake of ruminant fat is unchanged. The current dietary
intake of TFA in the UK (0.7% of food energy in adults)
(DH 2012) is below the recommended population
maximum (2% of food energy intake) (DH 1991), with
milk and milk products contributing to around 25% of
this intake (DH 2011). Consequently, TFA intake from
ruminant sources is not seen as a major cause of concern
to cardiovascular health at a population level (Tardy
et al. 2011; Brouwer et al. 2013). However, it has yet to
be determined whether increasing rTFA intake, through
manipulation of the fatty acid profile of milk and dairy
products to decrease SFA content, impacts on cardiovas-
cular health (Livingstone et al. 2012).
Impact of modified dairy products on
cardiovascular disease risk factors
A review of the current evidence suggests that consump-
tion of modified feed-reduced SFA milk and milk prod-
ucts may be beneficial to CVD risk in healthy and
hypercholesterolaemic populations when compared to
commercially available whole milk dairy products
(Livingstone et al. 2012). However, it should be noted
that there is a distinct lack of human intervention-based
research (Givens 2012; Livingstone et al. 2012) and the
studies that have been performed have relied on plasma
lipid levels as a predictor of CVD risk and on butter as the
main test food. Some selected data illustrate that, in
comparison to conventional milk, cheese, butter and ice
cream (70 g/100 g SFA, 28 g/100 g cis-MUFA), total
cholesterol and LDL-cholesterol were significantly
lowered following a 3-week period of consuming
matched fat-modified dairy products (51 g/100 g SFA,
39 g/100 g cis-MUFA) (Noakes et al. 1996). Dairy prod-
ucts are complex, nutrient-dense foods and focusing on a
single outcome measure could lead to misleading
conclusions by failing to establish the impact on other
CVD risk factors.
Evidence suggests that some of the effects of SFA on
CVD risk are mediated by impairment in endothelial
function and subsequent establishment of atherosclerosis
(Nicholls et al. 2006; Blumenthal et al. 2010; Vafeiadou
et al. 2012) and by influencing postprandial lipaemia
(Berry & Sanders 2005). Endothelial dysfunction, an
early modifiable event in the coronary atherosclerotic
process, is positively associated with increased risk of
CVD (De Caterina 2000; Schachinger et al. 2000). Flow-
mediated dilation, which measures the vasodilatory
response of the brachial artery to an increase in blood
flow-associated shear stress and carotid intima-media
thickness, can be used to non-invasively assess
endothelial function and arterial structural changes,
respectively (Anderson 2006). As previously discussed, it
is recommended that arterial stiffness, a surrogate
marker of central arterial function, should also be evalu-
ated when exploring the impact of modified dairy con-
sumption on cardiovascular risk factors (Givens 2012).
Postprandial lipaemia, characterised by elevated and
prolonged triacylglycerol concentrations in the fed state,
is influenced by the type and quantity of the meal fat
(Chong et al. 2010; Jackson& Lovegrove 2012; Jackson
et al. 2012). Postprandial lipaemia is a significant inde-
pendent risk marker of CVD that requires attention in
future modified fat studies (Nordestgaard et al. 2007).
Further research is warranted to examine the impact of
fat-modified or any total low-fat or full-fat dairy con-
sumption on holistic measures of CVD including vascu-
lar function, arterial stiffness, postprandial lipaemia and
inflammation.
This is currently being addressed at the University of
Reading in theRESET (REplacement of SaturatEd fat in
dairy on Total cholesterol) Study (ClinicalTrials.gov
NCT02089035), a 3-year Medical Research Council
funded project that is investigating the impact of reduc-
ing SFA intake by usingmodifiedmilk and dairy products
on vascular function and CVD risk biomarkers, without
limiting dairy product consumption. This will be
achieved by producingmilk and dairy products that have
a substantial proportion of the SFA replaced with cis-
MUFA. In a randomised, crossover, double-blind, con-
trolled study, it will be determined whether modified
dairy product consumption improves vascular function
and other CVD risk biomarkers relative to typical com-
mercially available products in both acute and chronic
settings. The project, which started in late 2013, will
provide unique evidence to inform public health policy
on food-based dietary recommendations for CVD risk
reduction.
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Conclusion
Much of the UK population currently exceeds the
dietary SFA recommendation of <11% of food energy
intake, with milk and dairy products as a group making
a considerable contribution to SFA intake in the average
UK diet. While it is intuitive to consider further reducing
dairy consumption as a means of decreasing SFA intake,
epidemiological data suggest that this strategy may be
counterproductive, given the array of cardio-metabolic
benefits that milk products appear to offer to human
health. Fat-reduced or fat-modified dairy product con-
sumption may offer a more feasible option for reducing
intake of SFA with minimal change to habitual eating
patterns and, hence, CVD risk at a population level.
Nevertheless, before the impact of both fat-reduced and
modified dairy consumption on CVD risk reduction can
be evaluated, it is essential to conduct more robust,
controlled human intervention-based research using
both traditional and novel assessments of cardiovascu-
lar risk. Additionally, more research is required to dif-
ferentiate between dairy food matrices.
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Interpretive summary: 
 
Food chain approach to lowering saturated fat in milk and dairy products: the RESET 
study 
Kliem 
Supplementing dairy cow diets with high-oleic sunflower oil produces milk lower in saturated 
fatty acids/higher in monounsaturated fatty acids compared with the fatty acid profile of typical 
UK retail milk. This composition was maintained when this dietary strategy was used on a 
number of occasions over two years, with no difference in profile between UHT milk, butter 
and Cheddar cheese made from this milk. This dietary strategy could be used to manufacture 
modified dairy products which may have beneficial effects on human health. 
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ABSTRACT 
Despite a decline in overall consumption of saturated fatty acids (SFA) by UK adults over the 
past decade, intakes still exceed recommended levels, which may contribute to increased risk 
of cardiovascular disease. Milk and dairy products are a major source of SFA in the UK adult 
diet, and one strategy to minimise SFA in the food chain is to supplement lactating cow diets 
with unsaturated fatty acid-rich plant oils, thereby replacing some milk SFA with cis-
monounsaturated fatty acids (MUFA). Human intervention studies are required to determine 
whether consuming dairy products with SFA partially replaced with cis-MUFA reduces 
cardiovascular disease risk. However, a major hurdle to the implementation of such studies is 
the requirement for large volumes of SFA-reduced, MUFA-enriched dairy products with a 
consistent composition. Therefore, in this study a diet containing high oleic acid sunflower oil 
was fed to lactating cows over two production periods spanning almost two years to partially 
replace milk fat SFA with cis-MUFA. Resulting milk (modified) was used for UHT milk, butter 
and Cheddar cheese production, and compared with products with fatty acid (FA) profiles 
typical of retail products (conventional). The SFA concentration of lipid from modified 
products was lower than that of conventional products (70 vs 53 g/100 g FA, respectively), and 
was replaced by cis-MUFA (mainly cis-9 18:1) and trans-MUFA. FA profile of modified 
products was consistent over the production periods with no effect of processing. This food 
chain approach was successful in producing modified dairy products of consistent FA profile, 
suitable for use in a human intervention study. 
 
Keywords: Milk, dairy product, saturated fatty acid, monounsaturated fatty acid 
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INTRODUCTION 
Milk and dairy products are a major source of fat and fatty acids (FA) in the UK adult diet, 
contributing to 18 % total fat, 28 % saturated fatty acid (SFA), 38 % trans fatty acid (TFA) 
intake (Bates et al., 2016) and 12 % cis-monounsaturated fatty acid (MUFA) intake (Hobbs, 
personal communication). The contribution of dairy products to UK SFA intake has declined 
slightly since 2003 (Henderson et al., 2003), probably due to a decrease in whole fat milk 
consumption between 2003-2013 (DEFRA, 2013), but at the population level total SFA intake 
still exceeds current recommendations (12.1 % total energy intake (EI); Bates et al., 2016) vs 
11 % total EI; Department of Health, 1994, or 10 % total EI; WHO, 2010). A reduction in 
dietary TFA from industrially hydrogenated food sources has led to an increase in contribution 
of these fatty acids from dairy products but overall TFA consumption has declined (Henderson 
et al., 2003; Bates et al., 2016) and is below the maximum recommended intake of 2 % total 
energy (SACN, 2007). 
 
It has been shown that replacing dietary SFA with cis-PUFA reduces CVD risk factors, 
including fasting serum total, LDL and total:HDL-cholesterol concentrations (Vafeiadou et al., 
2015).  The most effective means of replacing SFA with UFA in milk fat is by altering the dairy 
cow diet (Kliem & Shingfield, 2016). Due to the more extensive rumen biohydrogenation of 
dietary PUFA compared with cis-MUFA (Shingfield et al., 2008), and the greater proportion of 
cis-MUFA compared with PUFA in milk fat (Kliem et al., 2013), replacement with cis-MUFA 
offers a greater potential for SFA reduction in milk fat. To date only nine studies have assessed 
the impact of consuming dairy products modified using this dietary strategy (replacing milk 
SFA with either MUFA or PUFA) on cardiovascular health outcomes in humans (Livingstone 
et al., 2012). Five of these studies used only butter as the test dairy product, thus not representing 
the nutritional composition of a range of dairy products and food matrices. Two studies (Noakes 
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et al., 1996; Seidel et al., 2005) included a range of dairy products modified by changing the 
cow diet in their interventions, but these only lasted for relatively short periods of time (up to 
three weeks) and involved small numbers of participants. It is not known whether the FA 
composition of milk and dairy products produced this way would be consistent over longer 
periods of time, especially as milk FA response to dietary oilseeds appears to vary according to 
differences in other dietary nutrients (Lerch et al., 2012a). 
 
The main objectives of this study were twofold; firstly to identify whether UHT milk, butter 
and Cheddar cheese could be produced with a consistent FA profile over a two-year period, 
from milk modified using an oleic-acid rich supplementation strategy. A consistent composition 
is essential if this technique is to be applied on a larger scale. The current study utilised a high 
oleic acid (cis-9 18:1) sunflower oil to maximise the replacement of SFA with MUFA, after 
previous research highlighted the potential of these oils (Loor et al., 2002; Kliem et al., 2011). 
The second objective was to compare the FA composition of the modified dairy products with 
products containing FA profiles typical of UK retail milk during winter months (average SFA 
71.5 g/100 g total FA, cis-MUFA 21.2 g/100 g FA; Kliem et al., 2013), and for this to be 
consistent across products. 
 
MATERIALS AND METHODS 
This study was part of the larger, Medical Research Council-funded RESET (REplacement of 
SaturaEd fat in dairy on Total cholesterol, Clinicaltrials Gov ID: NCT02089035) study which 
aimed to investigate the impact of SFA-reduced, MUFA-enriched dairy product consumption 
on traditional and novel markers of CVD risk.  
 
Production of Modified Milk 
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Between December 2013 and May 2015, groups of multiparous Holstein-Friesian cows were 
recruited to produce milk with a modified FA profile. For the purposes of the RESET human 
intervention study, production was divided into two periods; Production period 1 (P1) took 
place between December 2013 and September 2014, involving a total of 58 cows (mean ± 
standard error parity 4.0 ± 0.12; milk yield at start 35.0 ± 0.77 litres/day, and days in lactation 
181 ± 7.7), producing a total of approximately 12,500 litres of milk which was used to produce 
modified UHT milk, butter and cheese for the human intervention. Production period 2 (P2) 
took place between November 2014 and May 2015, involving a total of 41 cows (mean +/- 
standard error parity 4.0 ± 0.12; milk yield at start 33.4 ± 0.91 litres/day, and days in lactation 
205 ± 7.2) producing a total of 16,350 litres of milk. Cows recruited to produce modified milk 
were adapted to a TMR diet an example of which is presented in Table 1. Attempts were made 
to replicate this diet for each production batch. The diet had a forage:concentrate ratio of 50:50 
on a DM basis, with the forage consisting of maize silage, grass silage, grass hay and wheat 
straw. The diet was supplemented with 43 g/kg DM of high oleic acid sunflower oil (AAK Ltd., 
Hull, East Yorkshire, HU9 5PX, UK) so that it would supply a cow consuming 23 kg DM per 
day with 1 kg oil. Cows were adapted to this diet for a period of four weeks before any milk 
collection was made. Subsamples of modified milk were taken and preserved with potassium 
dichromate (1 mg/ml; Lactabs; Thompson and Capper, Runcorn, UK) following the adaptation 
period for milk compositional analysis. A further subsample was frozen to measure the FA 
profile prior to product manufacture. 
 
Manufacture of Dairy Products 
UHT Milk Processing. UHT milk, i.e. both modified and conventionally-produced 
milk, was produced three times, twice during P1 and once during P2. The first P1 production 
run was carried out at Reaseheath College (Nantwich, UK) with the remaining production runs 
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carried out at Frampton’s Ltd (Shepton Mallet Somerset, UK). Raw conventional milk was 
provided by Arla Foods UK (Taw Valley Creamery, North Tawton, UK), and represented retail 
milk with a typical UK winter dairy FA profile. Conventional milk was standardised to match 
the fat content of the modified milk using skimmed milk provided by A.E Rodda & Son Ltd., 
(Redruth, Cornwall, UK), for the purposes of the human intervention study. Raw conventional 
milk was pumped to a tank and skimmed milk, at the level required to match the modified milk 
fat content, was added. The milk was agitated in the tank for 5 minutes and a sample removed 
and analysed to ensure the fat content was correct. UHT processing was carried out in a pilot 
scale UHT plant. The milk was preheated to 85ºC using a plate heat exchanger and 
homogenised. The milk was then heated to 142ºC for 5 seconds using direct steam infusion and 
cooled to 15ºC and aseptically packaged into 5 kg aseptic bag (Reaseheath) or 330 ml aseptic 
cartons (Framptons). All UHT milk was stored at 4ºC until required. 
 
Cheddar cheese processing. Conventional Cheddar cheese was provided by Arla Foods 
UK (Taw Valley Creamery), to represent retail mild Cheddar cheese with a typical UK winter 
dairy FA profile. Modified Cheddar cheese was manufactured at the University of Reading Pilot 
Plant (Reading, UK). Both cheese types were produced once during P1 and P2. The processing 
parameters for the modified cheese were selected to mimic the commercial process used at Arla. 
Modified raw milk was pasteurised at 73ºC for 15 seconds in a high-temperature short-time 
pasteuriser (flow rate 300 L/h) using a plate heat exchanger. The milk was cooled to 32ºC and 
transferred to 100 L cheese vats. Starter culture (R 604, Chr. Hansen) was added (0.15 g/L) to 
the vat and allowed to ripen under stirring for 50 minutes. Enzyme (CHY-MAX, Chr. Hansen) 
was added (0.24 ml/L) and stirred for a further 3 minutes, before the stirrers were removed. 
Cutting time was 90 minutes after starter addition and was visually confirmed by the 
cheesemaker. The coagulum was cut by hand using a coagulum cutting knives. The temperature 
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was increased slowly until it reached 42ºC and this scalding process continued for 1h. Stirring 
then commenced and continued for 1 h. Whey was subsequently drawn off the cheese vat.  The 
resulting curd underwent a cheddaring process by piling and turning the curd 4 times. The curd 
was then milled using a cheese mill and dry salted (0.02 kg/kg) and placed into a stainless steel 
cheese mould. The mould was placed in a horizontal cheese press and pressed at 7 kPa 
overnight. The next day the cheese was vacuum packed and placed in an 8ºC ripening room for 
three months. After ripening, cheese was apportioned into 350 g, vacuum packed and stored at 
2ºC.  
 
Butter processing. Conventional butter was provided by Arla Foods UK (Taw Valley 
Creamery) from winter butter stocks during P1 and P2. Modified P1 butter was manufactured 
at Reaseheath College (Nantwich, UK) and modified P2 butter was manufactured at Ty 
Tanglwyst Dairy (Bridgend, South Wales).  In both cases cream was separated from the milk 
using a disc bowl separator, pasteurised, and aged at 4ºC overnight. The cream was transferred 
to a churn and churned until butter grains were formed. The buttermilk was drained off and the 
butter grains were further worked to create a continuous emulsion. Salt was then added (1.7 
g/100 g) and the butter was further worked to ensure even distribution of the salt. Butter was 
apportioned into 250 g, packaged in butter wrap and stored at -20°C until required. 
 
Chemical Analysis of Milk and Dairy Products 
A sample of high oleic acid sunflower oil used during P1 and P2 and subsample of the TMR 
diet was analysed for FA profile using a modified version of the one step transesterification of 
Sukhija & Palmquist, (1988). Briefly, 50 mg oil or 300 mg TMR was incubated with an internal 
standard (methyl heneicosanoate, 51535, Sigma Aldrich Company Ltd., Dorset, UK) at 60°C 
in the presence of 0.4 M sulphuric acid in methanol and toluene as an extraction solvent, for 2 
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h (oil) or 3 h (TMR). Following neutralisation, resulting fatty acid methyl esters (FAME) in 
toluene were allowed to stand over sodium sulphate for 30 min to remove methanol residues 
before being quantified by gas chromatography (GC; Bruker 350, Bruker, Germany). The GC 
was equipped with a flame ionisation detector and 100 m fused silica capillary column (CP-SIL 
88, Agilent Technologies, Cheshire, UK), and GC conditions were as published previously 
(Kliem et al., 2013). Carbon deficiency in the flame ionization detector response for FAME 
containing 4- to 10-carbon atoms was accounted for using a combined correction factor which 
also converted FAME to FA (Ulberth et al., 1999). FA were quantified using internal standard 
peak area, and results were also expressed as g/100 g FA. 
 
Samples of milk taken just prior to dairy product production and UHT milk (modified and 
conventional) was analysed for FA profile according to the method of Kliem et al. (2013). 
Briefly, lipid in 1 ml thawed, warmed (to 40°C) milk was extracted in duplicate using a mixture 
of diethyl ether and hexane (IDF 1: 2010(E), International Dairy Federation, 2010, Brussels, 
Belgium) and extracts were transesterified to FAME according to previously described 
procedures (Kliem et al., 2013). GC conditions and FAME identification were as described 
above. Methyl esters not available as authentic standards were identified by gas 
chromatography-mass spectrometry (GC-MS; Thermo Trace GC coupled to ITQ 1100 mass 
spectrometer using helium as a carrier gas) analysis of 4, 4-dimethyloxazoline (DMOX) 
derivatives prepared from FAME. Preparation of DMOX derivatives and parameters used for 
GC-MS analysis were largely in accordance with earlier reports (Shingfield et al., 2006), 
however a split ratio of 1:14 was used for injection and the online reference library of DMOX 
electron impact ionisation spectra was http://lipidlibrary.aocs.org. Results were expressed as 
g/100 g FA. Lipid in 50 mg conventional and modified butter was first warmed gently before 1 
ml distilled water added, and mixed vigorously to emulsify butter fat. Extraction and 
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methylation continued as with milk and results were expressed as g/100 g total FA. Lipid in 3 
g conventional and modified cheese was firstly hydrolysed using 100 ml 3M HCl, and the 
resulting residue filtered through Whatman 1 filter paper prior to drying at 60°C for 18 h. Lipid 
was extracted from the residue using petroleum ether (Brown & Mueller-Harvey, 1999), and 
the amount of lipid calculated gravimetrically. Lipid was then gently warmed before 50 mg was 
transferred to clean glass tubes, and methylation of extracted FA was conducted as for milk and 
butter. 
  
Nutritional analysis (energy, protein, fat, carbohydrate, ash and moisture) of the dairy products 
from each cohort was conducted in duplicate by SGS United Kingdom Ltd. (ISO 17025 
accredited laboratory; Ellesmere Port, Cheshire, UK). To calculate protein content the obtained 
nitrogen result was multiplied by the standard dairy nitrogen conversion factor (6.38) to account 
for the fraction of non-protein nitrogen in each sample (Maubois & Lorient, 
2016). Micronutrient content analysis (calcium, magnesium, sodium and phosphorus) was 
conducted in duplicate by inductively coupled plasma-optical emission spectrometry 
(Quaternary Scientific (QUEST), University of Reading, Berkshire, UK). Results were 
expressed on a dry and fresh weight basis. 
 
Data Analysis 
For each product separately, nutrient composition data were analysed using an ANOVA 
(Minitab17) which included effects of production period and treatment. FA composition of all 
products were analysed using an ANOVA (Minitab17) which initially included effects of 
product, production period, treatment, and period by treatment interactions. When there was no 
effect of product this was removed from the model. Least squares means ± s.e.m. are reported, 
and differences were considered significant at P < 0.01 to account for multiplicity. 
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RESULTS 
The FA profile of the high oleic acid sunflower oil used during production P1 and P2 is 
presented in Table 2. There was a slight change in FA profile during P2, when it contained a 
lower proportion of cis-9 18:1 and higher proportion of both 16:0 and 18:2 n-6.  
 
The macronutrient composition of the dairy products is presented in Table 3. There was no 
significant effect of production period or treatment on macronutrient content. 
 
There was no effect of product for each individual FA identified and hence the term was 
removed from the model, and the FA data presented are means across milk, cheese and butter. 
Lipid from modified dairy products had a lower (P<0.001) total SFA content than lipid from 
conventional dairy products, which was mainly due to a 12 g/100 g FA lower concentration of 
16:0, but also all SFA ≤ 14:0 including branched chain SFA such as 13:0 anteiso, 14:0 iso and 
15:0 anteiso (Table 4). In contrast, concentration of 18:0 was higher (P<0.001) in the modified 
dairy products. There was no effect of production period on SFA content apart from 17:0 iso 
and 20:0 which were more abundant in P1 products (P<0.01). 
 
Treatment also had an effect on both cis- and trans- MUFA (Table 4), with lipid from modified 
dairy products having a higher (P<0.001) concentration of both. Of the cis-MUFA, cis-9 18:1 
was the most abundant (Table 5), and concentration was at least 50 % greater in modified dairy 
compared with conventional products (Table 5). There were also notable differences in most of 
the other 18:1 isomers identified, modified products containing higher (P<0.01) lipid 
concentrations of cis-11, cis-13, trans-6-8, trans-9, trans-10, trans-12, trans-15 and trans-16 
18:1 (the predominant isomer switching from trans-11 18:1 in control products to trans-10 18:1 
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in modified products). Aside from the 18:1 isomers, there were treatment differences in cis-9 
10:1, cis-9 12:1, trans-9 14:1, cis-13 16:1 and cis-9 17:1, all of which were lower (P<0.01) in 
modified dairy products.  
 
Total n-6 and n-3 PUFA concentrations were not different between lipid from conventional and 
modified products (Table 4). In contrast, the concentration of total conjugated linoleic acid 
(CLA) isomers was greater (P=0.001) in modified products (Table 4). Of the non-methylene 
interrupted 18:2 isomers, cis-9, trans-13, cis-9, trans-14 and cis-9, trans-12 18:2 were higher 
(P<0.01) in concentration in modified products (Table 6). There was an effect of period for cis-
9, trans-13 which was more abundant (P<0.05) in P1 products (Table 6). 
 
DISCUSSION 
One of the main challenges of food chain interventions is to maintain a supply of the test food 
that is consistently different to the control product over the period of the study. This study 
produced greater volumes of modified dairy products over a longer period of time than other 
published studies (Livingstone et al., 2012). It has been reported previously that the milk FA 
profile resulting from supplementation with oilseeds can be affected by the chemical 
composition of other dietary constituents such as starch, or changes in DM intake (Lerch et al., 
2012a). Therefore, it is important to demonstrate consistency for the purposes of both controlled 
human dietary intervention studies, and also for future commercial application and consumer 
consumption. 
 
Overall there was little difference in macronutrient composition of both the control and 
modified milk and dairy products, and this was consistent over the two production periods. 
Feeding unsaturated oils to dairy cows often suppresses milk fat concentration (Halmemies-
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Beauchet-Filleau et al., 2011), mainly due to the inhibitory effect of intermediates of rumen 
biohydrogenation on mammary FA synthesis (Bauman et al., 2011). In the current study, 
modified cheese was numerically lower (- 5.6 g/100 g) in fat content than the control cheese 
due to the raw modified milk being lower in total fat. It was necessary to standardise the raw 
conventional milk prior to UHT so that the fat content matched that of the modified milk for 
the purposes of the human intervention study. A study reporting the fat content of Mozzarella 
cheese made from milk where cows were fed incremental amounts of a linseed supplement 
reported no linear effect on cheese lipid content (Oeffner et al., 2013). However this study fed 
an extruded linseed supplement, which may have afforded the constituent oil some degree of 
protection from rumen biohydrogenation. This suggests that a more suitable approach for 
production of modified milk on a commercial scale may be to use oilseed supplements which 
are protected from rumen biohydrogenation.  
 
Despite being produced across two production period over the course of two years, there was 
no effect of production period on differences between the main FA and groups in modified and 
control products, even with minor differences in FA profile of the supplemental oil fed to cows 
during the two production periods. Decreases in milk fat concentrations of de novo-synthesised 
SFA and increases in 18:0 and cis-9 18:1 following oilseed supplementation were found to be 
comparable over two consecutive lactations, but changes in most trans-18:1 and 18:2 isomers 
varied depending on year (Lerch et al., 2012b). This was probably due to differences in starch 
contents of the experimental diets across the two years (Lerch et al., 2012a). Transient changes 
in concentration of certain CLA and trans-18:1 isomers have been observed in response to 
oilseed supplementation over shorter periods of time (Roy et al., 2006). However the current 
study employed a dietary adaptation period of 4 weeks prior to milk collection, which should 
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have minimised any variation and successfully produced consistent modified milk essential for 
effective utilisation in the RESET human intervention study.  
 
There were differences in most individual FA concentrations between conventional and 
modified products. All short (4:0-10:0) and medium (12:0-16:0) chain SFA were lower in 
modified products, which was balanced by higher 18:0, cis-9 18:1 and intermediates of 
biohydrogenation concentrations which supports previous studies (Loor et al., 2002; Kliem et 
al., 2011). A meta-analysis of recent data reported that the majority of the milk SFA responses 
to plant oil supplements in dairy cow diets is due to decreases in 12:0, 14:0 and 16:0 
concentrations (Kliem & Shingfield, 2016). This can mainly be attributed to increases in the 
supply of ≥ 16 carbon FA leaving the rumen and inhibiting acetyl CoA carboxylase 
transcription and activity in the mammary gland (Barber et al., 1997). 
 
SFA in modified milk were mostly replaced with cis-9 18:1, which was the predominant FA in 
the oil supplement. The current study aimed to feed 1 kg oil/cow/day, which equated to around 
800 g additional cis-9 18:1. In this unprotected oil form it would be expected that some rumen 
biohydrogenation of cis-9 18:1 would occur as has been reported in detailed in vivo studies (e.g. 
Loor et al., 2002), however there was a 10 g/100 g FA difference in cis-9 18:1 concentration 
between conventional and modified products in the current study, in line with previous studies 
(Kliem et al., 2011). Milk fat cis-9 18:1 is derived from two sources – diet and endogenous 
desaturation of 18:0 by mammary epithelial cell ∆9-desaturase. One in vivo study estimated that 
this enzyme was responsible for almost 60 % of cis-9 18:1 present in milk fat (Mosley & 
McGuire, 2007). Dairy products from the current study contained a higher concentration of 
18:0 than control products, which may have contributed to the increase in milk fat cis-9 18:1. 
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A proportion of dairy SFA was also replaced by TFA, which are intermediates of rumen 
biohydrogenation of dietary unsaturated FA (Harfoot & Hazlewood, 1997). The majority of 
TFA identified in the current study were trans 18:1 isomers. In vitro studies have established 
that cis-9 18:1 is converted to a range of trans 18:1 isomers during incubation with rumen-
derived microorganisms (McKain et al., 2010). Furthermore, trans-9 18:1 has been shown to 
further isomerise during in vitro incubation with rumen bacteria to a range of positional trans 
18:1 isomers (Proell et al., 2002). The predominant isomer in the conventional dairy products 
was trans-11 18:1, but in the modified products, trans-10 18:1 predominated. Trans-10 18:1 is 
thought to arise as an intermediate of 18:2 n-6 biohydrogenation in response to changed rumen 
conditions on certain diets (Bauman et al., 2011), such as those which lower rumen pH 
(Palmquist et al., 2005). A recent review concluded that the predominance of trans-10 18:1 in 
ruminant products is more common than previously thought (Aldai et al., 2013), however very 
few milk-based studies have resulted in concentrations of trans-10 18:1 of the level observed 
in the current study. Roy et al. (2006) and Shingfield et al. (2005) both reported relatively high 
concentrations of trans-10 18:1 in milk fat after feeding oilseed supplements (18 and 13 g/100 
g total FA, respectively), with suggested possible reasons being increased supply of 18:2 n-6 
and low rumen pH. In the current study, 18:2 n-6 content of the oil was low, so the high trans-
10 18:1 content of modified milk would have been primarily due to isomerisation of cis-9 18:1 
within the rumen. This was suggested after a similar effect was observed when olive oil (high 
in cis-9 18:1) was fed to dairy sheep (Gomez-Cortes et al., 2008). Trans-10 18:1 has often been 
thought partially responsible for milk fat depression, but studies involving abomasally-infused 
trans-10 18:1 have reported inconsistent results (Lock et al., 2006; Shingfield et al., 2009)  
 
Enriched concentrations of CLA in milk are usually due to an increased supply of 18:2 n-6 or 
18:3 n-3 to the rumen, biohydrogenation of which results in increased trans-11 18:1 available 
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to mammary ∆9 desaturase and therefore increased cis-9, trans-11 CLA, the predominant 
isomer (Palmquist et al., 2005). In the current study modified products had a higher overall 
CLA concentration than conventional products, but there was no difference in trans-11 18:1. 
Either desaturation of trans-11 18:1 was extremely efficient, or the increase in CLA 
concentration observed was due to increases in other CLA isomers.  
 
The observed difference in SFA and MUFA content between control and modified products is 
comparable to that of previous studies (Livingstone et al., 2012). However few previous studies 
reported a detailed FA profile. The studies of Tholstrup et al. (2006) and Lacroix et al. (2012) 
were specifically designed to observe the effects of increased ruminant-derived TFA, and as 
such the modified products contained enriched concentrations of trans-11 18:1 in particular. 
The current study reported a greater concentration of trans-10 18:1 in modified products and 
the potential for these TFA to impact on CVD risk factors remains to be investigated.  
 
CONCLUSIONS 
In conclusion, feeding a specially formulated diet containing a high oleic acid sunflower oil to 
dairy cows over two production periods resulted in dairy products with a consistent FA profile, 
lower in SFA (including 12:0, 14:0 and 16:0), and higher in cis- and trans-MUFA (particularly 
cis-9 18:1 and trans-10 18:1) than conventionally-produced dairy products. Processing the 
modified milk into UHT milk, butter and Cheddar cheese had minor effects on FA profile. This 
technique is therefore suitable for the production of modified dairy products, with a consistent 
FA profile, which are suitable for use in large-scale intervention studies, where products with 
consistent composition are required over a longer period of time. This technique is also suitable 
for production of modified dairy foods on a commercial scale.  
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Table 1. Ingredients and analysed chemical composition of the cow diet used for each 
production batch (g/kg dry matter (DM) or as stated) 
 g/kg DM 
Ingredients  
    Maize silage 350 
    Grass silage 52 
    Grass hay 33 
    Straw 33 
    Wheat by-product1 86 
    Concentrate mix2 372 
    Calcium salts of palm oil distillate3 11 
    Salt4 4 
    Limestone 4 
    Minerals and vitamins 11 
    High oleic acid sunflower oil5 43 
Chemical composition  
    DM (g/kg fresh) 515 
    Organic matter 932 
    Crude protein 144 
    Neutral detergent fibre 351 
    Acid detergent fibre 199 
    Starch 212 
    ME (MJ/kg DM)6 12.6 
Fatty acids  
    16:0 2.9 
    18:0 0.9 
    18:1 cis-9 14.6 
    18:2 n-6 6.1 
    18:3 n-3 0.05 
    Total fatty acids 30.0 
1CTraffordgold®; KW Alternative Feeds Ltd., Barrow Hill Barns, Andover, SP11 7RG, UK  
2 Containing (g/kg DM): Cracked wheat, 180; Soyabean meal 160; Rapeseed meal, 175; Sugar 
beet feed, 140; Wheat distillers, 140; Soya hulls, 120; Molasses, 33; Megalac®, 17; Urea, 11; 
Minerals (KW Alternative Feeds Ltd., Barrow Hill Barns, Andover, SP11 7RG, UK), 22).  
3 Megalac®; Volac International Ltd., Royston, Hertfordshire, SG8 5QX, UK 
4 Dairy Direct, Church Farm, Bury St Edmunds, IP28 6PX, UK. 
5AAK (UK) Ltd., Hull, East Yorkshire, HU9 5PX, UK. 
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Table 2. Fatty acid composition of the high oleic acid sunflower oil used during the two 
production periods (g/100 g total fatty acids) 
Fatty acid Production period 1 Production period 2 
16:0 3.6 4.1 
18:0 3.1 2.7 
18:1 cis-9 82.1 80.4 
18:2 n-6 7.5 10.1 
18:3 n-3 0.26 0.27 
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Table 3. Macronutrient composition of the modified and conventional dairy products (average across production periods 1 and 2; units as stated, 
least square means ± s.e.m.) 
 UHT milk  Butter  Cheddar cheese 
 Conventional Modified s.e.m.  Conventional Modified s.e.m.  Conventional Modified s.e.m. 
Energy (kJ/100 g) 220 232 1.4  3037 3024 22.1  1688 1527 10.1 
Energy (kcal/100 g) 52.5 55.4 0.33  739 735 5.4  407 368 2.4 
Total carbohydrate (g/100 g) 4.4 4.7 0.02  1.93 0.98 0.108  3.1 2.6 0.24 
Ash (g/100 g) 0.72 0.77 0.010  1.8 1.6 0.08  4.0 3.9 0.50 
Moisture (g/100 g) 88.8 88.3 0.01  14.9 16.0 0.46  36.2 39.2 0.50 
Nitrogen (g/100 g) 0.47 0.51 0.02  0.04 0.07 0.007  3.7 4.2 0.07 
Protein (g/100 g)1 3.0 3.3 0.03  0.23 0.44 0.041  23.1 26.4 0.42 
Fat (g/100 g) 2.5 2.6 0.14  81.1 81.1 0.63  33.6 28.0 0.19 
24 
 
Calcium (mg/100 g dry) 1147 1090 28.8  19.1 20.6 2.78  1242 1428 105.0 
               (mg/100 g fresh) 126 119 7.1  17.0 17.9 2.32  801 911 58.4 
Magnesium (mg/100 g dry) 105 101 0.1  2.1 2.1 0.24  46.6 47.4 1.65 
                    (mg/100 g fresh) 11.5 11.1 0.35  1.9 1.8 0.20  30.1 30.3 0.80 
Sodium (mg/100 g dry) 378 417 22.7  795 577 87.7  1123 1187 82.2 
              (mg/100 g fresh) 41.4 45.5 1.19  707 502 73.8  726 760 46.4 
Phosphorus (mg/100 g dry) 896 819 30.0  25.4 27.0 3.68  836 939 57.0 
                    (mg/100 g fresh) 98.1 89.2 6.31  22.6 23.5 3.11  539 599 30.7 
1Calculated by nitrogen conversion factor 6.38 (Maubois & Lorient, 2016) 
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Table 4. Mean fatty acid composition of the lipid from all modified and conventional dairy products over two production periods (g/100 g total 
fatty acids, least squares means for milk, butter and cheese ± s.e.m) 
 Period 1  Period 2 s.e.m.1 P2 
 Conventional Modified  Conventional Modified  Production 
period 
Treatment Interaction 
4:0 2.9 2.2  2.9 2.1 0.06 0.668 <0.001 0.124 
6:0 1.8 1.1  1.9 1.0 0.04 0.732 <0.001 0.057 
8:0 1.11 0.62  1.14 0.54 0.030 0.420 <0.001 0.088 
10:0 2.7 1.5  2.8 1.2 0.07 0.056 <0.001 0.033 
10:1 cis-9 0.28 0.13  0.29 0.13 0.011 0.727 <0.001 0.547 
11:0 0.053 0.004  0.025 0.002 0.0138 0.329 0.031 0.375 
12:0 3.5 2.0  3.5 1.6 0.13 0.194 <0.001 0.133 
12:1 cis-9 0.10 0.05  0.10 0.05 0.005 0.893 <0.001 0.453 
13:0 0.10 0.05  0.09 0.05 0.010 0.601 0.003 0.859 
13:0 anteiso 0.09 0.06  0.09 0.05 0.004 0.618 <0.001 0.418 
14:0 11.3 8.5  11.4 7.4 0.30 0.188 <0.001 0.077 
14:0 iso 0.08 0.07  0.09 0.07 0.005 0.669 0.008 0.842 
26 
 
14:1 cis-9 1.02 0.95  1.04 1.01 0.041 0.366 0.231 0.663 
14:1 trans-9 0.22 0.16  0.24 0.17 0.010 0.210 <0.001 0.686 
15:0 1.10 0.71  1.14 0.71 0.038 0.613 <0.001 0.585 
15:0 anteiso 0.43 0.38  0.42 0.35 0.008 0.021 <0.001 0.406 
16:0 33.3 20.9  33.8 22.2 0.69 0.220 <0.001 0.602 
16:0 iso 0.20 0.19  0.20 0.20 0.010 0.650 0.721 0.629 
16:1 cis-9 + 17:0 anteiso 1.7 1.6  1.5 1.5 0.07 0.050 0.596 0.340 
16:1 cis-11 0.21 0.13  0.42 0.40 0.065 0.007 0.516 0.651 
16:1 cis-13 0.15 0.05  0.17 0.05 0.011 0.412 <0.001 0.417 
16:1 trans-9 0.03 0.10  0.10 0.05 0.101 0.377 0.001 0.640 
17:0 iso 0.33 0.36  0.29 0.31 0.012 0.008 0.073 0.588 
17:0 0.48 0.36  0.49 0.33 0.005 0.090 <0.001 0.013 
17:1 cis-9 0.20 0.16  0.20 0.15 0.003 0.333 <0.001 0.089 
18:0 9.6 14.0  9.4 13.0 0.32 0.089 <0.001 0.217 
18:0 iso 0.03 0.02  0.06 0.03 0.008 0.026 0.019 0.026 
∑ 18:1 trans 2.8 9.4  2.6 10.2 0.30 0.348 <0.001 0.130 
∑ 18:1 cis 20.0 29.6  19.3 30.3 0.74 0.994 <0.001 0.407 
27 
 
∑ CLA3 0.57 0.71  0.59 0.98 0.065 0.195 0.001 0.025 
∑ NMI4 18:2 2.1 2.3  2.1 2.5 0.17 0.605 0.084 0.857 
18:3 n-3 0.32 0.23  0.40 0.30 0.032 0.060 0.020 0.872 
19:05 0.10 0.10  0.08 0.08 0.016 0.326 0.970 0.966 
20:0 0.15 0.15  0.14 0.13 0.003 0.009 0.063 0.118 
20:1 cis-9 0.10 0.10  0.09 0.08 0.009 0.130 0.604 0.394 
20:1 cis-11 0.09 0.09  0.02 0.01 0.045 0.108 0.802 0.883 
20:2 n-6 0.005 0.008  0.012 0.005 0.0066 0.771 0.719 0.447 
20:3 n-6 0.06 0.07  0.07 0.06 0.008 0.634 0.255 0.918 
20:4 n-6 0.10 0.07  0.10 0.06 0.007 0.625 0.001 0.300 
20:5 n-3 0.05 0.01  0.05 0.02 0.008 0.488 0.002 0.321 
22:0 0.05 0.08  0.05 0.08 0.007 0.851 0.003 0.370 
22:2 n-6 0.020 0.006  0.034 0.003 0.0119 0.727 0.082 0.554 
22:5 n-3 0.08 0.04  0.08 0.04 0.009 0.582 0.002 0.717 
24:0 0.02 0.03  0.04 0.04 0.008 0.189 0.478 0.531 
∑ SFA6 70.3 54.3  70.9 52.2 0.97 0.479 <0.001 0.204 
∑ cis-MUFA7 23.0 32.2  22.5 32.9 0.67 0.932 <0.001 0.372 
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∑ trans-MUFA7 3.3 10.0  3.2 10.8 0.29 0.268 <0.001 0.125 
∑ trans fatty acids 4.0 10.7  3.8 11.8 0.31 0.208 <0.001 0.082 
∑ n-3 PUFA8 0.63 0.48  0.72 0.59 0.054 0.096 0.033 0.791 
∑ n-6 PUFA8 1.7 1.9  1.9 2.0 0.18 0.547 0.578 0.865 
1 Standard error of the mean for n=12 measurements 
2 Refers to the significance of overall effect of period, treatment and their interaction 
3 CLA – conjugated linoleic acid 
4 NMI - non methylene-interrupted 
5 Co-elutes with 18:1 cis-15 
6 SFA – saturated fatty acids 
7 MUFA – monounsaturated fatty acids 
8 PUFA – polyunsaturated fatty acids  
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Table 5. Mean 18:1 isomer composition of the lipid from all modified and conventional dairy products over two production periods (g/100 g 
total fatty acids, least squares means for milk, butter and cheese ± s.e.m) 
 Period 1  Period 2 s.e.m.1 P2 
 Conventional Modified  Conventional Modified  Production 
period 
Treatment Interaction 
cis-9 18:13 18.8 28.2  18.4 28.9 0.72 0.859 <0.001 0.439 
cis-11 18:1 0.61 0.81  0.44 0.70 0.048 0.023 0.001 0.522 
cis-12 18:1 0.22 0.16  0.21 0.19 0.016 0.467 0.042 0.318 
cis-13 18:1 0.09 0.16  0.08 0.11 0.017 0.103 0.017 0.364 
cis-16 18:1 0.06 0.06  0.05 0.04 0.005 0.091 0.454 0.294 
trans-6, -7, -8 18:1 0.24 1.28  0.24 1.25 0.290 0.955 0.008 0.961 
trans-9 18:1 0.20 0.94  0.18 1.39 0.119 0.102 <0.001 0.082 
trans-10 18:1 0.36 4.01  0.41 2.49 0.413 0.113 <0.001 0.095 
trans-11 18:1 1.10 0.94  0.85 1.81 0.428 0.490 0.375 0.227 
trans-12 18:1 0.38 1.01  0.32 1.09 0.065 0.816 <0.001 0.310 
trans-15 18:1 0.40 0.94  0.47 1.82 0.231 0.074 0.004 0.119 
trans-16 18:14 0.31 0.35  0.31 0.48 0.024 0.023 0.003 0.026 
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1 Standard error of the mean for n=12 measurements 
2 Refers to the significance of overall effect of period, treatment and their interaction 
3 Co-elutes with 18:1 trans-13/14 
4 Co-elutes with 18:1 cis-14. 
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Table 6. Mean non-methylene-interrupted 18:2 isomer composition of the lipid from all modified and conventional dairy products over two 
production periods (all values as mg/100 g total fatty acids, least square means for milk, butter and cheese ± s.e.m.) 
 Period 1  Period 2 s.e.m.1 P2 
 Conventional Modified  Conventional Modified  Production 
period 
Treatment Interaction 
cis-9, trans-13 18:2 182 238  177 334 11.4 0.004 <0.001 0.002 
cis-10, trans-14 18:2 122.6 122.6  100.0 92.1 9.12 0.020 0.679 0.680 
cis-9, trans-14 18:2 80.4 100.8  75.4 107.9 5.83 0.861 0.002 0.330 
cis-9, trans-12 18:2 33.7 50.4  26.9 54.0 3.78 0.697 <0.001 0.206 
trans-9, cis-12 18:2 7.5 8.2  46.0 15.5 10.80 0.067 0.205 0.187 
trans-11, cis-15 18:2 122.5 105.5  66.7 134.4 23.56 0.585 0.312 0.110 
cis-9, cis-12 18:2 1449 1629  1563 1686 141.3 0.561 0.316 0.845 
1 Standard error of the mean for n=12 measurements 
2 Refers to the significance of overall effect of period, treatment and their interaction 
 
